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Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase, commonly over-
expressed in cancer that is well known to be a key regulator of cancer cell proliferation, 
survival, migration and invasion. It has recently been shown to modulate the anti-
tumour immune response via transcriptional regulation of chemokines and cytokines. 
These findings have fuelled interest in FAK as a plausible therapeutic target in cancer 
and FAK kinase inhibitors are currently in Phase I and II clinical trials.  
 
To date, much of the research on FAK has focused on its role at focal adhesions, 
detailing its major functions in cell motility and cancer cell invasion. However, 16 
years ago, FAK was shown to translocate to the nucleus and it is now well established 
that this occurs under conditions of cellular stress such as oncogenic transformation. 
In the nucleus, FAK binds to a number of transcription factors such as P53, MDM2, 
IL33, RUNX1 and SP1. These nuclear interactions have been linked to proliferation, 
survival, differentiation and regulation of the anti-tumour immune response and cell 
cycle. However, despite these findings, the mechanism by which FAK regulates gene 
expression in the nucleus has yet to be defined. With FAK kinase inhibitors currently 
in clinical trials, it is important to understand the molecular mechanisms associated 
with FAK’s transcriptional regulation, the role of the kinase activity, and the potential 
therapeutic benefits of targeting FAK’s nuclear function.  
 
We therefore investigated the mechanism by which FAK regulates transcription by 
integration of a number of ‘omics’ approaches to define the nuclear FAK interactome 
and FAK-dependent gene programmes, as well as FAK’s role in regulating chromatin 
accessibility and transcription factor binding. Integration of these datasets predicted 
that FAK regulates the binding of AP-1 and ETS transcription factors to chromatin. 
Furthermore, our findings indicate that a subset of FAK-regulated genes display 
changes in chromatin accessibility. Chromatin ImmunoPrecipitation (ChIP) validation 
experiments on the enhancer region of one of these genes, IL33, show reduced binding 
of JUN upon loss of FAK’s kinase activity. This predicts that FAK is regulating 
chromatin accessibility at this region of the IL33 gene.  
 
 iv 
The work presented in this thesis therefore identifies a novel mechanism by which 
FAK regulates transcription; further experiments will be required to define the 
epigenetic complexes responsible for FAK-dependent chromatin accessibility 
changes. This work adds to our understanding of how an integrin adhesion protein can 





























Focal adhesion kinase (FAK) is a protein that is used by cells when they grow and 
stick to their surroundings. When someone has cancer, one of the main risks is that the 
cancer may spread (or metastasise) causing cancers elsewhere in the body that are 
more difficult to treat. It has been shown in laboratory experiments, that when FAK is 
blocked, the risk of the cancer spreading can be reduced. More recently FAK has also 
been shown to move to the cell compartment where the regulation of genetic 
information (genes) occur – called the nucleus. Here FAK has been shown to interact 
with proteins called transcription factors that bind to regions next to genes (genomic 
regions) to turn genes on or off. By binding these transcription factors in the nucleus, 
FAK can regulate inflammation which has long been linked to the development of 
cancer. Therapies that target the body’s immune system to boost its own tumour killing 
activity offer a new form of cancer treatment with fewer negative side effects than 
chemotherapy. My work has investigated the mechanism by which FAK regulates the 
expression of genes that are important in cancer, in particular inflammatory genes. To 
do this, I have integrated a number of datasets defining 1) the proteins that FAK binds 
in the nucleus, 2) the genomic regions that FAK is regulating and 3) whether this turns 
on or off these genes that are FAK-regulated. My work has shown that FAK does 
indeed regulate a transcription factor to enhance the expression of a gene involved in 
cancer-inflammation. This work shows that FAK in the nucleus is an important 
regulator of the expression of genes in cancer by impacting a number of key 
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Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that is a key signal 
integrator regulating adhesion, migration and survival pathways. It is known to be 
upregulated in cancer and as such, is now a focus of cancer therapeutics as an 
alternative therapy to conventional toxic chemotherapy. It has recently been described 
to be a key regulator of gene expression of immunosuppressive cytokines by binding 
to transcriptional complexes in the nucleus: this drives cancer progression by 
suppressing anti-tumour immunity, making it a key cancer target to enhance the 
effectiveness of cancer immunotherapy. That said, the mechanisms by which FAK 
regulates transcription have never been defined and this was the basis of my project. 
In order to introduce my project, I will firstly describe the hallmarks of cancer, as FAK 
has been shown to be a key regulator of many of these. This will be followed by a 
description of the approaches used to target cancer. Then I will describe the structure 
and physiological functions of FAK, before describing its cancer-associated functions. 
This introduction is followed by a description of the studies showing that FAK in the 
nucleus is a key regulator of gene expression in cancer, identifying it is an important 
cancer target, and discussion of clinical trials that use FAK inhibitors. This 
introduction will conclude by expanding on the Aims of my project. 
 
1.1 The hallmarks of cancer 
Cancer is a multi-step disease characterised by aberrant cell proliferation resulting in 
the growth of a tumour, which may spread from the primary site to other organs of the 
body. Following an initiating event, cancer is driven by a number of features - 1) 
sustaining proliferation advantage, 2) deregulated cellular energetics, 3) resisting cell 
death, 4) genome instability and mutation, 5) induction of angiogenesis, 6) activating 
invasion and metastasis, 7) tumour promoting inflammation, 8) enabling replicative 
immortality, 9) avoiding immune destruction and 10) evading growth suppressors. 
These were described as the hallmarks of cancer in the seminal review by Hanahan 
and Weinberg in 2011 (Figure 1.1).  
 
1.1.1 Sustaining proliferative advantage  
Cancer cells acquire these characteristics by genetic reprograming of key signalling 
pathways (i.e. MAPK, WNT, P53) which are widely known to regulate a number of 
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cellular processes important in cancer development and survival such as proliferation, 
cell migration and differentiation. Activation of cancer-causing ‘oncogenes’ cause loss 
of proliferation control and ultimately cancer by disrupting the aforementioned 
signalling pathways amongst others. Key examples of oncogenes include BRAF which 
is mutated in 60% of melanomas which is a key regulator of the RAS-RAF-MEK-
ERK-MAPK pathway, driving cancer-associated processes including proliferation 
(Davies et al., 2002). 
  
1.1.2 Deregulated cell energetics  
In addition to acquiring proliferative signals, tumours require sufficient oxygen and 
nutrients to survive and proliferate (reviewed in Gentric et al., 2016). Lack of 
availability of these essential components can often lead to nutrient deprivation and 
regions of hypoxia (i.e. deprivation of oxygen in tissues) (reviewed in Muz et al., 2015, 
reviewed in Gentric et al., 2016). To combat this, tumours often undergo a ‘metabolic 
switch’ termed the Warburg effect, where tumour cells favour glycolytic metabolism 
over the more efficient oxidative phosphorylation (reviewed in Gentric et al., 2016). 
This “metabolic switch” arises due to changes in expression of metabolic gene 
programs associated with mitochondrial regulation. For example, it has been shown 
that P53 induces the expression of PUMA, which inhibits the function of 
mitochondrial pyruvate carrier (MPC) resulting in decreased mitochondrial pyruvate 
uptake and increased glycolysis (Kim et al., 2019).  
 
1.1.3 Resisting cell death  
Apoptosis is a process by which the cell undergoes programmed cell death following 
insults such as DNA damage, infection, oncogenesis or exposure to cytotoxic agents 
in cancer treatment. When a cell undergoes apoptosis, it exhibits morphological 
changes including detachment of extracellular matrix (ECM) and loss of cell-cell 
interactions (reviewed in Elmore et al., 2007). This is controlled by pro-apoptotic 
proteins such as FAS, BAX, NOXA and PUMA that stimulate apoptosis in both 
adherent and suspension cells via the activation of caspases (reviewed in Harris and 
Levine, 2005). When caspases are activated they cleave proteins such as those that 
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maintain membrane integrity (reviewed in Elmore et al., 2007). The most notable 
DNA damage sensor and inducer of apoptosis is P53 which is a key inducer of FAS, 
BAX, NOXA and PUMA-induced apoptosis (reviewed in Harris and Levine, 2005). 
Resisting cell death is a key hallmark of cancer and is one of the contributing factors 
allowing cells to grow indefinitely (reviewed in Hanahan and Weinberg, 2000). 
Indeed, cancer cells often have mutation or deletion of P53 that contributes to 
resistance to apoptosis. For example, a study has shown that mutations in the P53 gene 
results in reduced BAX mRNA expression and resistance to apoptosis mediated by the 
chemotherapy agent, cisplatin, in human ovarian cancer cells (Perego et al., 1996).  
 
1.1.4 Genome instability and mutation  
Acquisition of a multitude of hallmarks is dependent on the genetic changes in 
neoplastic cells. Particular mutations allow genetic advantage of subclones of cells, 
which enable their outgrowth and overpopulation in the tissue in the local environment 
(reviewed in Hanahan and Weinberg, 2011). Tumour progression can be depicted as a 
series of clonal expansions, each brought about by the random acquisition of a mutant 
genotype that provides a growth advantage (reviewed in Hanahan and Weinberg, 
2011). Cancer cells increase mutational burden by breaking down the genomic 
surveillance machinery which prevent cells from undergoing apoptosis when cells 
acquire DNA damage (reviewed in Hanahan and Weinberg, 2011): for example, 
mutations in the core DNA repair machinery i.e. BRCA1 which repairs DNA via non-
homologous end-joining and homologous recombination DNA repair pathways 
(reviewed in Gorodetska et al., 2019). A meta-analysis study found that women with 
a germline BRCA1 mutation have a 55% risk of developing breast cancer and a 39% 
risk of developing ovarian cancer by the time they are 70 (Chen et al., 2007).  
 
1.1.5 Inducing angiogenesis  
Angiogenesis is the formation of new blood vessels and is essential for maintaining 
tumour growth. Tumours alter the ratio of pro- and anti-angiogenic factors, a process 
termed the ‘angiogenic switch’ (reviewed in Baeriswyl and Christofori, 2009). Well 
established angiogenesis stimulators include vascular endothelial growth factor-A 
(VEGF-A) and thrombospondin-1 (TSP-1) (reviewed in Hanahan and Weinberg, 
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2011). Hypoxia is believed to be the main driver of angiogenesis, as drops in oxygen 
levels induce the activity of the transcription factor hypoxia-inducible factor 1-α (HIF-
1-α), which ultimately drives the expression of VEGF and its receptor (VEGFR) 
(reviewed in Nishida et al., 2006). Endothelial cells activated by VEGF produce matrix 
metalloproteases (MMPs) which break down the ECM allowing endothelial cells to 
migrate (reviewed in Nishida et al., 2006). The endothelial cells also divide into hollow 
tubes that can mature slowly into blood vessels (reviewed in Nishida et al., 2006). 
Furthermore, blood vessel formation allows tumour cells to break away from the 
tumour to spread to a different area of the body in a process called metastasis (reviewed 
in Nishida et al., 2006). 
 
1.1.6 Induction of invasion and metastasis  
Metastasis is responsible for approximately 90% of cancer-associated deaths 
(reviewed in Lambert et al., 2017). The dissemination of primary tumour cells to 
distant sites is termed the ‘invasion-metastasis cascade’ which is a process consisting 
of a multitude of steps (reviewed in Jiang et al., 2015). These include 1) acquisition of 
invasive potential, 2) accelerated growth and invasion of the basement membrane into 
surrounding tissues, 3) angiogenesis, blood and/or lymphatic vessel invasion and 
release into the circulation, followed by 4) colonisation and invasion of secondary sites 
and formation of micro- or marco-metastasis (reviewed in Jiang et al., 2015). A 
process called epithelial-mesenchymal transition (EMT) is associated with invasion 
and metastasis (reviewed in Fouad et al., 2017). EMT is a normal process utilised in 
wound healing and embryogenesis that is hijacked by cancer cells to allow loss of 
differentiated epithelial characteristics and acquisition of an undifferentiated, stem-
like mesenchymal phenotype (reviewed in Fouad et al., 2017). Cells that have 
undergone EMT are more invasive but it has been reported that EMT is non-essential 
for all steps of metastasis, yet may be important for chemoresistance (Fisher et al., 
2015). The EMT process is driven by a set of master transcription factors – SLUG, 
TWIST, SNAIL, ZEB1 (reviewed in Lambert et al., 2017). For example, TWIST1 
drives the expression of matrix metalloprotease 2 (MMP2) and its expression is 
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1.1.7 Tumour promoting inflammation 
The ‘seed and soil’ hypothesis was proposed by Paget in 1889, who suggested that 
cancer cell ‘seeds’ need the correct environment ‘soil’ to grow and metastasise.  As a 
tumour grows, it becomes deprived of oxygen and nutrients. Therefore, the tumour 
scavenges oxygen and nutrients by stimulating angiogenesis (reviewed in Balkwill, 
Capasso and Hagemann, 2012). Cancer cells can cause abnormal secretion of 
inflammatory mediators called cytokines, which kick start blood vessel formation and 
drive tumour growth by generating an immuno-suppressive environment to protect the 
tumour from attack by cytotoxic CD8+ T cells (reviewed in Jiang and Zhu, 2015). 
Thus, inflammation is key for cancer progression by creating an immunosuppressive 
tumour microenvironment (TME) which supports tumour growth. 
 
The TME is complex, comprised of non-malignant cells, stromal cells and a diverse 
range of immune cells (reviewed in Balkwill, Capasso and Hagemann, 2012). The 
immune populations in the TME include tumour-killing cells such as cytotoxic CD8+ 
memory T cells, natural (NK) killer cells and immuno-suppressive cells including 
CD4+ T helper cells, regulatory CD4+ T-cells (Treg) and tumour associated 
macrophages (TAMs) (reviewed in Balkwill, Capasso and Hagemann, 2012).  
Furthermore, there are dendritic cells which become damaged due to the hypoxic and 
inflammatory TME resulting in them not being able to stimulate an immune response 
to tumour-associated antigens (Tachibana et al., 2005).  Additionally, the TME is also 
comprised of non-malignant cells or stroma such as cancer associated fibroblasts 
(CAFs), vascular endothelial cells and pericytes, as well as ECM proteins (i.e. 
collagen, elastin and fibronectin) (reviewed in Balkwill, Capasso and Hagemann, 
2012). CAFs arise when fibroblasts become activated through wound healing and 
fibrosis, promoting the production of cytokines, chemokines and other immune 
modulators (reviewed in Bremnes, Capasso and Hagemann, 2011). CAFs inhibit 
tumour growth in the early stages of tumourigenesis, but promote tumour growth in 
the late stages of cancer (reviewed in Cirri and Chiarugi, 2011). The immune and non-
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1.1.8 Enabling replicative immortality  
As cells go through replication cycles, they often acquire mutations and stop dividing 
(senescence) (reviewed in Hanahan and Weinberg, 2000). Mechanistically this occurs 
because the ends of chromosomes (telomeres) contain thousands of repeats of a 6p 
sequence element (TTAGGG), which occurs because the eukaryotic DNA replication 
machinery cannot efficiently replicate the 3’ end of chromosomes during S phase 
(reviewed in Hanahan and Weinberg, 2000). As cells go through successive cell 
cycles, they lose their ability to protect the end of chromosome DNA and the 
TTAGGG nucleotide repeats reduce in size after each cell division due to the ‘end 
replication problem’ (reviewed in Hanahan and Weinberg, 2000). Telomeric DNA is 
maintained by the telomerase enzyme which adds hexanucleotide DNA repeats to the 
end of telemetric DNA, preventing cell senescence and enabling replicative mortality 
of cancer cells (reviewed in Shay, 2016). Telomerase is often upregulated in malignant 
cells and its importance for tumour growth is exemplified by studies showing that 
inhibition of telomerase perturbs growth in human breast and colon cancer cells (Hahn 
et al., 1999). 
 
1.1.9 Avoiding immune destruction  
Although tumour-killing CD8+ T cells enter the TME, a complex network of 
immunosuppressive cells and cytokines impair their tumour killing activity and lead 
to them becoming exhausted (reviewed in Jiang and Zhu, 2015). Exhausted T cells are 
characterized by the expression of a number of inhibitory cell surface receptors 
including programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte 
antigen-4 (CTLA-4), where binding of these receptors to their ligands perturbs T cell 
activity (reviewed in Jiang and Zhu, 2015). Tumours over-express the PD-1 receptor 
ligand, PD-1L, which is a predictor of poor prognosis (Gao et al., 2009). Thus, the PD-
L1/PD-1 axis is a key regulator of T cell exhaustion in cancer.  
 
CD8+ T cells are assisted in their tumour killing function by CD4+ T helper 1 cells, 
which are known to secrete interleukin-2 (IL-2) and interferon-gamma (IFN-). High 
numbers of CD8+ T cells correlate with good prognosis (Fridman et al., 2012). 
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Tumours can avoid immune destruction by inhibiting the activity of CD8+ T cells by 
attracting CD4+ FoxP3+ CD25+ T cells (Tregs) into the TME (reviewed in Vignali et 
al., 2008). Tregs are important for suppressing the immune system to prohibit aberrant 
inflammation preventing autoimmune and chronic inflammatory conditions, as well as 
suppressing the anti-tumour immune response (reviewed in Vignali et al., 2008). For 
example, Tregs can release inhibitory cytokines such as IL-10 and transforming 
growth factor β (TGF-β) which suppress the tumor killing activity of effector T cells 
(reviewed in Jiang and Zhu, 2015). Additionally, Tregs can be recruited to the tumour 
by the tumour stroma secreting the cytokine CXCL10, which leads to an 
immunosuppressive and pro-tumourigenic microenvironment (Lunardi et al., 2014). 
Thus, Tregs can be modulate CD8+ T cells by multiple mechanisms to promote an 
immunosuppressive TME. 
 
Further immune cells that contribute to avoiding immune destruction include tumour 
associated macrophages (TAMs) and myeloid-suppressor cells. TAMs are 
macrophages that collect in the TME and are stimulated to enter tumours by a number 
of chemical signals including M-CSF, CCL2, VEGF and angiopoietin-2 (reviewed in 
Jiang and Zhu, 2015). The latter recruits blood monocytes which travel through tumour 
vessels and encourage polarisation of macrophages into the TME (reviewed in Jiang 
and Zhu, 2015). TAMs are pro-tumourigenic and are correlated with poor prognosis 
in patients (reviewed in Lewis and Pollard, 2006). The build-up of myeloid-suppressor 
cells is an established mechanism of stimulating tumour formation by suppressing T 
cell activation and inducing T cell exhaustion (reviewed in Jiang and Zhu, 2015).  
 
Tumours can display a desmoplastic reaction that is characterised by a surplus of 
connective tissue surrounding an invasive tumour (reviewed in DeClerk, 2012). 
Desmoplasia is caused by an increased synthesis of ECM proteins, including collagen, 
secreted by cells such as myofibroblasts (reviewed in Barksy et al., 1984). It is 
believed that this provides a barrier for CD8+ T cell infiltration, prohibiting anti-
tumour immune responses (Jiang et al., 2016). Thus, the immune cells and ECM in 
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1.1.10 Evading growth suppressors  
In healthy cells there are many anti-proliferative signals that can stop unnecessary and 
uncontrolled proliferation which can lead to cancer. Anti-growth signals can cause 
proliferation block by being forced into the quiescent state (reviewed in Hanahan and 
Weinberg, 2000). In this state the proliferation cycle can be reactivated if a cell is 
stimulated by certain extracellular stimuli. The RB gene is often mutated in human 
cancer especially retinoblastoma, osteosarcoma and small cell lung cancer (SCLC) 
(reviewed in Engel et al., 2015) and is a key growth suppressor in its phosphorylated 
form (pRB). pRB perturbs proliferation by sequestration and modulation of the 
function of the E2F transcription factor which controls genes that regulate the G1 to S 
Figure 1.1 | The hallmarks of cancer. Tumours use a multitude of 
mechanisms to survive including resisting cell death, enabling 
replicative mortality, inducing invasion/metastasis, evasion of 
growth suppressors, induction of angiogenesis and sustainment of 
proliferative advantage. Emerging hallmarks of cancer include 
establishing tumour-promoting inflammation and aversions of 
immune destruction. Dysregulated epigenetics and genome 
instability can drive these pro-tumour processes. Figure from 
Hanahan and Weinberg, 2011.   
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phase of the cell cycle (reviewed in Hanahan and Weinberg, 2000). Another example, 
is P53 which can stimulate G1 arrest by regulating the expression of P21, that is known 
to inhibit cyclin E-CDK2 (reviewed in Harris and Levine, 2005).  Cyclin E-CDK2 
modulates the ability of the RB protein to repress E2F1 activity and this promotes the 
transcription of genes involved in preparation of the cell to progress from G1 to S phase 
of the cell cycle (reviewed in Harris and Levine, 2005).  
 
1.2 Targeting cancer  
For reasons mentioned above, cancer is a complex disease that is difficult to treat due 
to the heterogeneity of tumours (consisting of a complex mixture of stromal and cancer 
cells), acquisition of drug resistance mechanisms and the requirement for combination 
therapies that may target non-cancer cell components of the tumour (reviewed in 
Hanahan and Weinberg, 2011). Radiotherapy and surgery are ultimately the most 
effective treatments. Whether a patient gets surgery depends on the stage of their 
cancer, whether it has metastasised, their general health and the location of the tumour 
(Cancerresearchuk.org, 2019a). Surgery involves the excision of the tumour and is 
often used in combination with radiotherapy or chemotherapy (reviewed in Wyld, 
Audisio and Poston, 2015). Radiotherapy uses ionising radiation that can directly kill 
cancer cells or result in genetic changes in the cell that leads to cell death. Although 
there is some damage to healthy tissues, cancer cells do not repair themselves as 
efficiently after radiation damage as healthy cells (reviewed in Baskar et al., 2012). 
There are different options for delivery of radiation to the tumour such as delivering it 
externally or in the form of radioactive capsules inserted near the tumour site 
(reviewed in Baskar et al., 2012). There are also different types of radiation beams 
used including x-rays, gamma rays, electron beams, or proton beam therapies 
(reviewed in Baskar et al., 2012). Proton beam therapy has received much attention 
and promise as a superior form of radiation therapy as it can deliver more targeted high 
energy particles to the tumour site, with minimal damage of surrounding tissue 
(reviewed in Tian et al., 2018).  
 
However, radiation or surgery may not eradicate the tumour, especially in the case of 
late stage tumours. In such cases, systemic treatments might be required alone or in 
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combination with radiotherapy or surgery. Chemotherapy is the most common 
systemic treatment for cancer and most work in a similar manner (reviewed in 
Palumbo et al., 2013). Its success is based on the fact that cancer cells have a higher 
mitotic rate and constant requirement for nutrients compared to non-malignant cells 
(reviewed in Palumbo et al., 2013). These drugs are often non-specific so can kill 
healthy cells as well as cancer cells and therefore have a number of toxic side effects 
that may be difficult to manage (e.g. nausea, vomiting, hair loss, fatigue). Conventional 
chemotherapeutics include alkylating agents (e.g. cisplatin, oxaplatin), antimetabolics 
(e.g. methodextrate, fluorourcil), anti-tumour antibiotics (e.g. doxorubicin, 
bleomycin), topoisomerase inhibitors (e.g. etoposide) and microtubule stabilizers (e.g. 
paclitaxel, docetaxel) (reviewed in Palumbo et al., 2013). However, chemotherapy and 
many new cancer therapies can exhibit problems with intrinsic (i.e. characteristics 
already present in the tumours that confer resistance to drug prior to treatment) and 
acquired resistance (i.e. resistance to a drug that develops during treatment).  There are 
many mechanisms by which resistance can occur, including mutations in genes 
controlling apoptosis (i.e. P53), activation of molecules downstream of the target 
molecules, and activation of proteins on the plasma membrane that control efflux of 
chemicals from the cell (reviewed in Choi, 2005). 
 
Although conventional chemotherapy generally can be successful, some patients do 
not respond to cytotoxic drugs or refuse to take them due to the toxic side effects. New 
therapies are being increasingly developed that are more targeted, including those that 
target certain pathways dysregulated in cancer. These include drugs targeting the RAS-
RAF-MEK-MAPK pathway, which is a major pathway that mediates growth factor-
induced proliferation. The BRAF gene encodes an upstream effector kinase, and has 
an activating mutation in 60% of melanoma and a lower frequency of mutation in a 
number of different cancers (Davies et al., 2002). Since this discovery there has been 
much focus in designing inhibitors to target BRAF in melanoma, but this has 
unfortunately been met with problems of resistance due to re-activation of the MAPK 
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As previously described, inflammation is a key driver of cancer growth (see section 
1.1.7), and there has been much interest in manipulating the immune system in order 
to stimulate an anti-tumour immune response.  Cancer immunotherapies are a form of 
treatment that attempts to trigger the immune system’s own natural defences to fight 
cancer (reviewed in Mellaman et al., 2011). Immunotherapies can come in various 
forms including targeted antibodies, cancer vaccines, adoptive cell transfer and 
checkpoint inhibitors (reviewed in Mellaman et al., 2011).  
 
Adoptive cell therapy is where immune cells taken from the patients are engineered to 
stimulate anti-tumour activity of the T cells and then inserted into the patient (reviewed 
in Sharpe and Mount, 2015). For example, CAR T cell therapy is where T cells are 
genetically engineered to express chimeric antigen receptor (CAR), which combines 
antibody specificity with T-cell activator function (reviewed in Sharpe and Mount, 
2015). CARs are composed of an antigen-binding domain (usually directed to a protein 
on the tumour that is over expressed), an anchor to attach the CAR to the T cell and an 
internal signalling domain to mediate signal transduction into the T cells (reviewed in 
Sharpe and Mount, 2015). CD19 is expressed during B cell development and therefore 
is expressed in virtually all B-cell cancers and CAR targeting the CD19 protein on B 
cells is the most investigated CAR-T cell therapy thus far (reviewed in Maude et al., 
2015). CD19-CAR T cells have been reported to cause complete remission in 90% of 
acute lymphoblastic leukaemia patients in one ground-breaking study (Maude et al., 
2014). However, CD19-CAR T cell therapy causes patients to develop cytokine 
release syndrome (CRS) which is an inflammatory disorder caused by excessive 
release of cytokines (reviewed in Maude et al., 2015). This has been shown to be 
reversed with an anti-IL-6 receptor antibody tocilizumab in patients with severe side 
effects (Maude et al., 2014). 
 
The use of vaccines to prevent cancers of viral origin such as hepatitis B virus and 
human papillomavirus (HPV) have had considerable success (reviewed in Mellaman 
et al., 2011). However, developing therapeutic vaccines for existing cancers are more 
problematic for multiple reasons: cancer cells suppress the immune system; large 
tumours do not respond well to vaccines; when patients are old or sick they have a 
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weakened immune system (Cancer.net, 2018). There is one FDA approved therapeutic 
vaccine for prostate cancer, Sipuleucel-T, which is where antigen presenting cells 
(APCs) which stimulate the CD4+ helper T cell response and CD8+ T cells, are taken 
from the patient and incubated with a recombinant fusion protein containing prostatic 
acid phosphatase (PAP), which is commonly expressed on prostate tumours and 
granuloycte-macrophage colony stimulating factor (GM-CSF), an immune activator 
(reviewed in Anassi et al., 2011). This process activates the APCs and stimulates them 
to attack PAP-expressing prostate cancer cells when implanted back into the patients 
(reviewed in Anassi et al., 2011). Sipuleucel-T has been shown to prolong overall 
survival in patients with metastatic castration-resistant prostate cancer, with 
manageable side effects including chills, fever and headache (Kantoff et al., 2010).  
 
As previously described, tumours use multiple mechanisms to evade immune mediated 
tumour clearance such as expression of the PDL1 receptor on tumours which binds to 
the PD1 receptor in cancer killing T cells ‘exhausting’ the immune response. As 
previously mentioned, overexpression of PDL1 on tumours is a predictor of poor 
prognosis (Gao et al., 2009) and antibodies that target the PD1/PDL1 axis is a valid 
therapeutic option in cancer therapy (reviewed in Mellaman et al., 2011). Indeed, this 
therapy has been shown to induce tumour regression and stabilisation of a number of 
advanced cancers (Brahmer et al., 2012). Antibodies against the immune checkpoint 
molecule CTLA4, that is expressed on T cells, and when activated dampens down the 
immune response, has shown to improve overall survival in patients with metastatic 
melanoma (Hodi et al., 2010). Side effects of both medications were immune-related 
conditions that were reported to be manageable (Hodi et al., 2010, Brahmer et al., 
2012). That said, many cancers do not respond well to immuno-therapy such as 
pancreatic ductal adenocarcinoma (PDAC), which is at least in part cause by a strong 
‘desmoplastic reaction’ (see section 1.2.9) (Jiang et al., 2019). Thus, immunotherapy 
could potentially be an effective treatment for cancer with manageable side effects. 
However, much work will be required to understand the mechanism of resistance in 
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1.3 Introduction to FAK 
FAK is a non-receptor kinase that has been associated with almost all of the hallmarks 
of cancer and as such, in this next section I will focus on providing some background 
to the structure and function of FAK. Then I will proceed to present the data identifying 
FAK as a key regulator of cancer-related hallmarks.  
 
1.3.1 FAK discovery and early studies  
FAK is a ubiquitously expressed 125kD protein which was discovered in 1992 as a 
substrate of the viral SRC oncogene and as a highly tyrosine-phosphorylated protein 
that localised to cell adhesion sites called focal adhesions (Schaller et al., 1995). Focal 
adhesions are large macromolecular sub-cellular structures formed when the ECM 
contacts cell-adhesion molecule heterodimeric receptors called integrins (reviewed in 
Mitra et al., 2005). Integrins are a major family of plasma membrane receptors that 
consist of heterodimers of non-covalently associated single pass-type I transmembrane 
protein α and β subunits (Harburger and Calderwood, 2009). These cell adhesion 
receptors can sense the surrounding environment thereby providing information about 
the location, cell adhesion state and surrounding ECM molecules (outside-in 
signalling) or control the affinity for ECM ligands by changing the conformation of 
their extracellular domains (inside-out signalling) (reviewed in Hynes, 2002). Both 
modes of signalling require focal adhesion protein complex formation around the 
cytoplasmic tails of integrins to generate large macromolecular assemblies that can 
consist of over 100 proteins, and FAK is a crucial focal adhesion kinase component 
operating downstream of integrins (reviewed in Mitra et al., 2005).  
 
The first mouse model to study FAK function was made in 1995 by Ilic and colleagues 
who found that FAK-deficient mice generated by gene targeting died due to mesoderm 
defects during development. These embryos displayed reduced motility in vitro, which 
could explain developmental defects, as cell motility is important for embryonic 
development (Ilic et al., 1995). The mesodermal developmental defect could also be 
due to loss of FAK mediated suppression of P53-mediated apoptosis (Ilic et al., 1998).  
The FAK-deficient phenotype was very similar to that of a fibronectin-deficient 
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phenotype, suggesting that FAK is a key player in mediating fibronectin-integrin 
signalling at this stage of development (IIic et al., 1995).  
 
This work was followed by studies identifying that FAK binds to a number of focal 
adhesion complex proteins including talin (Chen et al., 1995), Paxillin (Hildebrand et 
al., 1995), HIC-5 (Nishiya et al., 2001), ezrin (Poullet et al., 2001) and p130CAS 
(Polte and Hanks, 1995). FAK has was shown to interact with kinases such as the p85 
regulatory subunit of phosphoinositide 3-kinase (PI3K), which was shown to be 
enhanced by stimulation with growth factors such as VEGF (Qi et al., 2001) and 
platelet derived growth factor (PDGF) (Chen and Guan, 1994). These findings along 
with other studies showing that FAK functions upstream of GRB2/RAS/MAPK 
signalling indicated a key role of FAK in growth factor signalling (Schlaepfer et al., 
1994). This work fuelled many structural and functional studies in the next two 
decades using advanced techniques such a proteomics, X-ray crystallography and 
fluorescence resonance energy transfer (FRET) to gain detailed mechanistic insight 
into the structure and function of FAK.  
 
1.3.2 Proteomics identified that FAK is a key component of 
integrin adhesion complexes (IACs) 
IACs are highly complex and dynamic structures that are functional links to the 
cytoskeleton and other cell compartments and cellular processes. The use of 
proteomics has been highly informative in determining the composition and core 
components of IACs (reviewed in Byron and Frame, 2016).  Proteomics is the study 
of the entire set of proteins expressed in a cell at a particular time. Interactome 
proteomics is the study of proteins binding to a target protein that uses antibodies that 
bind to the target protein, which allows purification of any potential interactors with 
the target protein. Furthermore, cells can be fractionated which allows the study of the 
interactome of a particular protein in a particular cell compartment (e.g. the nucleus). 
Bioinformatic analysis, using programs such as STRING or Ingenuity Pathway 
analysis (IPA) integrates a number of proteomics datasets to identify all known 
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Interactome proteomics is a very informative approach to study interaction partners 
and functions of a particular protein, but it can be difficult to determine the key 
components of these networks as many interactome data have combined interaction 
information from datasets performed under different conditions and cell types 
(reviewed in Byron, Humphries and Humphries, 2012). With this in mind, Horton et 
al., 2015 used bioinformatics to determine the common protein components in 5 
different IAC proteomic datasets to define the core components of IACs (Figure 
1.2A). This resulted in a consensus adhesome of 60 proteins, with 4 clear structural 
nodules – α-actinin-zyxin-VASP, talin-vinculin, FAK-paxillin and ILK-PINCH-
Kindlin (Horton et al., 2015, Figure 1.2B). Thus, integration of different proteomic 
Figure 1.2 | The consensus adhesome. A) Experimental design used by Horton et al., 
2015 in order to define the core IAC components and 4 nodules of the ‘consensus 
adhesome’ on the far right. B) Protein-protein interactions between core components of 
the consensus adhesome are scored based on experimental evidence of that interaction, 
indicated by the thickness of the lines. Thick black border indicates components of the 
consensus adhesome. Yellow nodes indicate proteins present in the consensus adhesome 
as defined in (Horton et al., 2015) that bind to actin, while white nodes indicate consensus 
adhesome components that do not bind actin. Actin (unlabelled yellow circles) is depicted 
for illustrative purposes but is not a component of the consensus adhesome. Arrow points 
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datasets has robustly identified that FAK is a key component of IACs and is temporally 
regulated in these complexes. 
 
1.3.3 FAK general structure 
FAKs structure facilitates its scaffolding, kinase and nuclear localisation, which in turn 
regulates physiological and cancer-associated processes. FAK is composed of a N-
terminal FERM (F for 4.1 protein, E for ezrin, R for radixin and M for moesin) domain, 
C-terminal focal adhesion targeting domain (FAT), three proline rich regions and a 
central kinase domain (reviewed in Frame et al., 2010, Figure 1.3). In this section, I 
will discuss the FAK structural domains individually with particular focus on key 
publications using advanced techniques such as fluorescence energy resonance energy 
transfer (FRET), NMR, and X-ray crystallography that were used to study the structure 




Figure 1.3 | FAK general structure. FAK consists of an N-terminal FERM domain, a 
central kinase domain and a C-terminal focal adhesion targeting (FAT) domain. It has a 
number of phosphorylation sites within its structure which regulate its binding to various 
protein partners as depicted in the figure. Kinase activation of FAK requires 
autophosphorylation site at tyrosine 397 (red). Proline rich regions (denoted as PRR) which 
bind to SRC homology 3 Domain (SH3)-domain containing proteins such as p130CAS are 
indicated. Regions of FAK where protein interaction partners bind are indicated.  
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1.3.4 FAT domain  
Early studies showed that the C-terminal portion of FAK is required for FAKs 
localisation at focal adhesions, while abolition of the N-terminal or FAK’s kinase 
activity had no effect on its focal adhesion localisation (Hildebrand et al., 1993). 
Crystallography and NMR studies showed that the FAT domain consists of 4 helices 
that form a right-turn elongated bundle that is stabilised by hydrophobic interactions 
(Lui et al., 2002a, Hayashi et al., 2002). This domain binds scaffolding proteins such 
as Paxillin, potentially targeting it to focal adhesions (Hidlebrand et al., 1995). It was 
shown by mutagenesis that Paxillin binding involves two hydrophobic patches on 
opposite faces of the bundle and the authors proposed a model in which two LD motifs 
of Paxillin adopt amphipathic helices that insert into the hydrophobic core of the FAT 
domain creating a six helix bundle (Hayashi et al., 2002). The FAT domain is regulated 
by phosphorylation of Y926 that binds the SH2 domain of GRB2 (Schlaepfer et al., 
1994). The solution structure showed it is not possible for GRB2 and Paxillin to bind 
at the same time as the binding SH2 (SRC homology 2) and leucine-aspartate repeat 
(LD) motifs overlap (Lui et al., 2002a). Therefore, GRB2 binding may cause release 
of FAK from focal adhesions, allowing it to participate in downstream signaling (Liu 
et al., 2002a). Interestingly, HIC-5 has been shown to bind FAK at Paxillin-binding 
motifs (Fujita et al., 1998) and further studies showed that HIC-5 inhibited integrin-
induced cell spreading on fibronectin by competitive binding of FAK binding with 
paxillin (Nishiya et al., 2001). This would prevent downstream integrin-mediated 
signal transduction and it is interesting to speculate whether this could modulate 
differential pathways that are not dependent on FAK-Paxillin binding.  
 
It has been controversial whether Paxillin actually recruits FAK to focal adhesions. 
FAK has been shown to bind to β-integrin tails (Schaller et al., 1995) but the validity 
of these findings in vivo has been questioned. FAK binds the integrin binding protein 
talin (Chen et al., 1995) and FAK is necessary for talin recruitment to nascent and 
spreading but not mature focal adhesions (Lawson et al., 2012). However, talin is 
required for FAK localisation to mature adhesions, suggesting that talin and FAK may 
be required for recruitment of each other to different focal adhesions under different 
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circumstances (Serrels and Frame, 2012). Thus, the protein partner that targets FAK 
to focal adhesions remains to be determined.  
 
The C-terminal of FAK can be expressed as a truncated FAK protein called FRNK, 
which acts as an endogenous inhibitor of FAK function by blocking focal adhesion 
formation on fibronectin (Richardson and Parsons, 1996). A study found that FRNK 
expression was restricted to the post-natal period but then decreased dramatically in 
adult smooth muscle cells (Taylor et al., 2001). Interestingly, FRNK expression was 
upregulated during balloon-induced carotid artery injury (Taylor et al., 2001). 
Together these results suggest expression of FRNK may be important in regulating 
vascular development and remodelling (Taylor et al., 2001).   
 
1.3.5 FERM domain  
Four-point-one ezrin radixin moesin (FERM) domains are present in a number of 
mammalian proteins (reviewed in Frame et al., 2010). The functions of FERM domain 
containing proteins suggest they link the plasma membrane with the cytoskeleton by 
direct protein binding or association with phosphoinositides (reviewed in Frame et al., 
2010). Structural and cell biology findings have made the FAK FERM domain one of 
the most well studied FERM domain containing proteins (reviewed in Frame et al., 
2010). It has been identified that the FERM domain of FAK contains three structural 
modules reminiscent of a clover leaf (denoted F1, F2 and F3) (Ceccarelli et al., 2006). 
The authors noted that the FERM domain of FAK is distantly related to other FERM 
proteins and the divergent structure may be indicative of a different function 
(Ceccarelli et al., 2006). Prior to this study, it was shown that FAK’s FERM domain 
could interact with the kinase domain of FAK and inhibit its function. The N-terminus 
of FAK acts in trans (intermolecular) to inhibit FAK phosphorylation when expressed 
in vivo or in vitro (Cooper et al., 2003). The FERM domain is essential for the 
regulation of FAK kinase activity (see below) but also has established roles as a 
scaffold in protein-protein interaction complexes (reviewed in Frame et al., 2010). It 
was shown that the FERM domain is likely important for growth factor signalling as 
it can bind the hepatocyte growth factor receptor MET, epidermal growth factor 
receptor (EGFR) and platelet derived growth factor receptor (PDGFR) (Chen et al., 
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2011). MET was shown to phosphorylate FAK on Y194, which was predicted to cause 
a conformational change in the FERM domain which disrupts the intramolecular 
inhibitory interaction between the FERM and kinase domain, leading to FAK 
activation (Chen et al., 2011).  
 
1.3.6 FAK kinase domain 
The FAK kinase structure has a bilobal structure (denoted the N-terminal and C-
terminal lobes) reminiscent of other protein kinases. The N- terminal lobe contains 5 
stranded anti-parallel β-sheets, while the larger C-terminal lobe is mostly α-helical and 
contains an activation loop (Nowakowski et al., 2002). When integrin and growth 
factor receptors are activated, FAK becomes rapidly phosphorylated at Y397, a site of 
autophosphorylation, enhancing its catalytic activity (Schaller et al., 1994). This 
creates a SH2 (Src homology 2) binding site for SRC (Calalb et al., 1995) and SRC 
then phosphorylates Y576 and Y577 and this stimulates maximal catalytic activity of 
FAK (reviewed in Mitra et al., 2005). Detailed structural insight into the mechanism 
by which FAK is regulated came from a study by Lietha and colleagues where they 
determined the mechanism by which FAK auto-regulates its kinase activity (Lietha et 
al., 2008). They determined the autoinhibited structure of the FAK FERM domain, 
kinase linker and kinase domain, finding that residues 567-573 in the activation loop 
extend near the FERM domain, partially blocking the catalytic cleft (Figure 1.4A). 
Furthermore, the FERM domain makes extensive interactions with the kinase C- lobe 
when FAK is autoinhibited impeding access to the catalytic active site and 
phosphorylation by the tyrosine kinase SRC (Figure 1.4A). Finally, it was found that 
the autophosphorylation of Y397 is inhibited, as the kinase linker region where it 
resides is incorporated into the β-sheet in the FERM domain (Figure 1.4A). They later 
found that in the structure of the active kinase that the activation loop is allowed free 
access to the active site (Lietha et al., 2008). Overlaying the active structure over the 
inactive structure of the kinase domain indicated that the pY576 in the phosphorylated 
activation loop collides with the FERM domain determined in the inactive FERM-
linker-kinase structure (Figure 1.4B). This suggests that the active form does not 
conform to the position of the FAK FERM domain in the inactive state and therefore 
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the FERM domain is not excluding the kinase domain in the active conformation 
(Lietha et al., 2008). 
 
Based on these findings, a model of FAK kinase autoinhibition and activation was 
proposed. Lietha and colleagues suggested that in the autoinhibited structure, the 
FERM domain blocks the FAK active site and sequesters the Y397 and activation loop 
(Figure 1.5, left). Then, an activating molecule which is thought to be a lipid (see 
below) binds to the F2 FERM domain and then disrupts the kinase domain interaction 
with the FERM domain (Figure 1.5, middle) (Lietha et al., 2008). Disassembly of the 
autoinhibited conformation allows FAK to autophosphorylate Y397, which then 
allows docking of the SRC kinase SH2 domain to the pY397 and SRC SH3 domain to 
the Proline rich (PxxP) in the linker regions (Lietha et al., 2008). SRC then 
phosphorylates Y576 and Y577 in the activation loop of FAK, thereby stimulating full 
catalytic activity (Figure 1.5, right) (Lietha et al., 2008). 
 
A 
Figure 1.4 | Structure of autoinhibited FAK. A) The structure of the 
autoinhibited kinase domain with FERM, linker and kinase regions in ribbon 
representation. The FERM domain (blue) binds the kinase domain (red). 
Main interaction is between the F2 FERM domain binds the kinase C-
domain. The Y397 of the kinase domain is located between the kinase N-
lobe and the FERM F1 lobe in the autoinhibited structure. Dashed lines 
indicate the disordered regions in the kinase linker. B) Overlay of inactive 
and active FAK kinase structures. The structure of the autoinhibited structure 
is depicted with the FERM domain in surface representation. The kinase and 
linker structures are in ribbon representation. The inactive and active kinase 
were imposed based on their C-lobe. The pY576 and A579 in the activated 
kinase are represented by space filling representation. Figures taken from 
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The SRC-FAK complex then phosphorylates and recruits a number of other signalling 
proteins including p130CAS, p85 regulatory subunit of PI3K and GRB2 (reviewed in 
Frame et al., 2010). FAK can be phosphorylated at many other sites including serine 
(722, 732, 843, 910) and tyrosine (397, 407, 576, 577, 861, 925) residues. However, it 
has been shown my mass spectrometry that there are an additional 25 uncharacterised 
phosphorylation sites (15 serine, 5 threonine and 5 tyrosine residues) in the FAK 
structure, suggesting there may be many more mechanisms of FAK regulation yet to 
be identified (Grigera et al., 2005).  
 
In a revolutionary study, Goni and colleagues used a combination of FRET and 
molecular dynamic simulation to study the link between integrin signalling and FAK 
activation. Their findings concluded that FAK interacts with phosphatidylinositol 4,5-
bisphosphate (PIP2) in a basic patch (KAKTLRK) in the FERM domain and binding 
of PIP2 mediates FAK autophosphorylation (Goni et al., 2014).  This work also showed 
by electron microscopy that addition of PIP2 induces FAK clustering, but mutation of 
the basic patch in the FERM domain perturbs cluster formation (Goni et al., 2014). 
Furthermore, FRET studies showed that PIP2 stimulates partial opening, while 
addition of SRC was required to induce full domain opening of the FAK FRET sensor 
(Goni et al., 2014). They proposed a model in which PIP2 levels generated by plasma 
membrane-recruited PIP5Kγ induces partial opening of the FAK structure exposing 
Figure 1.5 | Model of FAK kinase activation. On the left, the FERM domain blocks the 
active site of the kinase and sequesters the activation loop and Y397 phosphorylation 
sites. Lietha and colleagues believe the PxxP motif present in the linker binds to the F3 
lobe of the FERM domain, based on previous findings (Ceccarelli et al., 2006). An 
uncharacterised activating stimulus, later inidicated to be a lipid (Goni et al., 2014), is 
required to displace the FERM domain by competitive binding to the F2 FERM surface. 
FAK’s kinase autophophorylates Y397 and allows access for Src kinase to the linkers. 
Src then phosphorylates the Y576 and Y577 of the activation loop residues, which 
stimulates full catalytic activity of FAK kinase. Figure is based on the findings presented 




OMICs based identification of the mechanisms that underpin FAK’s  
regulation of gene expression  23 
the auto-phosphorylation site of FAK and allowing auto-phosphorylation. SRC then 
binds pY397 and phosphorylates Y576/Y577 in the activation loop that stimulates full 
FAK catalytic activation (Goni et al., 2014). The kinase domain is then released from 
the membrane clustered FERM domain (Goni et al., 2014).  
 
Despite these structural studies elucidating the mechanism of FAK activation very few 
substrates of FAK have been identified. However, FAK’s kinase activity is very 
important for its role in physiological and cancer-related processes and as such, FAK 
kinase inhibitors are in clinical trials (sees section 1.6.1). It is likely that based on the 
studies presented in Lietha et al., 2008 and Goni at al., 2014 that FAK’s kinase activity 
is required for a conformational change that differentially regulates its signalling 
functions and interaction with protein partners that can regulate key cancer processes.  
 
1.4 FAK conventional functions  
In this section, I will speak about FAK’s biological functions before proceeding to 
discussing its role in cancer.  
 
1.4.1 Motility  
FAK has been shown to be a key regulator of cell motility and this is controlled by 
various pathways (reviewed in Mitra et al., 2005). The best characterised is via the 
binding and phosphorylation of p130CAS by SRC/FAK (Cary et al., 1998). 
Phosphorylation of p130CAS allows it to associate with the adaptor protein CRK and 
this complex regulates membrane ruffling and cell migration by regulating DOCK180 
and the small GTPase RAC1 (Cho et al., 2000, Cheresh, 1999). FAK can also stimulate 
cell migration by binding PI3K (Reiske et al., 1999) and the adaptor molecular, GRB7 
(Han et al., 2000). Thus, FAK is a key signal integrator functioning downstream of 
integrins to regulate cell migration.  
 
Assembly and disassembly of actin-based structures such as lamellipodia and 
invadopodia require the Rho family of small guanosine triphosphatases (GTPase) such 
as RHOA, CDC42 and RAC1 (reviewed in Lawson and Ridley, 2018). FAK has been 
shown to suppress RHO activity in order to stimulate focal adhesion turnover (Ren et 
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al., 2000). FAK activates RHO GTPases by binding guanine nucleotide exchange 
factors (GEFs) such as p190RHOGEF (Zhai et al., 2003) and this interaction is 
important for regulation of focal adhesion formation during fibronectin-stimulated cell 
motility (Lim et al., 2008a). FAK also binds to GTPase activating proteins (GAPs), 
including GRAF which is a GAP for RHO and CDC42 (Hildebrand et al., 1996) and 
ASAP1 which is a GAP for the ARF subfamily of GTPases (Liu et al., 2002b). Thus, 
FAK is involved in the coupling regulation of RHO GTPases.  
 
FAK has been shown to be involved in formation of actin-based structures by directly 
binding to ARP2/3 to enhance ARP2/3 dependent actin polymerization, leading to 
lamellipodia formation (Serrels et al., 2007). Furthermore, FAK can phosphorylate N-
WASP, a CDC42 downstream effector, which allows its cytoplasmic translocation 
where it activates the ARP2/3 complex and facilitates actin polymerization at the 
leading edge of migrating cells (Wu et al., 2004). FAK can also stimulate directional 
migration by complexing with a scaffolding protein, RACK1 and c-AMP degrading 
phosphodiesterase PDE4D5 at nascent adhesions (Serrels et al., 2011). Thus, FAK is 
a key regulator of cell migration by binding to adaptor proteins and actin-regulators.  
 
1.4.2 Angiogenesis  
Cell-ECM adhesion promotes migration of endothelial cells (EC) at various stages of 
the angiogenic process (reviewed in Rizzo, 2004). FAK is important for EC migration 
in vitro and in vivo (Peng et al., 2004). It has been shown to do this by regulating the 
activity of VEGF which induces the formation of new blood vessels (Peng et al., 
2004). Studies have shown VEGF-induced activation of PI3K was dependent on FAK 
and this led to VEGF-A-induced migration of porcine aortic endothelial cells 
expressing VEGF receptor-2 (VEGFR-2) (Qi and Claesson-Welsh, 2001). 
Additionally, FAKs nuclear localisation (see section 1.4) and its kinase activity have 
shown to direct VEGFR2 gene transcription to regulate endothelial cell proliferation 
and migration (Sun et al., 2018). An additional regulator of angiogenesis, 
angiopoietin-1, has been shown to increase FAK phosphorylation during angiogenesis 
in vitro (Kim et al., 2000) and a SRC/FAK/integrin αvβ5 complex has been shown to 
be essential in VEGF-stimulated angiogenesis in vivo (Eliceiri et al., 2002). 
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1.4.3 Proliferation 
FAK has been linked to regulation of cell proliferation in many contexts (Zhao et al., 
1998, Lim et al., 2008b, Sun et al., 2018). FAK has been shown to regulate expression 
of cyclin D1 levels to promote G1 cell cycle progression (Zhao, Reiske and Guan, 
1998) by modulating the activities of key transcription factors. For example, 
FAK/integrin signalling regulates the binding of the transcription factor EtsB on the 
cyclin D1 promoter (Zhao, Pestell and Guan, 2001). Thus, FAK regulates proliferation, 
at least in part, by regulating transcription factor function to regulate the expression of 
genes involved in the regulation of proliferation, such as cyclin D1. 
 
1.5 FAK is overexpressed in cancer and is a key 
regulator of cancer-associated processes 
It is well established that FAK is highly expressed in a number of human tumours 
including squamous cell carcinoma (SCC) (Agochiya et al., 1999), breast and 
colorectal (Owens et al., 1995), PDAC (Jiang et al., 2016) and this can be through 
increases in gene copy number and/or protein expression (Sulzmaier et al., 2014, 
Agochiya et al., 1999).  FAK has also shown to drive tumourigenesis in vivo in various 
mouse models such as in breast (Lahlou et al., 2007), SCC (Maclean et al., 2004), and 
colorectal cancer (Ashton et al., 2010). Furthermore, increased FAK expression 
correlates with invasive potential (Owens et al., 1995) and poor patient outcome 
(Golubovskaya et al., 2014). As such, a large body of evidence supporting FAK’s 
importance in cancer has led to the initiation of several Phase I and Phase II clinical 
trials using FAK kinase inhibitors (see section 1.6).  
 
FAK has been shown to control and co-ordinate many cancer-associated cellular 
processes including cell invasion (Owens et al.,1995), cell proliferation and survival 
(Lim et al., 2008b), angiogenesis (Tavora et al., 2010), resisting apoptotic signals 
(Zhang et al., 2004) and avoiding immune destruction (Serrels et al., 2015). Hence, 
FAK is an important mediator of many cellular processes that are linked to the 
hallmarks of cancer. Therefore, I will describe each hallmark associated with FAK and 
the role of FAK in this hallmark in detail below.  
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1.5.1 FAK is a key regulator of invasion and metastasis   
Early studies identified that FAK expression was correlated with the invasive capacity 
of tumours (Owens et al., 1995), linking it to the cancer hallmark activating invasion 
and metastasis. Mechanistic studies have found that FAK regulates focal adhesion 
dynamic assembly and turnover to promote invasion in breast cancer by regulating the 
turnover of invadopodia which are actin rich cell membrane protrusions essential for 
invasion (Chan et al., 2009).  Studies have found expression of FRNK inhibits cell 
invasion in v-SRC-transformed NIH 3T3, which was shown largely to be due to a 
reduction in MMP2 expression and secretion (Hauck et al., 2002). This suggests the 
SRC-FAK signalling complex at focal adhesions regulates the expression of MMP2, 
and matrix degradation.  
 
EMT is a process linked to cancer cell invasion. One driver of this process called TGF-
β is a cytokine that induces the expression of the transcription factor SNAIL, which is 
important in EMT induction. TGF- β has also been shown to cause delocalisation and 
reduced expression of E-cadherin, an important component of adherens junctions, 
whose loss of at cell-cell junctions results in an invasive, mesenchymal-like cell 
phenotype, which is a characteristic marker of EMT (Cicchini et al., 2006). SRC-
dependent activation of FAK is required for TGF-β-induced induction of 
mesenchymal and invasiveness markers in hepatocytes (Cicchini et al., 2008). FAK 
may also mediate TGF-β-induced EMT via induction of the AKT pathway (Deng et 
al., 2010).  It has also been shown that FAK/PI3K/AKT signalling is required for EMT 
and resistance to the drug sorafenib in hepatocellular carcinoma cells (HCC) (Zhang 
et al., 2016). Together these results suggest that FAK is a regulator of EMT by 
signalling via SNAIL and the AKT pathway.    
 
The WNT pathway is also an important regulator of EMT and it is commonly 
dysregulated in cancer (reviewed in Beachy, Karhadkar and Berman, 2004). Studies 
have shown that upon APC loss in the mouse, intestinal expression of FAK is increased 
in a c-MYC-dependent manner and is required to activate downstream effectors of the 
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WNT pathway and AKT/mTOR signalling, showing that FAK is an important driver 
of intestinal tumourigenesis (Ashton et al., 2010). Further studies have found FAK can 
also regulate the WNT/β-catenin pathway and intestinal tumourigenesis by 
phosphorylating GSKβ, which prevents β-catenin proteolytic degradation, thus 
causing aberrant activation of the WNT pathway (Gao et al., 2015). Together the above 
studies suggest FAK is an important mediator of tumour initiation and invasion by 
regulating WNT signalling.  
 
In the case of solid epithelial cancers, metastasis is responsible for approximately 90% 
of cancer-associated deaths and cancer cell invasion into the basement membrane is 
an essential step in metastatic cancer progression (reviewed in Lambert et al., 2017). 
This process requires changes in the focal adhesion and cytoskeleton dynamics of 
tumour cells, as well as changes in the expression of MMPs, which facilitate invasion 
by degrading the ECM.  High FAK expression has been correlated with 
Figure 1.6 | FAK is required for multiple steps in the invasion-metastasis cascade. 
The dissemination of primary tumour cells to distant sites is termed the ‘invasion-
metastasis cascade’ which is a process consisting of a number of steps. These include 
acquisition of invasive potential, accelerated growth and invasion of the basement 
membrane into surrounding tissues, angiogenesis, blood and/or lymphatic vessel invasion 
and release into the circulation, followed by colonisation and invasion of secondary sites 
and formation of micro- or marco-metastasis (reviewed in Jiang et al., 2015). A process 
called epithelial-mesenchymal transition (EMT) is a process associated with increasing the 
invasive capacity of cancer cells. All steps marked by a star are stages of invasion that 




OMICs based identification of the mechanisms that underpin FAK’s  
regulation of gene expression  28 
lymphovascular invasion in breast cancer and correlated with poor patient prognosis 
and reduced survival (Golubovskaya et al., 2014). Indeed, integrin β1-FAK signalling 
is important for proliferation of mouse mammary carcinoma cells that have spread to 
the lungs (Shibue et al., 2009). FAK is also required for angiogenesis in tumours 
(Tavora et al., 2016), another key requirement for metastasis (see section 1.4.4). Thus, 
FAK is a key regulator of metastasis by regulating EMT, invasion, matrix degradation, 
entry into the blood/lymphatics system and proliferation at the secondary site as 
summarised in Figure 1.6.  
 
1.5.2 FAK is required for sustaining proliferation and 
resisting growth suppressors  
FAK is required for SCC tumour cell proliferation in the absence of integrin adhesions 
in 3D but not in 2D cultures (Serrels et al., 2012), suggesting that FAK is required for 
proliferation when cells have lost attachment to the ECM. Furthermore, FAK has also 
been shown to regulate proliferation in a SCC model via downregulation of a key 
inhibitor of proliferation, IGFBP3 (Canel et al., 2017), also linking it to the cancer 
hallmark ‘evading growth suppression’.  
 
1.5.3 Inducing (tumour) angiogenesis  
FAK regulates angiogenesis linking it to the cancer hallmark ‘inducing angiogenesis’. 
Deletion of FAK from ECs in vivo inhibited tumour growth and angiogenesis, thus 
suggesting EC FAK is essential for tumour angiogenesis (Tavora et al., 2016). 
Furthermore, FAK/GRB2/MAPK signalling is important in promoting tumour 
angiogenesis (Mitra et al., 2006). Thus, these findings implicate the importance of 
FAK signalling complexes in the regulation of angiogenesis in physiological and 
tumour contexts.  
 
1.5.4 Regulation of cancer stem cells (CSCs) 
FAK has been shown to regulate CSCs in the tumour microenvironment. CSCs are 
considered to be immortal and can sell-renew, differentiate and are capable of causing 
cancer recurrence (reviewed in Wang et al., 2015). Several reports have shown that 
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FAK plays a role in self-renewal and tumour-initiating abilities of CSCs (Kolev et al., 
2017, Luo et al., 2009a). Furthermore, it was shown that inhibition of FAK’s kinase 
activity with either the VS-4718 or VS-6063 FAK kinase inhibitors significantly 
reduced the population of CSCs in xenograft models of triple-negative breast cancer 
(Kolev et al., 2017). The WNT/β-catenin pathway is also implicated in stem cell 
renewal and regeneration (reviewed in Beachy, Karhadkar and Berman, 2004) and 
interestingly it was shown that a constitutively active form of β-catenin could reverse 
the targeting of CSCs by FAK inhibition, while deletion of FAK in vitro shows defects 
in self-renewal and migration (Kolev et al., 2017). Deletion of FAK in the mouse 
MMTV-PyMT breast cancer model in vivo reduces the population of CSCs in tumours, 
suppressing mammary tumourigenesis (Luo et al., 2009a). Together these data suggest 
that FAK can modulate stem cell function by the regulation of WNT/β-catenin 
signalling. 
 
1.5.5 Resistance to (programmed) cell death 
FAK has well documented anti-apoptosis functions in a number of cancers such as 
SCC (Zhang et al., 2004), leukemia (Sonoda et al., 2000), colon cancer (Golubovskaya 
et al., 2003) and glioblastoma (Sonoda et al., 1999), linking it to the hallmark ‘resisting 
cell death’. In particular, FAK has been shown to suppress anoikis (Zhang et al., 2004), 
where the cell undergoes apoptosis as a result of detachment between healthy cells and 
the underlying ECM (Frisch and Francis, 1994). This process is often disrupted in 
cancer and can lead to metastasis (reviewed in Hanahan and Weinberg, 2011). As 
mentioned above, FAK is required for proliferation of SCC cells in 3D but not 2D 
(Serrels et al., 2012). Additionally, FAK has been shown to suppress apoptosis of cells 
upon treatment with agents such as hydrogen peroxide (Sonoda et al., 1999) and the 
cytotoxic agents, etoposide (Sonoda et al., 2000) and staurosporine (Golubovskaya et 
al., 2003).  
 
Studies have found that FAK regulates cell survival by signalling through pathways 
such as the PI3K/AKT (Sonoda et al., 1999), P53 (Zhang et al., 2004) and MAPK 
(Subauste et al., 2004). Indeed, FAK has been shown to directly interact with key 
components of the aforementioned pathways such as the p85 regulatory subunit of 
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PI3K (Qi et al., 2001) and P53 (Golubovskaya et al., 2005, Lim et al., 2008b). 
Interestingly, in the case of P53, the N-terminal of FAK was shown to directly interact 
with the transactivation domain of P53 and this was associated with a reduction of the 
transcriptional activity of P53 (Golubovskaya et al., 2005). FAK can suppresses P53-
mediated apoptosis (IIic et al., 1998) most likely by directly affecting the 
transcriptional activity of P53.  
 
1.5.6 Avoiding immune destruction  
As previously described, the tumour microenvironment is the environment 
surrounding the tumour supporting growth, which is characterised by the presence of 
immune cells and non-malignant cells that support tumour growth (reviewed in 
Balkwill, Capasso and Hagemann, 2012). The cells of the TME are modulated by 
cytokines secreted by the tumour, fibroblasts and from immune cells populating the 
microenvironment. These cytokines include chemokines such as CCL5 and CXCL10 
that attract regulatory T cells and thereby generate an immunosuppressive TME 
(Lunardi et al., 2014, Wang et al., 2017). FAK regulates the expression these 
immunosuppressive chemokines in the tumour microenvironment (Serrels et al., 2015, 
see section 1.7), linking it to the cancer hallmark ‘avoiding immune destruction’. 
 
A subset of tumours display a desmoplastic reaction where there is a growth of fibrous 
tissue around the tumour, which can act as a barrier to cytotoxic T cell infiltration 
(Jiang et al., 2016). This is a characteristic of PDAC for example which has a 3% 5-
year survival rate (Cancer Research UK, 2019b). This makes these tumours very 
difficult to treat with immunotherapies, as evidenced by trials showing that these 
tumours are not generally responsive to anti-PD-1 and anti-CTL4 checkpoint blockage 
therapies (Kunk et al., 2016). Jiang and colleagues found that FAK activity correlates 
with enhanced fibrosis and low CD8+ T cell infiltration (Jiang et al., 2016). 
Furthermore, they found treatment with a FAK kinase inhibitor (VS-4718) limited 
tumour progression in the KPC mouse model, which is a mouse model of PDAC (Jiang 
et al., 2016). The perturbed tumour progression was associated with reduced tumour 
fibrosis and a reduction of immunosuppressive cells in the TME, rendering these 
tumours more responsive to T cell immunotherapy and PD-1 antagonists (Jiang et al., 
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2016). This suggests FAK is a key regulator of the TME by 1) influencing the 
expression and secretion of immuno-suppressive cytokines and chemokines and 2) 
creating a fibrotic TME, perturbing CD8+ T cell infiltration and immune-mediated 
anti-tumour effects.   
 
1.6 Nuclear FAK, a novel regulator of gene 
expression  
Next, I will discuss novel functions of FAK in the nucleus that have emerged recently 
and which is associated with a number of the hallmarks of cancer and is the focus of 
my PhD project.   
 
 
1.6.1 FAK binds to transcription factors in the nucleus to 
regulate gene expression  
To date, much of the research on FAK has focused on its role at focal adhesions, 
delineating its major functions in cell motility and cancer cell invasion. However, more 
than a decade ago, FAK was described to translocate to the nucleus in rat myocardium 
subjected to hypertonic stress (Yi et al., 2003). Since this initial observation, nuclear 
FAK has been shown to interact with a limited number of transcriptional regulators, 
which include P53 (Lim et al., 2008b), GATA4 (Lim et al., 2012), MBD2 (Luo et al., 
2009b) MEF2 (Cardoso et al., 2016), TAF9 (Serrels et al., 2015), IL33 (Serrels et al., 
2017), RUNX1 (Canel et al., 2017) and nucleophosmin (NS) (Tancioni et al., 2015). 
These nuclear interactions have been linked to regulation of proliferation (Lim et al., 
2008b, Canel et al., 2017), inflammation (Lim et al., 2012, Serrels et al., 2015), 
myoblast differentiation (Luo et al., 2009b) and tumour growth (Serrels et al., 2015, 
Tancioni et al., 2015). Thus, FAK seems to be able to regulate transcription of target 
genes by binding to transcription factors, yet, thus far, this has not been extensively 
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1.6.2 FAK translocates to the nucleus when cells are 
exposed to stress  
In 2008, it was shown that FAK contained a nuclear localisation sequence within its 
N-terminal FERM domain (Lim et al., 2008b) and a nuclear export sequence (NES) in 
its kinase domain (Ossovskaya et al., 2008). From the relatively small body of 
literature published on nuclear FAK it is evident that FAK translocates to the nucleus 
under conditions of cellular stress. For example, treatment of cells with cytotoxic 
agents like staurosporine (Lim et al., 2008b) or hydrogen peroxide (Luo et al., 2009b), 
cytokines like TNFα (Lim et al., 2012), or oncogenic transformation (Serrels et al., 
2015), have all been shown to increase the levels of nuclear FAK. Interestingly, other 
focal adhesion proteins including HIC-5 (Shibanuma et al., 2003) and Paxillin (Sathe 
et al., 2016) have also been shown to translocate to the nucleus in response to stress 
induced by hydrogen peroxide or disruption of focal adhesion dynamics, respectively. 
Additionally, the receptor tyrosine kinase PDGFRβ in response to platelet derived 
growth factor (PDGFBB) was shown to translocate to the nucleus to regulate 
chromatin remodeling and subsequent P21 expression (Papadopoulos et al., 2018). 
Together this suggests that nuclear 
translocation of FAK, and potentially focal 
adhesion components and receptors, could be 
a mechanism of signalling from the cell 
surface to the nucleus.   
 
Despite this interest in nuclear FAK function, 
the mechanism has not yet been determined 
by which FAK translocates to the nucleus. 
Furthermore, it is not known whether FAK 
kinase activity regulates its nuclear 
translocation. Recent studies have shown 
that FAK kinase activity stimulated by 
Myo1E binding to the FAK proline rich 
region 1 results in pY397 FAK enrichment in 
the nucleus in Myo1E-reconstitued cells 
Figure 1.7 | FAK-FERM domain is 
essential for FAK nuclear 
translocation. FAK WT SCC, FAK -/- 
SCC and FAK Δ355 SCC (FAK-FERM 
domain mutant) cells were 
fractionated and subjected to SDS-
PAGE analysis. Membrane was 
probed for FAK, PARP (nuclear 
marker) and GAPDH (cytoplasmic 
marker). N=nuclear fraction and 
C=cytoplasmic fraction. Courtesy of B. 
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(Heima et al., 2017). Additionally, nuclear FAK was reduced by treating cells with the 
FAK inhibitor PF-562271 and SRC nuclear levels were also decreased (Heima et al., 
2017). In contrast, it has been reported that FAK inhibition increases nuclear 
translocation (Lim et al., 2012). Further work from the Frame group has shown that 
FAK’s FERM domain is essential for nuclear translocation, as a FERM domain mutant 
resides within the cytoplasm (Figure 1.7). Whether FAK’s kinase activity regulates 
its nuclear translocation and the mechanism by which FAK translocates to the nucleus 
remains to be determined.  
 
1.6.3 Nuclear FAK regulates inflammation  
The first study showing that nuclear FAK regulates inflammation was by Lim and 
colleagues showing that nuclear FAK enhances GATA4 E3 ligase dependent 
degradation, perturbing VCAM1 expression and suppressing inflammation (Lim et al., 
2012, Figure 1.9A). This was followed by work from our laboratory and others that 
have highlighted the importance of FAK in regulation of the pro-tumorigenic 
microenvironment, linking nuclear FAK function to the cancer hallmark – avoiding 
immune destruction. For example, the Frame group recently showed a requirement for 
nuclear FAK in the transcriptional regulation of chemokines and cytokines required to 
support tumour growth through evasion of the anti-tumour immune response which 
will be discussed in more detail in section 1.7 (Serrels et al., 2015, Serrels et al., 2017, 
Figure 1.9B). Furthermore, work from the Kairbaan Hodivala-Dilke group 
demonstrated that endothelial-FAK is required for NF-κB mediated production of 
cytokines in response to DNA-damaging agents such as doxorubicin (Tavora et al., 
2014). This group also noted an increase in nuclear FAK levels under these conditions, 
but did not test directly whether nuclear FAK was mediating the chemokine response 
(personal communication, B. Serrels). Thus, FAK is important for the establishment 
of a pro-tumorigenic micro-environment, likely through transcriptional regulation of 
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1.6.4 Nuclear FAK regulates proliferation and apoptosis  
As previously described, P53 controls proliferation and apoptotic signals and thus is 
considered to be a tumour suppressor (reviewed in Hanahan and Weinberg, 2011). 
Early studies into nuclear FAK signalling suggested that FAK can translocate to the 
nucleus in response to the cytotoxic agent staurosporine and binds P53, enhancing P53 
degradation via the modulating the interaction between P53 and the E3 ubiquitin 
protein ligase, MDM2 (Lim et al., 2008b). This enhanced P53 degradation, results in 
increased proliferation and survival (Lim et al., 2008b, Figure 1.9C).  Recent data 
suggests that Merlin may mediate the interaction between the P53-FAK and MDM2-
P53 complex in mesothelioma cells (Ou et al, 2016). Additionally, FAK was also 
shown to regulate the nuclear localisation of enhancer of zeste homologue 2 (EZH2) 
and its tri-methylation activity on H3K27Me3 mark in hepatocellular carcinoma 
(HCC) to regulate proliferation and tumour growth (Gnani et al., 2017). Furthermore, 
Canel and colleagues showed that FAK suppresses the mRNA expression of the 
proliferation-inhibitor, IGFBP3, in SCC cells suppressing the transcriptional activity 
of RUNX1 by forming a repressive complex with SIN3A (Canel et al., 2017, Figure 
1.9D). Together these data link nuclear FAK to the cancer hallmarks ‘sustaining 
proliferative advantage and resisting cell death’. 
 
1.6.5 Nuclear FAK regulates angiogenesis  
Multiple studies have shown that FAK is important in the regulation of angiogenesis 
(see section 1.3.3 and 1.4.6) and nuclear FAK has recently been shown to be a key 
regulator of angiogenesis linking it to the cancer hallmark ‘inducing angiogenesis’. 
Vascular endothelial growth factor receptor 2 (VEGFR2) is a key regulator of 
angiogenesis as it can bind VEGF-C and VEGF-D to regulate blood vessel formation 
(Zhou et al., 2019), and FAK regulates VEGFR2 by associating with the RNA Pol II 
complex at the VEGFR2 promoter, resulting in stimulation of EC proliferation and 
migration (Sun et al., 2018). Thus, nuclear FAK is a key regulator of angiogenesis by 
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1.6.6 Nuclear FAK regulates muscle cell function  
As described in section 1.5.2, nuclear FAK translocates to the nucleus in rat 
myocardium subjected to hypertonic stress (Yi et al., 2003). Following on from this 
work, it was shown that nuclear FAK is a key regulator of muscle cells via complexing 
with transcriptional regulators (Luo et al., 2009b, Cardoso et al., 2016). Indeed, FAK 
accumulates in the nucleus in myotubes in response to hydrogen peroxide and binds 
MBD2 to regulate the expression of myogenin, a key regulator of muscle 
differentiation (Luo et al., 2009b). MBD2 is a component of the transcriptional 
repressor NuRD chromatin remodelling complex (Lai and Wade, 2011) and the 
authors proposed that FAK sequesters MDB2 thereby dissociating the NuRD complex, 
relieving transcriptional repression at the myogenin promoter (Luo et al., 2009b). 
Further studies showed that FAK binds to the transcription factor, myocyte enhancer 
factor-2 (MEF2) via the FAK-FAT domain, in response to mechanical stress in 
cardiomyocytes. ChIP experiments showed that the FAK:MEF2 complex was bound 
Figure 1.8 | Summary of nuclear FAK signalling pathways. FAK-regulates 
multiple transcription factors to regulate expression of a subset of genes. FAK also 
regulates the degradation of transcription factors such as C) P53 (Lim et al., 2008b) 
and A) GATA3 (Lim et al., 2012) by kinase-independent mechanisms. B) FAK 
regulates the anti-tumour immune response via kinase dependent mechanisms 
(Serrels et al., 2015, 2017); however it is not established whether FAK binding to IL33 
is kinase dependent or independent. Secondly it has not been determined the 
mechanism in which FAK regulates the expression of IL33. C) FAK enhances P53 
degradation by scaffolding P53 to the MDM2. D) FAK binds RUNX1 and SIN3A to 
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to the promoter of the stress responsive gene JUN to enhance its expression (Cardoso 
et al., 2016). Thus, FAK is a key regulator of muscle cell function by interacting with 
components of chromatin remodifying complexes and transcription factors. 
 
1.6.7 Role of FAKs kinase activity in the nucleus? 
Although, FAK has been proposed to bind a number of transcription factors in the 
nucleus, it has not yet been shown to phosphorylate any of these nuclear binding 
partners and therefore may primarily have an adaptor function in the nucleus (reviewed 
in Schoenherr et al., 2018). However, FAK kinase activity is important for its nuclear 
function as a regulator of gene expression in SCC cells (Serrels et al., 2015, see section 
1.7) and findings have indicated that when FAK kinase is activated, it has an 
alternative conformation (Lietha et al., 2008). Therefore, it remains possible that FAKs 
auto-inhibited conformation may be important for scaffolding functions in the nucleus 
as FAK kinase-independent interactions have been reported with key transcription 
factors (i.e. P53, Lim et al., 2008b). A summary of what is known of FAK’s role in 
the nucleus is presented in Figure 1.8. 
 
1.7 Targeting FAK in cancer  
As described above, both of FAK’s canonical adhesion and nuclear functions are 
relevant to the hallmarks of cancer. There has been much interest in targeting FAK in 
human cancer and as such clinical trials testing FAK inhibitors in cancer patients are 
ongoing. 
 
Many pharmaceutical companies have generated small molecule inhibitors of FAK 
which are ATP mimetics, and directly inhibit FAKs kinase activity (reviewed in Yoon 
et al., 2015).  There are a number of FAK inhibitors available to date including PF-
573,228, GSK2256098, VS-4718 and VS-6063 (reviewed in Yoon et al., 2015). 
Studies have shown that inhibition of FAK’s kinase activity is useful in reducing 
malignancy in a number of cancer cell lines and in vivo (Golubovskaya et al., 2003, 
Serrels et al., 2015). These in vitro and in vivo findings have stimulated the induction 
of a number of clinical trials many of which have been completed showing good 
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tolerability of FAK kinase inhibitors (clinicalTrials.gov, NCT01951690, 
NCT01138033, NCT00666926, NCT01905111, NCT01335269).  
 
Studies have tried to establish biomarkers that render tumours more sensitive to FAK 
inhibitor treatment. It was proposed that mesothelioma tumours that display loss of the 
tumour suppressor protein, merlin, have greater sensitivity to FAK inhibition by VS-
6063 (Shapiro et al., 2014). Merlin is involved in adherens junction maturation and 
therefore loss of merlin results in unstable cell-cell adhesions, rendering cells more 
dependent on FAK/integrin signalling (Shapiro et al., 2014). This study led to a phase 
II trial (clinicalTrials.gov, NCT01870609), combining cisplatin and VS-6063 in 
mesothelioma patients that display merlin loss. However, the study was terminated 
due to lack of efficacy of the drug.  
 
FAK kinase inhibition may not be effective as a monotherapy as it results in growth 
suppression rather than cell death. Indeed, it has been reported that FAK inhibition 
alone results in disease stabilisation rather than tumour regression (Soria et al., 2016). 
Furthermore, acquired resistance to FAK kinase inhibitors has been observed when 
treating PDAC mouse tumours (Jiang et al., 2019). Thus, targeting multiple pathways 
in addition to FAK signalling may be more effective in preventing resistance in 
tumours and providing more durable responses.  
 
Recent in vivo studies have identified that combinatorial therapies including FAK 
kinase inhibitors are showing promising results. For example, our laboratory has used 
a multi-parametric, high content phenotypic screening approach to determine 
compounds that enhance FAK inhibition (unpublished, J. Dawson). This led to the 
identification that HDAC inhibitors when combined with FAK kinase inhibition 
perturbed proliferation of a number of cancer cell lines (Unpublished, J. Dawson). 
Furthermore, a study by Hirata and colleagues showed in a mouse melanoma model, 
that the ERK/MAPK pathway is reactivated upon treatment with the BRAF inhibitor 
PLX4720, and this is linked to increased stromal density (Hirata et al., 2015). They 
found that the stromal cells, melanoma associated fibroblasts (MAFs), proximal to the 
cancer cells, remodel the matrix which reactivates the ERK/MAPK pathway through 
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the ß1-integrin-FAK-SRC pathway (Hirata et al., 2015). They showed that treating 
mice with a combination of PLX4720 and a FAK inhibitor resulted in a reduction in 
tumour volume in patient derived xenografts (Hirata et al., 2015). These findings 
suggested that this drug combination might benefit melanoma patients who have 
increased MAF infiltration, elevated fibrous ECM and activated SRC/FAK signalling 
(reviewed in Frame and Serrels, 2015). Trials are currently recruiting combining the 
dual RAF/MEK inhibitor, RO5126766 and the VS-6063 (clinicalTrials.gov, 
NCT03875820) in patients with non-small cell lung cancer (NSCLC). Furthermore, an 
active trial is ongoing combining the MEK inhibitor trametinib with GSK2256098 in 
patients with advanced pancreatic cancer to determine the anti-tumour effect of this 
drug combination (clinicalTrials.gov, NCT02428270).  
 
The findings that FAK kinase inhibition using the VS-4719 FAK inhibitor causes a 
reduction in Treg cells and an increase in CD8+ T cells in tumours (Serrels et al., 2015 
– see section 1.7.1) provides a strong rationale for a combination treatment of a FAK 
kinase inhibitor with anti-PD-1 or anti-PD-1L antibodies. Trials are currently ongoing 
combining FAK inhibitors (VS-6063) with anti-PD-1 antibodies in a number of 
cancers including breast and mesothelioma (clinicalTrials.gov, NCT02758587). 
Furthermore, a US Phase I trial is recruiting in patients who have advanced pancreatic 
tumours, where the FAK kinase inhibitor (VS-6063) is given in combination with both 
an anti-PD-1 antibody and the chemotherapeutic agent gemcitabine 
(clinicalTrials.gov, NCT02546531). Results from animal studies combining FAK 
kinase inhibitors, PD-1 antagonists and gemcitabine yielded very encouraging results 
(Jiang et al., 2016), and the results of all combination of FAK inhibitors with 
immunotherapy are eagerly awaited.   
 
As with all immunotherapy, and molecularly targeted therapies, it is difficult to predict 
which patients will benefit from combination of anti-PD-1 and FAK kinase inhibitor 
therapy combinations. However, work from our colleague Alan Serrels has identified 
tumours that express the co-stimulatory molecule CD80 are more receptive to 
inhibition of FAKs kinase activity using a FAK kinase inhibitor BI 853520 (personal 
communication, M. Frame). Furthermore, the authors identified that the co-expression 
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of CD80 and FAK preferentially occurs in cancer cell lines from patients with Burkitt’s 
lymphoma, chronic myeloid leukemia, diffuse large B-cell lymphoma and Hodgkin’s 
lymphoma. FAK inhibitors have not been tested in patients with these cancer types, 
but this work suggests that this could be an effective treatment for these patients 
(personal communication, M. Frame). 
 
1.8 Change in thought; FAK may primarily work via 
transcription and immune evasion  
As presented, it is clear that FAK is an important regulator of cancer. A number of 
findings from our laboratory has identified that FAK regulates gene expression in 
cancer cells via control of cytokines and chemokines that suppress the anti-tumour 
immune response (Serrels et al., 2015). Following work identified that FAK regulates 
the transcription factor IL33 to control the expression of immunosuppressive cytokines 
such as CCL5 (Serrels et al., 2017). IL33 is a nuclear and secreted cytokine (Lu et al., 
2016). In its secreted form it functions as an alarmin which is a molecule that is 
released from cells that have been injured or infected to stimulate an immune response 
(Lu et al., 2016). Secreted IL33 alerts immune cells that express its receptor ST2 and 
has been shown to be important for stimulating the CD8+ T cell response (Lu et al., 
2016). The function of IL33 in the nucleus is poorly defined. It has been shown to 
regulate the mRNA and protein expression of the transcription factor NF-κB P65 
subunit by binding to the P65 promoter and this is associated with the expression of 
the NF-κB-target genes, ICAM1 and VCAM1 (Choi et al., 2012). The finding that 
IL33 functions downstream of FAK in the regulation of immunosuppressive cytokines 
suggested a potential mechanism in which nuclear FAK signalling regulates the anti-
tumour immune response (Serrels et al., 2017). Furthermore, our laboratory found that 
FAK regulates the transcription factor RUNX1 to regulate proliferation by suppressing 
the expression of IGFBP3 mRNA (Canel et al., 2017). This work further added to 
knowledge on the mechanism by which nuclear FAK signalling can regulate cancer-
associated functions.  In the following section, I will describe the findings published 
in these papers, as these form the basis for my PhD project. This will be followed by 
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the aims of my PhD project. Firstly, I will describe the cell lines used in these studies 
and my thesis.  
 
Our laboratory deleted FAK in SCC cells using a Cre-Lox recombination system in 
2012 (described in materials and methods). SCCs were induced in K14CreER 
FAKflox/flox FVB mice by performing the dimethylbenz[a]anthracene/12-O-
tetradecanoylphorbol 13-acetate two-stage cutaneous chemical carcinogenesis 
protocol (McLean et al., 2004). SCCs were excised and cells isolated and cultured in 
the presence of 4-hydroxytamoxifen to induce FAK deletion (Serrels et al., 2012). 
FAK WT, FAK-nuclear localisation defective (FAK NLS) and FAK-kinase defective 
(FAK KD) proteins were re-expressed in the FAK -/- cell line using standard retroviral 
induction. A summary of the SCC cell lines used by our laboratory and in my thesis 
can be found in Table 1.1.  
 
1.8.1 FAK has been shown to translocate to the nucleus in 
response to cellular stress such as oncogenic 
transformation 
As described in section 1.5, FAK translocates to the nucleus in response to cellular 
stress such as treatment with cytotoxic agents (Lim et al., 2008b) or hydrogen peroxide 
(Cardoso et al., 2016), suggesting that nuclear FAK signalling could be a response to 
cellular stress. FAK is present in the nucleus of FAK WT SCC cells, whereas there 
was no detectable amount of FAK in the nuclear compartment of the normal 
keratinocytes from which SCCs are derived suggesting that nuclear FAK translocation 
is also regulated by oncogenic transformation. Nuclear FAK is important for tumour 
Table 1.1 | Mouse SCC cell lines generated by Frame group. SCC lines were 
previously generated (McLean et al., 2004, Serrels et al., 2012) as described in 
material and methods using a Cre-Lox recombination system. KD = Kinase-
defective, NLS = Nuclear localisation defective.  
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growth, as expression of a nuclear localisation impaired mutant of FAK (FAK NLS) 
results in tumour regression in syngeneic immune competent FVB mice (Serrels et al., 
2015). However, the mechanisms and physiological reasons by which FAK is 
translocated to the nucleus are yet to be defined.   
 
1.8.2 Nuclear FAK controls transcription of 
immunosuppressive cytokines and chemokines  
As mentioned our laboratory has found that nuclear FAK regulates the anti-tumour 
immune response via the transcriptional regulation of chemokines and cytokines 
(Serrels et al., 2015). Specifically, it was found that FAK is enriched in the chromatin 
fraction where it interacts with regulators of chemokine expression, such as the basal 
transcription factor complex component TAF9. Expression of CCL5 and other 
cytokines was shown to protect SCC tumours from immune destruction by CD8+ T 
cells in immune competent FVB mice via attraction of Tregs into the TME. The 
authors further identified a paracrine signalling axis between CCL5 and its receptors 
CCR1,2,3 in the FAK WT tumours and tumour infiltrating Tregs. Considering these 
findings, the authors proposed a model by which nuclear FAK regulates transcription 
of immunosuppressive chemokines (such as CCL5 and CXCL10) to promote tumour 
growth via interaction with transcriptional regulators such as TAF9 in the nucleus. 
This work had strong clinical implications as treatment of SCC tumours with the FAK 
kinase inhibitor VS-4718 resulted in a decrease of Treg infiltration into the tumour and 
complete tumour regression, which suggested that use of FAK inhibitors in clinical 
trials may promote immune-mediated tumour regression. It was not determined 
whether FAK kinase activity can regulate binding to these chromatin modifying 
complexes/transcriptional regulators and whether this was due to structural changes 
imposed by the kinase-activated FAK structural conformation (Serrels et al., 2015).   
 
1.8.3 FAK interacts with a network of chromatin modifiers 
and transcriptional regulators   
The mechanism by which FAK-dependent transcription factors regulate the anti-
tumour immune response was further investigated by performing FAK nuclear 
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proteomics identifying that FAK interacts with a complex network of transcription 
factors in the nucleus which included the nuclear cytokine IL33 (Serrels et al., 2015).  
 
Nuclear FAK was shown to control the expression of the cytokine IL33 by the 
interaction of transcription factors and transcriptional regulators (Serrels et al., 2017). 
Further, nuclear FAK and IL33 were confirmed to bind in the nucleus of SCC cells 
which regulates the expression of CCL5 and the IL33 soluble decoy receptor ST2 
(sST), through the interaction with transcription factors and transcriptional regulators. 
sST is the soluble form of the IL33 receptor which inhibits the activity of secreted 
IL33, and thereby perturbs immune responses mediated by secreted IL33 (reviewed in 
Milovanovic et al., 2012). The authors proposed a model based on their findings that 
FAK/IL33 regulated expression and secretion of sST and CCL5 into the TME results 
in suppression of the anti-tumour immune response by suppressing the activing of 
secreted IL33 and promoting Treg infiltration (Serrels et al., 2017).  
 
Further work provided insight into FAK’s role in the nucleus as a key regulator of 
transcription in cancer by the finding that nuclear FAK regulates the expression of the 
secreted protein IGFBP3, which was shown to be a negative regulator of the cell cycle 
and tumour growth in SCC tumours (Canel et al., 2017). Nuclear FAK was shown to 
bind to a transcription factor, RUNX1 which regulates IGFBP3 expression and a 
suppressor of RUNX1 transcriptional activity, SIN3A. Further investigation found that 
FAK controlled the nuclear levels of SIN3A expression and ultimately thereby 
controlled SIN3A interaction with RUNX1. The authors proposed a mechanism by 
which FAK regulates the expression of IGFBP3, namely by changing the 
transcriptional activity of RUNX1, which in turn regulated the cell cycle and tumour 
growth. This work showed that FAK can modulate transcriptional complexes in the 
nucleus to regulate the expression of growth suppressors to drive tumour growth 
(Canel et al., 2017). 
 
1.9 Aims  
These studies provided insight into the function of FAK in the nucleus and led to the 
hypothesis that FAK regulates transcription of particular genes by binding to 
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transcription factors and chromatin modifying complexes. Building on these 
hypotheses, I set out to investigate 1) FAK binding partners in the nucleus using 
proximal proteomics, 2) FAK-dependent transcription factor promoter/enhancer 
recruitment to chromatin and chromatin accessibility changes at particular genes by 
use of ATAC-seq and 3) to determine the FAK-dependent transcriptome in SCC cells 
using mRNA-seq. I then integrated these datasets in order to understand which 
transcription factors are responsible for FAK-dependent gene expression changes and 
the nuclear proteins that FAK binds which may scaffold to transcription factor 
complexes. By using these approaches, I aimed to gain increased information on the 
mechanisms by which FAK is regulating the expression of specific genes – in 
particular those associated with FAKs cancer-associated functions.  
 
The techniques I will use to tackle each of these aims are;  
 
1) Proximal proteomics to define novel FAK-binders in the nucleus. 
Specifically, I will use published protocols RIME (Mohammed et al., 2016) 
and BioID (Roux et al., 2013). RIME is a protocol that uses formaldehyde 
cross-linking to capture protein-protein complexes and protein-DNA 
complexes in the nucleus. It only captures interactions in close proximity to the 
protein of interest as formaldehyde has a short spacer arm of 2Å. BioID is a 
biochemical labelling approach in which a Biotin ligase tag (BirA*) is added 
to your protein of interest which biotinylates any protein in close proximity 
when biotin is added to cell culture media. All proteomics datasets will be 
generated using nuclear lysates to enrich for transcription factor complexes.  
 
2) ATAC-seq (Buenrostro et al., 2015) will be performed to define FAK, FAK 
kinase and FAK nuclear localisation dependent changes in transcription factor 
recruitment to chromatin and chromatin accessibility changes at gene 
promoters of interest. This protocol uses a hyperactive Tn5 transposase which 
digests only at open regions of chromatin, followed by seqeucing of the DNA 
within the exposed chromatin. Accessible regions determined by ATAC-seq 
display increased coverage at a particular region of the genome. The sequence 
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within the ATAC-seq peaks will be analysed and if it contains a motif sequence 
that a transcription factor is known to bind; the transcription factor which binds 
to that genomic region can be predicted. Any predicted FAK-dependent 
transcription factor binding changes will be determined by performing 
chromatin immunoprecipitation-PCR (ChIP-PCR), which utilises 
formaldehyde cross-linking to capture protein-DNA interactions. The DNA in 
which the protein is binding to can be analysed by qPCR by designing primers 
to capture the transcription factor motif on the genomic region of interest. This 
will confirm whether a transcription factor displays FAK-dependent binding to 
a particular genomic region either as a result of FAK-dependent chromatin 
accessibility changes in that region or FAK-regulated transcription factor 
recruitment. 
 
3) mRNA-seq will be used to determine FAK and FAK-kinase dependent genes 
programs. mRNA-seq is a widely used technique in which RNA samples are 
converted to cDNA and sequenced to analyse changes in transcript levels 
between different cell lines and conditions. This is building on previous 
microarray work presented in Serrels et al., 2015, which identified FAK-
dependent gene programs, but stopped short of identifying FAK kinase 














OMICs based identification of the mechanisms that underpin FAK’s  
regulation of gene expression  45 

































OMICs based identification of the mechanisms that underpin FAK’s  
regulation of gene expression  46 
2.1 Materials  
Table 2.1 Reagent list 
 
Reagent  Supplier  Cat. no. 
1 x MEM Gibco 11090081 
100x NEAA Sigma-Aldrich 6895 
Agencourt AMPure XP magnetic beads  Beckman Coulter  A63880 
Agilent High Sensitivity DNA Bioanalysis kit  Agilent 5067-4626 
Agilent Bioanalyzer RNA 6000 pico assay Agilent  5067-1513 
Amersham™ ECL™ Rainbow™ Marker - Full 
range 
Sigma-Aldrich GERPN800E 
Ampicillin sodium salt  Sigma-Aldrich A9518 
BamHI  New England Bio Labs 
(NEB) 
R0136S  
Biotin powder  Sigma-Aldrich  B4639 
Calcein  Invitrogen 1430 
cOmplete™ ULTRA Tablets, Mini, EASYpack 
Protease Inhibitor Cocktail  
Roche 5892970001 
DMEM, High Glucose Sigma-Aldrich D6429  
Dynabeads Protein A   Invitrogen 10001D 
Dynabeads Protein G beads  Invitrogen 10004D 
Hygromycin  Millipore 400052 
G418 Sigma-Aldrich A1720 
Growth Factor reduced Matrigel Corning 356231 
L-Glutamine 200mM Gibco 2503081 
Lipofectamine 2000 Qiagen  11668019 
Lipofectamine RNAiMax transfection reagent Thermo Fisher  13778030 
MEM vitamin solution  Sigma-Aldrich M6895 
 4–15% Mini-PROTEAN® TGX Stain-Free™ 
Protein Gels, 12 well, 20 µl 
Bio-Rad laboratories  456-1085 
Nextera DNA Flex Library Prep kit Illumina 20018703 
NotI  NEB  R0189S  
NEBNext High-Fidelity 2x PCR master mix  NEB  M0541 
One Shot™ MAX Efficiency™ DH5α-T1R 
Competent Cells 
Thermo Fisher Scientific 12297016 
Opti-MEM Reduced Serum Medium, GlutaMAX Thermo Fisher Scientific 51985026 
PhosSTOPTM  Roche 4906845001 
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Pierce BCA Protein Assay kit  Thermo Fisher Scientific 23225 
Pierce ECL Western blotting substrate  Thermo Fisher Scientific 32106 
Polybrene  Millipore 1003-G 
Proteinase K  Ambion AM2544 
Qiagen MinElute PCR purification kit  Qiagen  28004 
QIAGEN Plasmid Maxi kit  Qiagen  12162 
QIAquick Gel Extraction kit  Qiagen 28704 
QIAquick PCR purification kit  Qiagen  28104 
Qubit dsDNA HS Assay kit  Thermo Fisher Scientific  Q32851 
RNA-easy kit  Qiagen  74104 
RNaseA/T1 Ambion AM2286 
Sodium Pyruvate  Gibco 11360039 
Streptavidin MyOne C1 beads  Invitrogen 65002 
SuperScriptTM First-strand Synthesis System  Invitrogen 11904018 
SYBR Select Master Mix  Thermo Fisher scientific 4472908 
T4 DNA ligase New England Bio Labs  M0202S  
10x Tris/Glycine/SDS  Bio-Rad laboratories  1610772 
Trans-Blot® Turbo™ Midi Nitrocellulose Transfer 
Packs 
Bio-Rad laboratories 1704159 
 
Trypsin 0.05 % EDTA  Gibco 25300054 
Vectasheild Antifade mounting medium with DAPI Vector laboratories H1500 
 
Table 2.2 Buffers 
 
Buffer Composition  
RIPA  150 mM NaCl, 1% Triton X-100, 0.5% Sodium Deoxycholate, 
0.1% SDS, 50 mM Tris [pH 8] 
Cyto 10 mM Tris [pH 7.5], 0.05% NP-40, 3 mM MgCl2, 1 mM EGTA,  
MS Elution buffer 1 2 M Urea, 50 mM Tris-HCl [pH 7.5], Trypsin 1μg/μl 
MS Elution buffer 2 2 M Urea, 50 mM Tris-HCl [pH 7.5], 1 mM DTT 
ATAC-seq lysis buffer  10 mM Tris-HCl [pH 7.4], 10 mM NaCl, 3mM MgCl2, 0.1% 
IGEPAL CA-630 
ChiP lysis buffer  10 mM Tris-HCl [pH 7.5], 10 mM NaCl, 0.5% NP-40 
ChIP 1xRIPA 150 mM NaCl 50 mM Tris-HCl [pH 8], 150 mM NaCl, 1 mM EDTA, 0.2% 
SDS, 0.2% Sodium Deoxycholate, 1% Triton X-100 
ChIP 1xRIPA 500 mM NaCl 50 mM Tris-HCl [pH 8], 500 mM NaCl, 1 mM EDTA, 0.2% 
SDS, 0.2% Sodium Deoxycholate, 1% Triton X-100 
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SDS lysis buffer  50 mM Tris-HCl [pH 7.5], 1% SDS, 10 mM EDTA 
ChIP dilution buffer  50 mM Tris-HCl [pH 7.5], 167 mM NaCl, 1.1% Triton X-100, 
0.11% Sodium Deoxycholate 
Tris-EDTA 10 mM Tris-HCl [pH 8], 1 mM EDTA [pH 8] 
ChIP direct elution buffer  10 mM Tris-HCl [pH 8], 300 mM NaCl, 5 mM EDTA [pH 8], 
0.5% SDS 
High salt solubilisation buffer  50 mM Tris-HCl [pH 8.0], 2.5 M NaCl, 0.05% NP-40 
Chromatin extraction buffer 
with NP40 
10 mM HEPES [pH 7.9], 10 mM KCl, 1.5 mM MgCl2, 0.34 M 
sucrose, 10% glycerol, 0.2% NP-40 
Chromatin extraction buffer 
without NP40 
10 mM HEPES [pH 7.9], 10 mM KCl, 1.5 mM MgCl2, 0.34 M 
sucrose, 10% glycerol 
No-Salt buffer  10 mM HEPES [pH 7.9], 3 mM EDTA, 0.2 mM EGTA 




Table 2.3 Antibody list 
 
Antibody Supplier Cat. no. WB  ChIP  IP  IF 
JUN CST 9165 1/1000 0.48 
μg 
N/A N/A 
JUNB CST 3753 1/1000 N/A N/A N/A 





CST 3283 1/1000 N/A N/A N/A 
FAK BD 610087 1/1000 N/A N/A N/A 
HIC-5  BD 611165 1/1000 N/A N/A N/A 
Paxillin  CST 2542 1/1000 N/A N/A N/A 
WWOX Abcam ab137726 1/2000 N/A N/A N/A 
LPP CST 33895 1/1000 N/A N/A N/A 
GAPDH CST 5174 1/1000 N/A N/A N/A 
Histone H3 CST 4499 1/1000 N/A N/A N/A 
Streptavidin-
HRP 




Invitrogen  A-11094 N/A N/A N/A 1/200 
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Streptavidin 
Fluor 488  


















CST 7044 1/5000 N/A N/A N/A 
 
Table 2.4 In-house designed primers 
mRNA/genomic 
region  
















Table 2.5 Pre-designed primers 
 
Product name mRNA  Supplier Catalogue no. 
Mm_Jun_1_SG QuantiTect 
Primer Assay 
JUN Qiagen  QT00296541 
 
 
OMICs based identification of the mechanisms that underpin FAK’s  
regulation of gene expression  50 
Mm_Junb_1_SG QuantiTect 
Primer Assay 
JUNB Qiagen QT00241892 
Mm_Sfrp1_1_SG QuantiTect 
Primer Assay  
SFRP1 Qiagen  QT00167153 
Mm_Wnt7b_vb.1_SG 
QuantiTect Primer Assay 
WNT7B Qiagen QT02416127 
 
Table 2.6 shRNA/siRNAs used for knockdown experiments 
 
siRNA/shRNA Cat. No. Supplier 
Non-targeting siRNA #2 D-001210-02-05 Dharmacon 
siGenome JUN set of 4 siRNAs MQ-043776-01-0002 Dharmacon 
siGenome JUN Smartpool M-043776-01-00005 Dharmacon 
TRC lentivoral pLKO.1 Empty vector  RHS4080 Dharmacon 
TRC lentiviral RBMS3 shRNA #1 (clone ID: 
TRCN0000096889) 
RMM3981-201814942 Dharmacon 




Table 2.7 Reference list for bioinformatics programs 
Program Reference  
Bcbio-next 
gen pipline 
Bcbio-nextgen.readthedocs.io. (2020). Pipelines — bcbio-nextgen 1.1.5 
documentation. [online] Available at: https://bcbio-
nextgen.readthedocs.io/en/latest/contents/pipelines.html  
[Accessed 10 Jan. 2020]. 
Diffbind Ross-Innes, C.S., Stark, R., Teschendorff, A.E., Holmes, K.A., Ali, H.R., 
Dunning, M.J., Brown, G.D., Gojis, O., Ellis, I.O., Green, A.R., Ali, S., Chin, 
S., Palmieri, C., Caldas, C., Carroll, J.S. (2012). “Differential oestrogen 
receptor binding is associated with clinical outcome in breast cancer.” Nature, 
481(7381), pp. 389-93 
ChIPseeker Yu, G., Wang, L., He, Q. (2015). ‘ChIPseeker: an R/Bioconductor package for 
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2.2 Methods  
2.2.1 Cell culture 
Extraction and generation of FAK SCC cell model is depicted in Serrels et al., 2012. 
SCC cells were induced in K14CreER FAKflox/flox in FVB mice using the 
dimethylbenz[a]anthracene/12-O-tetradecanoylphorbol 13-acetate two-stage 
cutaneous chemical carcinogenesis protocol. Cells were extracted and cultured with 4-
hydroxytamoxifen to induce FAK deletion. Standard Retroviral induction was used to 
stably express FAK WT and FAK mutant constructs with either a mutation in FAK’s 
kinase linker (FAK KD, K454R) or its nuclear localization sequence (FAK NLS, 
R177A/R178A/R190A/R191A/R216A/R218A) into a FAK -/- clone (further details 
of the retroviral transduction protocol can be found in Serrels et  al., 2012).  Cells 
expressing the FAK WT and FAK mutant constructs were maintained in 0.25 mg/ml 
Hygromycin. A schematic of the mutants used in this thesis can be found in Figure 
2.1. 
 
Figure 2.1 | Schematic of FAK mutants used in thesis. A) FAK 
kinase-dead) and B) FAK nuclear-localisation mutants were generated 
in Serrels et al., 2012 and Serrels et al., 2015 by site-directed 
mutagenesis.  A) The FAK KD mutant has a K454R mutation in its 
kinase domain linker region which ablates FAK kinase activity. B) The 
FAK NLS mutant contains mutations in multiple regions of FAK NLS in 
the FERM domain, which perturbs FAK translocation to the nucleus. 
Region of mutations are indicated by red stripes. 
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FAK WT SCC, FAK -/- SCC, FAK NLS SCC, FAK KD SCC, FAK WT BirA, FAK 
KD BirA*, HIC-5 BirA* FAK WT, HIC-5 BirA* FAK-/-, FAK-/- BirA* EV and FAK 
WT BirA* EV were grown in minimum essential media (1 x MEM) supplemented 
with 10% FBS, 1% MEM Vitamin solution, 1% MEM Non-essential amino acids, 1% 
Sodium Pyruvate, and 1% L-Glutamine (all from Gibco). Human embryonic kidney 
293T cells were maintained in DMEM, high glucose containing 10% FBS. Cells were 
cultured at 37oC in 5% Carbon Dioxide and passaged with trypsin 0.05% EDTA 
(Gibco) every other day. When setting up experiments, all cells were plated on a 10cm 
dish (Corning) except for when performing inverted invasion and immunofluorescence 
assays, in which cells were set up in 12 well plates (Corning).  
 
2.2.2 Generation of BirA* expressing lines  
HIC-5 was amplified using the following primers 
F:GCGGCCGCATGGAGGACCTGGATGCCCTGC and R: 
GGATCCTCAGCCGAAGAGCTTCAGGAAAGC in a standard PCR reaction  under 
the following cycling conditions: – 98 oC for 10 seconds, 30x (98 oC for 10 seconds, 
60 oC for 10 seconds and 72 oC for 4 minutes). For subcloning into pQXCIN-BirA*-
Myc vector, the PCR product was run on an agarose gel and gel purified used Qiagen 
Gel purification kit. The PCR product and pQXCIN-BirA*-Myc vector were digested 
with 1 μl of NotI, 1 μl BamHI, 5 μl of buffer 3.1 (all from NEB), made up to a total of 
20 μl with ddH20 and then incubated at 37 oC for 2 hours. The digests were then PCR 
purified using PCR purification kit (Qiagen). Then the PCR products were ligated into 
the digested pQCXIN-BirA*-Myc vector using T4 DNA ligase (NEB), before the 
ligation products being transformed into DH5α competent cells (Thermo Fisher 
scientific) following manufacturer’s protocol. The bacteria were then plated onto 
ampicillin plates and incubated overnight at 37 oC. Colonies were then picked and 
grown in 5 ml of LB broth with 100 μg/ml ampicillin. After a diagnostic digest, the 
colonies which contained the HIC-5 insert were grown in 200 ml LB broth with 100 
μg/ml ampicillin and the plasmids were purified using a MaxiPrep kit (Qiagen) 
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The BirA empty vector pQCXIN-BirA*-Myc or HIC-5 pQCXIN-BirA*-Myc were 
transfected into Phoenix Ecotropic cells using Lipofectamine 2000 (Thermo Fisher 
scientific) according to manufacturer’s guideline. Two days post transfection the 
medium was passed through a 0.45 μm Millex-AC filter (Millipore), before mixing the 
virus titre containing media and SCC MEM media 50% FBS with polybrene 
(Millipore) to reach a final concentration of 5 μg/ml. This was added to FAK WT and 
FAK -/- SCC cells and left for 24 hours, prior to selection using G418 (400 μg/ml). Dr 
N. McGivern generated the FAK WT BirA*, FAK KD BirA* and FAK -/- BirA* EV 
SCC lines in a manner identical to as described above. 
 
2.2.3 shRNA-mediated depletion of RBMS3 
To generate lentiviral particles for knockdown of RBMS3, human embryonic kidney 
293T cells were transfected with 2 μg of RBMS3 shRNA or pLKO.1 empty vector (all 
from Dharmacon, TRC lentiviral) using Lipofectamine 2000 (Thermo Fisher 
scientific), following the manufacturers protocol. Two days after transfection the 
medium was passed through a 0.45 μm Millex-AC filter (Millipore), before mixing the 
virus titre containing media and SCC MEM media 50% FBS with polybrene 
(Millipore) to reach a final concentration of 5 μg/ml. This mixture was added to FAK 
-/- SCC cells, which were left for 24 hours and cells were then selected using 
puromycin (2 μg/ml).  
 
2.2.4 siRNA-mediated depletion of JUN 
FAK WT SCC cells were plated so they would be 60 - 80% confluent the following 
day. JUN or non-targeting control siRNA (all from Dharmacon, siGenome) was mixed 
with 500 μl Opti-MEM Reduced Serum Medium with GlutaMAX to a final 
concentration of 33 μM. Then 12 μl of RNAiMax Lipofectamine reagent (Invitrogen) 
was combined with 500 μl of Opti-MEM Reduced Serum Medium, GlutaMAX and 
incubated at room temperature for 10 minutes, before being mixed with the 
siRNA/Opti-MEM Reduced Serum Medium with GlutaMAX mix and incubated for 
15 minutes. This mixture was then added to FAK WT SCC cells in 4 ml Opti-MEM 
Reduced Serum Medium with GlutaMAX and incubated for 24 hours at 37°C, prior to 
generating whole cell lysates or RNA extracts. 
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2.2.5 Whole cell lysate preparation 
To prepare whole cell lysates, cells washed in ice-cold PBS and were lysed in RIPA 
buffer (containing cOmplete Ultra protease and PhosSTOP phosphatase inhibitor 
cocktail tablets, both from Roche) and incubated on ice for 15 minutes, scraped and 
centrifuged at 4 °C maximum speed for 15 minutes to clear lysates. Samples were 
stored at -20 oC for future use. 
 
2.2.6 Biochemical fractionation  
For fractionation experiments, cytoplasmic fractions were prepared by lysing cells in 
Cyto buffer (containing cOmplete Ultra protease and PhosSTOP phosphatase inhibitor 
cocktail, both from Roche) for 5 minutes at 4 °C, collected and centrifuged at 1000g 
for 5 minutes at 4°C. Supernatant was collected as the cytoplasmic fraction and the 
nuclear pellet was washed in Cyto buffer, centrifuged at 1000g for 5 minutes at 4 °C. 
The pellet was resuspended in RIPA buffer (containing cOmplete Ultra protease and 
PhosSTOP phosphatase inhibitor cocktail, both from Roche), incubated for 15 minutes 
at 4°C, and cleared by centrifuging at maximum speed for 15 minutes at 4 °C. Nuclear 
lysates were stored at -20 oC for future use. 
 
2.2.7 Immunoprecipitation  
The protein concentration of FAK WT SCC and FAK -/- SCC nuclear lysates was 
quantified using micro BCA protein assay kit (Thermo Scientific) as per 
manufacturer’s instructions. 1 mg of nuclear lysates was used for 
immunoprecipitations experiments along with 2 µg of target antibody and the same 
amount of IgG. Immunoprecipitations were incubated overnight at 4 oC with rotation. 
The following day, the immunoprecipitation samples were washed 3x with RIPA and 
2x with PBS before being boiled in 20 µl of 2x Laemmli sample buffer for 10 minutes. 
The samples were then analysed by western blot analysis as described in this section.  
 
2.2.8 Western blotting  
Western blotting was performed using BioRAD system following manufacturer’s 
instructions. Protein concentration was determined using a micro BCA protein assay 
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kit (Thermo Fisher Scientific) as per manufacturer’s instructions. In summary, samples 
were prepared for immunoblotting by boiling lysates for 5 minutes in 10 µl of Laemmli 
sample buffer (2x). For protein lysates, between 5-40 µg was always loaded. 
Immunoprecipitations were prepared by boiling for 10 minutes in 20 µl of Laemmli 
sample buffer (2x), in which the whole volume was loaded into gel wells. One well 
was always loaded with 5 µl of Amersham™ ECL™ Rainbow™ Marker - Full range 
(Sigma-Aldrich) to determine the molecular weight of the protein bands of the samples 
during imaging. Samples were ran on 5-14% gradient MINI-protein gel (Bio-Rad 
laboratories) at 100 V for 50 minutes in a Mini-PROTEAN® Tetra Vertical 
Electrophoresis Cell (Bio-Rad laboratories). Then the gel was transferred to a 
nitrocellulose membrane using Trans-Blot® Turbo™ Midi Nitrocellulose Transfer 
Packs (Bio-Rad laboratories) in a Transblot turbo Bio-Rad Power Pack (Bio-Rad 
laboratories) following the manufactures instructions. Specifically, the transfer pack 
was placed in a Bio-Rand Power Pack and transferred at 25 V for 10 minutes. The 
membrane was then blocked in 5% BSA or 5% milk in PBS + 0.1% Tween for one 
hour, with shaking. The primary antibody was put on at the concentration specified in 
Table 2.3 for that particular antibody primary in 5% BSA or 5% Milk with 0.1% 
Tween, overnight at 4 oC with shaking. The following day the membranes were 
washed three times in PBS + 0.1% Tween, with 15 minutes incubation during washes. 
A mouse or rabbit secondary antibody was applied (dependent on the species of the 
primary antibody) in 1/5000 or 1/10000 dilution, respectively, in blocking buffer 
(same buffer used for primary antibody incubation). The blots were then washed three 
times with PBS + 0.1% Tween, with 15 minutes incubation during washes. The blots 
were then developed using Pierce ECL Western blotting substrate (Thermo Fisher 
Scientific) following the manufacturer’s instructions and blots were imaged using the 
Universal Hood 3 Bio-Rad Imager (Bio-Rad Laboratories). Chemiluminescence 
images were taken at various exposures dependent on the intensity of the antibody 
staining on the membrane. Additionally, a colourimetric image to visualise protein 
markers, which was then overlaid onto the chemiluminescence image to confirm the 
protein bands on the gel match the molecular weight of the protein of interest. 
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2.2.9 Rapid immunoprecipitation of endogenous proteins  
FAK WT and FAK -/- SCC cells were incubated in 1% Formaldehyde-supplemented 
1 x MEM for 8 minutes with gentle agitation before quenching in 0.2 M Glycine. Cells 
were then collected in PBS and fractionated in LB1, LB2 and LB3 buffers (buffer 
compositions can be found in Mohammed et al., 2016). Nuclei were sonicated with 
5x1 minutes pulses at high power with 2 minutes rest in between on ice using the 
Diagenode Biorupter (Diagenode). Lysates were cleared and FAK was 
immunoprecipitated using an anti-FAK 4.47 agarose conjugated antibody. After 
extensive washing (10x) in RIPA and 2x in 100 mM Ammonium Bicarbonate 
(AMBIC) solution, beads were snap frozen and submitted for LC-MS/MS analysis.  
 
2.2.10  Streptavidin pull down experiments using BirA* 
system 
FAK WT BirA*, FAK KD BirA* or FAK -/- BirA* EV SCC cells were incubated with 
50 µM Biotin overnight prior to lysis in RIPA buffer. For the nuclear interactome 
analysis, FAK WT BirA*, FAK KD BirA*, BirA* EV SCCs or HIC-5 BirA* FAK 
WT, HIC-5 BirA* FAK -/-, FAK-/-BirA EV control SCC cells were incubated with 
50 µM biotin prior to fractionation following the ‘Biochemical fractionation protocol’ 
outlined in this section. Whole cell lysate or nuclear lysate samples were sonicated 
using a Diagenode BioRuptor (Diagenode), 3x1 minute pulses at high power with 2 
minutes rest in between on ice and cleared by centrifugation at maximum speed for 15 
minutes at 4°C. Protein concentration was determined using a micro BCA kit and up 
to 2 mg of protein lysate was incubated with MyOne C1 Streptavidin Dynabeads beads 
(Life Technologies) overnight at 4oC with rotation. Beads were washed 3x in RIPA 
and 2x in PBS, snap frozen and submitted for LC-MS/MS analysis. For validation 
experiments the beads were washed 3x in RIPA and 2x in PBS and then boiled in 2x 
Laemmli sample buffer for 10 minutes before immunoblot analysis. 
 
2.2.11 Proteomics – In bead digestion  
In bead digestion of RIME and BirA* proteomic samples was performed by Dr N. 
Quinn (Dr A. Von Kriegsheim group, IGMM, University of Edinburgh). The prepared 
samples following the ‘RIME’ or ‘Streptavidin pull down experiments using BirA* 
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system’ protocol detailed in this chapter were subjected to in bead digestion for 
preparation MS analysis. First, the peptides were eluted from the beads by adding 60µl 
MS Elution buffer 1 (containing 1 μg/μl trypsin) to the beads, which were incubated 
on the thermomixer for 30 minutes at 27 oC. The samples were centrifuged at 14000 
rpm for 30 seconds at 4 oC and the supernatant was then transferred to a new Eppendorf 
tube. Then 25 µl of MS Elution buffer 2 was added to the sample before centrifuging 
at 14000 rpm at 4 oC for 30 seconds. The supernatant was then collected into a new 
tube and incubated overnight at 4 oC. The following day, 20 µl of 5 mg/ml 
iodoacetamide was added to the samples and then the samples were incubated in the 
dark for 30 minutes at room temperature. The digestion was stopped by adding 1 µl of 
100% Trifluoroacetic Acid to the samples. The C18 column was activated by loading 
30 µl of 80% Acetonitrile/Trifluoroacetic Acid 0.1% followed by 30 µl 0.1% 
Trifluoroacetic Acid. The sample was loaded onto the activated column, which was 
then washed 2x with 25 µl of 0.1% Trifluoroacetic Acid. The peptides were eluted 
with 25 µl of 0.1% Trifluoroacetic Acid into fresh tube and dried in a SpeedVac. The 
pellets were then resuspended in 12 µl of 0.1% TFA for MS analysis. MS analysis was 
performed in the Edinburgh Cancer Research Centre Proteomics facility using the Q 
Exactive Plus mass spectrometer (Thermo Fisher Scientific).  
 
Dr A. Bryon carried out the label-free quantification (LFQ) of mass spectrometry data 
(MS) using MaxQuant (v 1.5.7.4). Peptide lists were searched against the UniProt 
mouse database (downloaded on 5 July 2017) and the Andromeda search engine for 
common contaminants. Modification settings were – carbamidomethylation (fixed), 
methionine oxidation (variable), N-terminal glutamine cyclisation (variable) and 
protein N-terminal acetylation (variable). For BioID experiments, in addition to the 
aforementioned modification settings, had lysine biotinylation set as a variable 
modification (up to five modifications per peptide).  The minimum length of a peptide 
used for downstream analyses was seven amino acids and one peptide ratio or more 
was required for LFQ. Proteins that matched to common contaminants or to the 
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Statistical analysis was performed using Perseus (version 1.5.2.6) in which all the test 
vs control sample LFQ intensities were compared using two-tailed Student’s t-test or 
one-way ANOVA with multiple comparisons, depending on the number of groups to 
be compared. 
 
2.2.12 Immunofluorescence  
FAK WT BirA*, FAK KD BirA*, and FAK -/- BirA* EV SCC cells were plated on 
coverslips and left to adhere for 24 h prior to fixation in 3.7% formaldehyde in PBS. 
Coverslips were washed 3x in TBS, blocked in 5% BSA/PBS for 30 minutes, washed 
3x in PBS and incubated with primary antibody diluted in block overnight. Coverslips 
were then washed a further 3x in TBS, incubated with Streptavidin Alexa Fluor 488 
or anti-rabbit Alexa Fluor 488 (both from Invitrogen), diluted in block for 30 minutes, 
washed and mounted in Vectashield Antifade mounting medium with DAPI  (Vector 
laboratories).  Slides were imaged using an Olympus FV-1000 confocal microscope 
(Olympus). 
 
2.2.13 Assay for Transposase-Accessible chromatin 
using sequencing (ATAC-seq)  
For ATAC-seq sample preparation, 200,000 FAK WT, FAK -/-, FAK KD cells and 
100,000 FAK NLS SCC cells were harvested by trypsinisation and centrifuged at 600 
g at 4 oC for 5 minutes. The cell pellet was gently washed with 50 µl of PBS and 
centrifuged at 600 g for 5 minutes. The cell pellet was gently resuspended with ATAC-
seq lysis buffer and then centrifuged immediately for 10 minutes at 600 g. The 
supernatant was discarded and the transposition reaction set up using the Nextera DNA 
Flex library Prep kit (Illumina). Specifically, the reaction mix was set up using 25 µl 
of TD reaction buffer, 4.7 µl of 2x TDE1 in the FAK WT SCCs, FAK-/- and FAK KD 
SCCs or 2 µl of 1x TDE1 of FAK NLS, before making up the remainder of the reaction 
mixtures up to 50 µl with nuclease-free H20. The nuclei pellet was resuspended in the 
transposition reaction mix and incubated for 30 minutes on the Eppendorf thermal 
mixer, before purification using the Qiagen MinElute PCR purification kit (Qiagen) 
and DNA elution using 10 µl of buffer EB. PCR was then amplified using 10 µl 
transposed DNA, 10 µl nuclease free water, 2.5 µl of barcoded PCR primer 1, 25 µl of 
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barcoded PCR primer 2 and 25 µl of NEBNext High-Fidelity 2x PCR master mix 
(NEB). The following cycling conditions were used: 1x cycle (5 minutes at 72 oC, 30 
seconds at 98 oC), followed by 5x cycles (10 seconds at 98 oC, 30 seconds at 63 oC, 1 
minute at 72 oC). This was followed by a qPCR to determine the amount of cycles 
needed to amplify library. A qPCR was set up using 5 μl of previously amplified DNA, 
0.4 µM of barcode primer 1, 0.4 µM primer 2, 5 µl of 2x SYBR green and 5 µl of NEB 
PCR master mix (New England BioLabs). The following cycling conditions were used 
for the qPCR: 1x cycle 30 seconds at 98 oC, 20x cycles (98 oC for 10 seconds, 63 oC 
for 30 seconds and 1 minute at 72 oC.). In order to calculate the additional cycles 
numbers required, the linear Rn was plotted versus cycle number before determining 
the cycle number that corresponds to one-third of the maximum fluorescent intensity 
of each sample. Then the remaining 45 µl PCR reaction was PCR amplified following 
the cycling template as follows: 1x cycle 30 seconds at 98 oC followed by the N cycles 
of 10 seconds at 98 oC, 30 seconds at 63oC, 1 minute at 72 oC. The amplified library 
was then purified using Qiagen Minelute PCR purification kit (Qiagen) and DNA was 
eluted in 20 µl EB buffer.  
 
In order to remove large DNA fragments  Agencourt AMPure XP magnetic beads 
(Beckman Coulter) (0.55x of the sample volume) was mixed with the DNA sample 
and incubated for 5 minutes at room temperature. Then the samples were added to the 
magnetic stand and the supernatant was collected. In order to remove excess adapter 
sequences, Agencourt AMPure XP magnetic beads (1.25x of the sample volume) were 
incubated for 5 minutes with the DNA sample before being put on to the magnetic 
stand. When the sample went clear the supernatant was discarded and the beads were 
kept. The beads were then washed twice with 500 µl of 80% ethanol with a 1 minute 
incubation time. Then the ethanol was completely removed and the Eppendorf tubes 
were removed from the magnetic rack and resuspended in 23 µl of nuclease-free H20. 
The samples were then incubated for 1 minute before being put back on the magnetic 
stand and the eluted DNA from the beads was stored in DNA lo-binding Eppendorfs 
at 4 oC. The DNA samples were quantified using Qubit (Thermo Fisher Scientific) and 
run on the Agilent Bioanalyser 2100 (Agilent) following the manufacturer’s 
instructions. The deep sequencing was performed at the University of Glasgow’s 
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sequencing service by Dr M. Bailey using a HiSeq 4000 Paired-end sequencing was 
performed on all samples.  All read lengths were 100 bp.  
 
Dr R. Upstill-Goddard performed the adapter trimming and alignment of the ATAC-
seq data to the mus musculus reference genome mm10 using the bcbio-nextgen ATAC-
seq pipeline. The quality control was performed using FastQC and adapter sequences 
trimmed from sequencing reads using atropos. Furthermore, sequence alignment was 
performed using bowtie, while greylisting was performing using chipseq-greylist. 
Accessible regions (i.e. ATAC-seq peaks) were called from the BAM files using 
MACS2 (v. 2.1.1.20160309), implementing the following parameters: -B -broad -q 
0.05 –nomodel -shift -100 -extsize 200 -g 1.87e9. Details of read alignment and 
number of ATAC-seq peaks identified per sample are included in Table 2.8.  
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FAK -/-1 31.80% 1.94% 82.2 62.80% 131 44% 43153 
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Differentially accessible regions between the FAK WT and that of the FAK -/-, FAK 
NLS and KD SCCs were identified using the R/Bioconductor package DiffBind. 
Differential peak calling was performed for each pairwise comparison and 
significantly differential peaks were defined as those with a FDR (false discovery rate) 
equal or below 0.05. Default parameters were used which can be found at 
https://bioconductor.org/packages/release/bioc/manuals/DiffBind/man/DiffBind.pdf.  
 
Dr R. Upstill-Goddard performed the motif enrichment within differentially accessible 
ATAC-seq peaks (motif enrichment analysis)   using HOMER (v.5.9), which identifies 
motif binding sites (i.e. genomic regions that matches known transcription factor 
motifs) in the differentially accessible peaks. The default parameters were used for the 
motif enrichment analysis using HOMER (genome masked -mask, region size -200, 
motif length -12, mismatches -2, -p1, number of motifs to find –s 25).  
 
ATAC-seq peaks were assigned to genes using ChIPseeker, where each peak was 
assigned to the gene with the closest transcriptional start site (TSS). The parameters 
used for ChIPseeker were tssRegion=c(-500, 2000), annoDb = "org.Mm.eg.db", TxDb 
= TxDb.Mmusculus.UCSC.mm10.knownGene. 
 
2.2.14 Chromatin immunoprecipitation  
For chromatin immunoprecipitation experiments, 4x106 FAK WT SCC and FAK KD 
SCC cells were plated on 10cm dishes (Corning). The following day, the medium was 
aspirated and the cells were incubated for 5 minutes in 7 ml of 1% formaldehyde in 1x 
MEM (no supplements or FBS added). The formaldehyde containing medium was 
then aspirated and the cells were incubated for 5 minutes in 200 mM Glycine in 1x 
MEM (no supplements or FBS added). The cells were then washed with 10 ml of PBS 
prior to incubation for 10 minutes in 7 ml of ChIP lysis buffer with PhosSTOPTM and 
cOmplete™ ULTRA Tablets, Mini EASYpack Protease Inhibitor Cocktail tablets 
added (both from Roche). The cells were then scraped in 1 ml of ChIP lysis buffer and 
centrifuged at 3000 rpm for 3 minutes at 4 oC. The pellet was then resuspended in 100 
µl of SDS lysis buffer and 400 µl of ChIP dilution buffer. Samples were sonicated 
using the Diagenode BioRupter at high power for 10 minutes with 30 seconds on/off, 
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which causes shearing of DNA fragments to 1000-200 bp in optimisation studies. The 
samples were then centrifuged at 13000 rpm for 15 minutes at 4oC. The supernatant 
was collected in a new tube and 50 µl taken for an input sample. A mixture of 
Dynabeads Protein A (Invitrogen) and Protein G (Invitrogen) Dynabeads were washed 
three times with 500 µl of cold 1xRIPA 150mM NaCl with PhosSTOPTM and 
cOmplete™ ULTRA and Mini EASYpack Protease Inhibitor Cocktail tablets (both 
from Roche). Then 50 µl of the bead mixture was added to the sonicated lysate along 
with 0.48 µg of JUN antibody or equal amount of rabbit IgG (both from CST). The 
immunoprecipitations were incubated with rotation at 4 oC overnight. The following 
day the beads were put on a magnetic stand and washed with 1000 µl cold 1x RIPA 
150 mM NaCl with PhosSTOPTM and cOmplete™ ULTRA and Mini EASYpack 
Protease Inhibitor Cocktail tablets (both from Roche), 1000 µl of cold RIPA 500 mM 
NaCl and twice with cold Tris-EDTA (TE) buffer. On the last Tris-EDTA wash, the 
beads were transferred to a new tube, the TE buffer was removed and resuspended in 
200 µl of ChIP direct elution buffer. Then 150 µl 150 mM RIPA NaCl buffer and 8 µl 
of 10% SDS solution was added to the input sample. Both the input and 
immunoprecipitation samples were incubated overnight at 65 oC. The following day 
the input and immunoprecipitation samples were incubated with 2 µl of RNaseA/T1 
(Ambion) for 30 minutes at 37 oC. Then the input and immunoprecipitation samples 
were incubated with 5 µl of 10 mg/ml proteinase K (Ambion) for 1 hour at 55 oC. The 
DNA was then purified using the QIAquick PCR purification kit (Qiagen) following 
manufacturer’s instructions.  ChIP and input DNA were eluted in 30 µl EB and 
subjected to qPCR analysis using primers capturing the JUN motif region on the IL33 
enhancer and those direct against upstream of the IL33 enhancer with no known AP-1 
binding motif to correct for background binding. Left over DNA from FAK WT SCC 
lines ChIP input sample was used to generate a standard curve to check and normalise 
results to primer efficiencies. The ChIP-PCR data was analysed by the standard % 
input method.  
 
2.2.15 Chromatin extraction  
The chromatin extraction protocol was taken from McAndrew et al., 2016. Briefly, 
1.5x106 of FAK WT SCC and FAK -/- SCCs were plated on 10 cm dishes overnight. 
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The following day, the cells were washed twice with cold PBS prior to being harvested 
in 400 µl of Chromatin extraction buffer containing NP-40. The lysates were then 
centrifuged for 5 minutes at 6500 g and the nuclear pellet was washed with 400 µl with 
Chromatin extraction buffer without NP-40. The lysate was centrifuged for 5 minutes 
at 6500 g and the pellet was resuspended in 400 µl of No-salt buffer and was incubated 
with rotation at 4 oC for 30 minutes. Then the samples were centrifuged for 5 minutes 
at 6500g and the pellet resuspended with 160 µl of high salt solubilisation buffer and 
was incubated with rotation at 4 oC for 30 minutes before being centrifuged for 10 
minutes at 21000 g. Proteins were precipitated by adding 16 µl TCA. After incubating 
on ice for 15 minutes the samples were then centrifuged for 15 minutes at 21000 g and 
the resulting pellet was washed twice with 500 µl of ice cold acetone. The pellets were 
air-dried and resuspended in 20 µl of 2x Laemmli sample buffer.  
 
2.2.16 RNA extraction  
RNA extraction was performed using RNeasy Mini kit (Qiagen) following 
manufactures instructions. Cells were always collected in 350 µl of RLT buffer with 
0.1% β-mercaptoethanol added.  
 
2.2.17 cDNA synthesis  
cDNA synthesis was performed using the SuperScriptTM First-strand Synthesis System 
(Invitrogen) following the random hexamers protocol in the manufacturer’s 
instructions (1 µl of Random hexamers was used in step 1). 2-5 µg of RNA was 
converted to cDNA on an assumed 1:1 ratio.  
 
2.2.18 qRT-PCR and ChIP-qPCR 
qRT-PCR and ChIP-qPCR analysis was performed using SYBR green mastermix 
(Thermo Scientific) following manufacturer’s instructions. The reaction volume in 
each well was always a total of 10 µl and 10 µM of primers were used. The following 
cycling conditions were used: 98oC for 10 seconds, 30x (98 oC for 10 seconds, 60 oC 
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2.2.19 mRNA-sequencing (mRNA-seq) 
RNA was extracted from FAK WT, FAK -/-, FAK NLS and FAK KD SCC cells using 
RNA-easy kit (Qiagen) following manufacturer’s instructions, whereby 350μl of 
buffer RLT with 0.1% β-mercaptoethanol was used for the initial step of the protocol. 
To check the samples for purity, the samples were run on the Agilent 2100 Bioanalyser 
using the Bioanalyzer RNA 6000 pico assay (Agilent). Samples that achieved a RNA 
integrity number (RIN) of 8 or above were considered a suitable quality for 
sequencing. The RIN value obtained from each sample are listed in Table 2.9. 
 
Table 2.9 RIN values for mRNA-seq samples 
Sample RIN value 
FAK WT 1 9.6 
FAK WT 2 9.6 
FAK WT 3 9.7 
FAK -/- 1 9.7 
FAK -/- 2 9.6 
FAK -/- 3 9.7 
FAK KD 1 9.6 
FAK KD 2 9.7 
FAK KD 3 9.6 
 
The samples were then shipped to BGI Hong Kong for paired-end sequencing using 
the Illumina HiSeq4000. BGI prepared the RNA for sequencing using the TruSeq 
RNA Library Prep Kit v2 (Illumina) following Low Sample (LS) protocol. In short, 
the protocol consisted of purification and fragmentation of the mRNA, first and second 
strand cDNA synthesis, repairing and acetylation of the 3’ cDNA ends, adapter 
ligation, PCR amplification, validation using the Agilent 2100 DNA High Sensitivity 
kit (Agilent) and normalisation and pooling of libraries for sequencing. All read 
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Table 2.10 mRNA-seq general statistics 





 Q20(%) GC(%) 
FAK WT1 70.3 70.3 98.20% 50.90% 
FAK WT2 84.7 84.7 98.10% 51.00% 
FAK WT3  78.1 78.1 98.20% 50.80% 
FAK -/-1 75.9 75.9 98.10% 51.10% 
FAK -/-2 57.6 57.6 98.10% 51.00% 
FAK -/-3 72.9 72.9 98.00% 53.10% 
FAK KD1  77 77 97.10% 50.90% 
FAK KD2 75.5 75.5 98.20% 50.80% 
FAK KD3 78 78 98.00% 51.00% 
 
Alignment to the Mus musculus GRCm38 reference transcriptome was performed 
using the pseudoalignment software kallisto (v.043.1). Default parameters were used 
which can be located at https://pachterlab.github.io/kallisto/manual. Transcript 
abundance was summarised to gene level (EnsDb.Mmusculus.v,79) and imported into 
differential expression analysis package R package DESeq2 (2.1.24.0)  for analysis 
using the R package tximport (1.2.0). Genes which had zero read counts were removed 
prior to differential expression analysis.  
 
Differential expression analysis was performed using DESeq2 (2.1.24.0) using default 
parameters, where FAK WT vs FAK -/- SCC cells, as well as FAK WT vs FAK -/- 
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The Wald test was used for hypothesis testing in DESeq2 and all P-values were 
corrected for multiple testing using the Benjamini-Hochberg method. Transcripts 
which acquired a corrected P-values below 0.05 were considered statistically 
significant between cell lines tested in the differentially expression analysis. 
Furthermore, genes that also required a fold change of below or above – 1 (halved) or 
+1 (doubled) were taken for further gene ontology analysis using IPA as described in 
section 2.2.22 and hierarchical clustering analysis.  
 
For hierarchical clustering analysis (Figure 4.2), the differential expression data was 
first z-scored before performing Pearson correlation with an average-linkage matrix 
using Cluster 3 (v.1.59) and data was visualised in Java TreeView (v.1.1.6).  
 
2.2.20 Inverted invasion assays 
To prepare the invasion assays, 100 µl of growth-factor reduced Matrigel/PBS (1:1) 
mix was added inside a transwell (corning) which was inserted into a 12 -well plate 
(Corning) and incubated for 30 minutes at 37 oC. The plate was turned upside down 
and 4x104 FAK WT SCC, FAK -/-PLKO and the FAK -/- RBMS3 shRNA1-2 SCCs 
were placed on the bottom of the transwell, the bottom of the plate was carefully put 
on top and was incubated for 4 hours at 37 oC. The transwells were then washed three 
times in PBS. The transwells were transferred to a new 12-well plate (Corning) with 1 
ml of serum free MEM media (containing 1% MEM Vitamin solution, 1% MEM Non-
essential amino acids, 1% Sodium Pyruvate, and 1% L-Glutamine) at the bottom of 
the wells and 100 µl of complete SCC MEM media (with 10% FBS as the 
chemoattractant) inside the transwell. Following a 3 day incubation at 37 oC, 500µl of 
calcein/PBS (1:1000) was added to the bottom of the well and to the transwell. After 
a 1 hour incubation at 37 oC, the cells were imaged on an Olympus FV1000 confocal 
microscope (Olympus). Z-stack images were taken with 10 µm sections up to 260 µm 
of the matrigel and the % of total area of cells migrating beyond 80 µm through the 
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2.2.21 Network analysis 
Network analysis was performed using the Qiagen Ingenuity pathway analysis (IPA). 
In Chapter 3, the following parameters were used in all network construction unless 
otherwise stated: Database sources (Ingenuity expert information, BioGrid, InAct), 
direct interaction, experimentally observed, protein-protein, all species. In Chapter 5, 
the same settings as just described above were used except only mammalian 
interactions were shown and functional interactions (i.e. protein-DNA interactions) 
were also indicated in the network. All networks were exported in the program 
Cytoscape for final figure presentation.  
 
2.2.22 Functional annotation analysis  
Functional annotation analysis was performed either by using IPA and DAVID gene 
ontology (https://david.ncifcrf.gov/). For the IPA GO analysis the protein list as 
determined by MS was uploaded to the IPA software and a disease and functions core 
analysis was performed. For the DAVID gene ontology analysis, the protein list was 
uploaded to the functional annotation tool using the mus musculus as the background 
reference. All terms with a Benjamini-Hochberg corrected P-value above 0.05 was 
considered statistically significant.  
 
2.2.23 Statistical analysis  
Statistical analysis was performed using the GraphPad Prism 8 (GraphPad Software, 
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Chapter 3 FAK interacts with a network of 
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3.1 Introduction  
As described in the Introduction, nuclear FAK regulates expression of genes and is 
present in the chromatin fraction isolated from SCC cells (Serrels et al., 2015, Figure 
3.1). However, the mechanism by which FAK regulates gene expression has yet to be 
established. In order to investigate the function of FAK in the nucleus, I performed 
nuclear interactome proteomics in order to identify the range of interaction partners of 
FAK in the nucleus.  
 
Use of standard proteomic techniques has shown that FAK binds to a putative network 
of over 1500 proteins in the nucleus (Serrels et al., 2015). With such a large dataset, it 
is very difficult to identify true and direct interaction partners of FAK. In order to 
isolate interactions that are more likely to be direct in comparison to standard 
proteomics techniques, I used proximity-based proteomics approaches - biotin-ligase 
tagging (BioID) and rapid immunoprecipitation of endogenous proteins (RIME). In 
section 3.2.1, I follow-up a novel nuclear interaction partner of FAK, namely HIC-5, 
a protein that shuttles between the cytoplasm and the nucleus, which I detected in FAK 
nuclear proximity-based datasets. To determine the function of this novel FAK 
interaction partner in the nucleus, I also performed BioID proteomics to identify 














Figure 3.1 | FAK is present in 
the chromatin fraction. FAK WT 
SCC nuclei were digested with 
MNase and soluble chromatin ran 
on a sucrose step gradient. The 
DNA from each fraction was 
analysed by agarose gel 
electrophoresis. Fraction 7 
(indicated by arrow) is the 
chromatin containing fraction 
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3.2 Aims 
• To apply proximity-dependent proteomics approaches to define novel nuclear 
interaction partners of FAK. 
• To identify key interaction partners by integrating the proximity-based 
proteomics datasets with that of the nuclear FAK interactome from the same 
cells (published in Serrels et al., 2015).  
• To use proximity-dependent biotin labelling to investigate the potential nuclear 
function of a nuclear FAK interaction partner identified in my proteomics 
datasets, namely HIC-5. 
3.3 Results 
The aim of this section was to apply proteomics to identify FAK binding proteins in 
the nucleus. Specifically, I made use of two published protocols, RIME and BioID. 
These protocols have been selected as they are specifically designed for isolating 
proteins that are in close proximity with the target protein. In section 3.3.3, I will 
integrate these proximity-based proteomics datasets with the nuclear FAK interactome 
dataset (published in Serrels et al., 2015) to determine which are the most robust 
interaction partners of FAK in the nucleus.  
 
3.3.1 Application of RIME to identify FAK nuclear interacting 
proteins 
RIME is a recently developed proteomics protocol that uses some of the principles that 
underpin ChIP, e.g. formaldehyde cross-linking and sonication, to enrich for 
transcription factor protein complexes (Mohammed et al., 2016). The use of 
formaldehyde results in more efficient crosslinking of protein:DNA complexes, but 
also crosslinks protein:protein complexes within a space of 2Å. The cells are first 
fractionated to enrich for nuclear proteins. Furthermore, the samples are then sonicated 
which breaks apart residual non-crosslinked complexes and fragments chromatin, to 
ease the purification of protein complexes associated with DNA. The samples are then 
subjected to co-immunoprecipitation using an antibody directed against the target 
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protein and submitted for mass spectrometry (MS) analysis in order to define the range 
of proteins that are interacting with the target protein.  
 
Firstly, I applied RIME to identify FAK protein complexes in FAK WT cells and also 
performed RIME in the FAK -/- SCC cells to control for background binding. Three 
biological replicates of protein lysates extracted from FAK WT and FAK -/- cells were 
nuclear fractionated, formaldehyde cross-linked, sonicated and 
immunoprecipitation/mass spectrometry was performed following the published 
RIME protocol (Mohammed et al., 2016). Label-free quantification (LFQ) intensities 
identified by mass spectrometry in the FAK WT and the FAK -/- SCC lines were 
statistically compared using a two-tailed unpaired t-test, in which all Benjamini-
Hochberg corrected P-values below 0.05 were considered statistically significant. 
Benjamini-Hochberg correction controls for the fact that sometimes small P-values 
can be obtained by chance in large datasets, resulting in incorrect rejection of the null 
hypothesis. This analysis identified 398 proteins that were significantly enriched in the 
FAK WT SCC cells in comparison to the FAK -/- SCC cells (listed in Table A1), from 
now on denoted as the FAK RIME interactome dataset. With mass spectrometry 
datasets, there are many computational tools to understand how the proteins in datasets 
may interact physically or functionally. I have mainly used Ingenuity pathway analysis 
(IPA) for protein interaction network construction, which is a program that integrates 
a number of protein interaction databases. Due to the large size of the FAK RIME 
interactome dataset it was not possible to present the full network. Instead I present 
subnetworks of FAK’s ‘nearest neighbours’ (i.e. known direct interaction partners of 
FAK), which highlighted several known FAK protein interactions, e.g. SRC, paxillin 
and GRB2 (Mitra et al., 2005) (Figure 3.2A). Furthermore, filtering for 
‘transcriptional regulator’ in the FAK WT RIME dataset using IPA indicated there 
were a number of proteins associated with the regulation of transcription that FAK 
interacts with, including PFDN-1, MEG-3 and NAA15 (Figure 3.2B). However, the 
dataset did not reveal any known FAK:transcriptional regulator complexes (e.g. P53; 
Lim et al., 2008b). Next, I performed Gene Ontology (GO) enrichment analysis on the 
whole FAK RIME dataset in order to determine if any of the proteins identified are 
involved in any cancer processes known to be regulated by FAK. GO enrichment 
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analysis indicated that the nuclear FAK-associated proteins identified by RIME were 
involved in various cellular processes that FAK has been shown to regulate, including 
formation of the MAPKKK cascade (P < 0.00001), invasion of cells (P < 0.00001) and 
cell survival (P < 0.00001) (Figure 3.3A). The RIME protocol therefore identified 
many FAK-binding proteins involved in several FAK-regulated processes and 
identified 12 novel transcriptional regulators. 
 
A more in-depth analysis of the proteins in the entire dataset using GO enrichment 
analysis, demonstrated that a significant proportion of the proteins identified were 
enriched in the cytoskeleton (P < 0.00001) and the ribosome (P < 0.00001) (Figure 
3.3B). This suggests that the subcellular fractionation within the RIME protocol may 
not be efficient.  
 
To address this, I looked at nuclear fractions of cells obtained using the RIME protocol 
to determine if the fractionation protocol within the RIME protocol was working 
efficiently. This identified that treatment of FAK NLS SCC cells with 1% 
formaldehyde, as per the standard published RIME protocol, results in a high level of 
Figure 3.2 | RIME experiments pull down known direct interaction partners of 
FAK and novel interactions with proteins associated with transcription. FAK WT 
SCC and FAK -/- SCC cells were fractionated following the published RIME protocol 
(Mohammed et al., 2016). FAK immunoprecipitations were submitted for mass 
spectrometry analysis and data was filtered using IPA software to enrich for A) direct 
interaction partners of FAK and B) transcriptional regulators. Non-specific streptavidin 
binding was controlled by performing a two-tailed unpaired t-test between the FAK WT 
SCC from that of FAK -/- SCC cell line data. Network files were imported into 
Cytoscape for final figure presentation. A) All known direct protein-protein interactions 
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contamination of the known cytoplasmic protein glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) in the nuclear fraction (Figure 3.4, lane 5). Therefore, I 
hypothesised that reducing the formaldehyde concentrations might reduce this 
contamination, as monitored by blotting for GAPDH in the nuclear fraction.  
Treatment of FAK NLS SCC cells with a series of formaldehyde concentrations 
ranging from 0.2%-0.8% showed a higher amount of the nuclear protein Poly (ADP-
ribose) polymerase (PARP) when crosslinked with 0.2% formaldehyde and lower 
protein levels of the cytoplasmic protein GAPDH (Figure 3.4, first lane). However, 
there was still a visible amount of GAPDH present in the nuclear fractions, even at 
lower formaldehyde concentrations, suggesting that formaldehyde cross-linking 
significantly reduced the effectiveness of fractionation to purify nuclear proteins. 
Figure 3.3 | GO analysis of FAK RIME interactome dataset. A) 
Subcellular localisation analysis was carried out by performing a 
functional annotation clustering analysis using the DAVID GO 
database. B) Functional analysis was carried out by performing 
Disease and Functions core analysis using IPA software. The –
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3.3.2 Use of BioID to determine proximal nuclear FAK 
interactome 
A second approach that I used for the identification of nuclear FAK protein complexes 
was BioID. BioID is a technology designed for the identification of proteins in close 
proximity to the target protein, and it utilises biochemical labelling to “tag” interaction 
partners (Roux et al., 2013). The BioID technology uses a Bifunctional 
ligase/repressor (BirA) isolated from E.coli which is genetically engineered to have an 
active site mutation (R118G) that destabilises the retention of the activated biotin 
molecules (biotinyl-5’-AMP), named BirA* (Roux et al., 2013). When tagged to a 
target protein using standard cloning techniques, the BirA* enzyme can react with 
primary amines of proteins in close proximity to the target protein when the cells are 
incubated with biotin (Roux et al., 2013). FAK WT and FAK KD proteins that contain 
a BirA* tag at the C-terminus were expressed via a vector in FAK -/- SCC cells. 
Additionally, a vector expressing just the BirA* enzyme that is not tagged to a protein 
was expressed in the FAK -/- SCC cells to control for spontaneous biotinylation. 
Before performing any proteomics experiments, I first validated the constructs for use 
by checking multiple parameters, including phosphorylation, protein localisation and 
the ability to bind to known protein complexes, e.g. SRC, Paxillin.  
 
Figure 3.4 | Optimisation of RIME protocol to increase 
effectiveness of fractionation. FAK NLS samples were treated 
with a range of formaldehyde concentrations ranging from 0.2%-1%.  
Cells were fractionated following the published RIME protocol 
(Mohammed et al., 2016) and subjected to SDS-PAGE analysis. The 
blot was probed for PARP (upper panel) and GAPDH (lower panel) 
to determine the quality of nuclear fractionation. 
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To check that the BirA* tag did not disrupt the subcellular localisation of FAK, FAK 
WT BirA*, FAK KD BirA* and FAK -/- BirA* empty vector (EV) control cells were 
plated on coverslips and stained with an N-terminal FAK antibody, followed by an 
Alexa Fluor 488 secondary antibody. Another set of FAK WT BirA*, FAK KD BirA* 
and FAK -/- BirA* EV control cells were stained with a streptavidin Alexa Fluor 488 
antibody. If the BirA* tag does not disrupt the localisation of the FAK proteins, I 
would expect to see clear focal adhesion staining of FAK. As can be seen from Figure 
3.5, FAK WT and FAK KD BirA*-tagged proteins localise to focal adhesions. FAK 
is not detected in the nucleus of SCC cells, as it is not clustered by membrane lipids 
there and therefore is more difficult to detect by immunofluorescence (Figure 3.5). 
Yet biochemical fractionation does clearly show that FAK is present in the nucleus 
and increased levels of FAK have been exhibited in cancer (Serrels et al., 2015), as 
discussed in the introduction to this thesis. Another set of FAK WT BirA*, FAK KD 
BirA* and FAK -/- BirA* EV control cells were plated on coverslips and stained with 
a streptavidin Alexa Fluor 488 antibody. FAK WT BirA*- and FAK KD BirA*-
expressing cells were also plated onto coverslips and stained with the streptavidin 
Figure 3.5 | BirA* tagged FAK localises to focal adhesions. FAK WT BirA*, FAK 
KD BirA* and FAK -/- BirA* EV control cells were plated onto coverslips. For FAK 
staining, cells were stained with an N-terminal FAK antibody, while cells stained with 
Streptavidin were fed with biotin before staining with a Streptavidin Alexa Fluor 488 
antibody. Upper panel shows coverslips stained with N-terminal FAK antibody Alexa 
Fluor 488, while lower panel shows coverslips stained with Streptavidin Alexa Fluor 
488. Scale bar represents 15μm. Locations of focal adhesions are indicated by blue 
arrows. It must be noted that there are many more focal adhesions present in the FAK 
WT BirA* and FAK KD BirA* images and that arrows are simply used in this case to 
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Alexa Fluor 488 antibody, which showed all the proteins in the cells that are 
biotinylated by the FAK WT BirA* or FAK KD BirA* proteins (Figure 3.5). The 
FAK WT BirA* and the FAK KD BirA* predominantly biotinylated focal adhesion 
and cytoplasmic proteins (Figure 3.5). The FAK -/- BirA* empty vector cells were 
stained with the streptavidin Alexa Fluor 488, which indicated non-specific 
biotinylation carried out by the untagged-BirA* protein expressed in the FAK -/- cells. 
As described in the Introduction to this thesis, FAK autophosphorylates itself on Y397 
to regulate its binding to SRC and activate its full catalytic activity (reviewed in Frame 
et al., 2010). Western blotting with an anti-FAK-pY397 antibody demonstrated that 
the kinase activity of FAK also has the capacity to auto-phosphorylate in the presence 
of a BirA* tag (Figure 3.6). Analysis of well-established FAK protein complexes 
demonstrated that addition of a BirA* tag does not interfere with either N-terminal Src 
or C-terminal Paxillin protein interactions (Figure 3.7). Furthermore, as expected, the 
interaction of FAK with SRC was kinase dependent, whereas its interaction with 
Paxillin was not (Figure 3.7, reviewed in Mitra et al., 2005). Collectively, these results 
suggest that the addition of a 30kDa BirA* tag to the C-terminus of FAK does not 
disrupt its sub-cellular localisation, Y397 phosphorylation and protein partner binding.  
 
Building on these observations, we prepared three biological replicates of  biotinylated 
whole cell lysates extracted from FAK WT and FAK -/- cell lines for MS analysis. 
This was done to confirm that using the BirA* system, expected FAK complexes are 
identified to validate the approach. LFQ intensities in the FAK WT BirA* and the 
FAK -/- BirA* EV control SCC lines were statistically compared using a two-tailed 
unpaired t-test, in which all P-values that are below 0.05 (without multiple testing 
Figure 3.6 | FAK WT BirA* is 
phosphorylated on Y397. Whole 
cell lysates from FAK WT BirA*, FAK 
KD BirA* and FAK -/- BirA* EV 
control cell lines were subjected to 
SDS-PAGE and probed for pY397 
FAK (upper panel) and FAK (lower 
panel). Dotted line indicates a 
sample in the middle of the blot was 
omitted due to lack of relevance. N=1 
Courtesy of B. Serrels 
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correction) were considered statistically significant.  This identified 57 significantly 
enriched proteins in the FAK WT BirA* dataset (listed in Table A2). MS analysis of 
whole cell lysates from FAK WT BirA* and FAK -/- BirA* EV control cells identified 
9 known FAK interacting proteins, including SRC, paxillin, CRK, ASAP1 and 
cortactin (Figure 3.8 – shown in pink). Furthermore, GO enrichment analysis of the 
reported localisation of proteins using DAVID GO analysis online software 
highlighted a significant overrepresentation of proteins associated with focal adhesions 
(P = 0.00144) and the cytoskeleton (P = 0.00104) (Figure 3.9A), subcellular locations 
at which FAK is known to be enriched. Additional GO analysis of the FAK BioID MS 
data using IPA indicated that identified proteins were implicated in processes known 
to be regulated by FAK, including cell spreading (P < 0.00001), invasion (P < 
0.00001), apoptosis (P = 0.000378), endocytosis (P = 0.00126) and formation of focal 
adhesions (P < 0.00001) (Figure 3.9B). 
 
To define the proximity-based nuclear interactome of the FAK WT BirA* cells, I 
generated three biological replicates of biotinylated nuclear lysates extracted from 
FAK WT and FAK -/- cell lines as described in Material and Methods. LFQ intensities 
Figure 3.7 | FAK-BirA binds to 
known focal adhesion proteins. 
FAK WT BirA*, FAK KD BirA*, and 
FAK -/- BirA* EV (control) SCC cell 
lines were treated overnight with 
biotin, before lysis. The resulting 
biotinylated proteins were captured 
using Streptavidin C1 Dynabeads 
magnetic beads, separated by SDS-
PAGE and probed for FAK (lower 
panel), SRC (upper panel) and 
paxillin (middle panel). Due to 
presence of the BirA tag, FAK 
molecular weight is approximately 
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in the FAK WT BirA* and the FAK -/- BirA* EV control cell lines were statistically 
compared using a two-tailed unpaired t-test, in which all Benjamini-Hochberg 
corrected P-values below 0.05 were considered statistically significant.  This identified 
42 significantly enriched proteins in the nuclear FAK WT BirA* dataset (listed in 
Table A3), denoted from now on as the nuclear FAK BioID interactome dataset. 
Interactome analysis using IPA suggested that FAK associates with a network of focal 
adhesion proteins in the nucleus, including HIC-5, SRC and GRB2 (focal adhesion 
proteins constituted 11% of the nuclear FAK WT BirA* dataset) (Figure 3.10). 
Additionally, 13 transcriptional regulators were identified as putative FAK nuclear 
interaction partners in this dataset, including LPP, WWOX and TOX4. To identify 
FAK-kinase dependent interactions, LFQ intensities were statistically compared 
between the FAK WT BirA* cells and FAK KD BirA* cells nuclear interactome 
datasets using a two-tailed unpaired t-test. All interactions which had corrected P-
values of 0.05 were considered statistically significant. We found that 13 potential 
FAK interactors were found to be significantly enriched in the FAK WT BirA* in 
comparison to the FAK KD BirA* SCC cell line (Figure 3.10 - pink and Figure 
3.11A-B), suggesting that these are FAK kinase-dependent. These include known 
kinase-dependent interactors, such as SRC, CRK and ASAP1, as well as 
transcriptional regulators such as TOX4 and WWOX. Novel kinase-dependent 
interactions included PRKCDBP and MURC. The caveolae-associated protein FLOT2 
was the only FAK interaction partner that was enriched in the FAK KD BirA* cells 
with respect to FAK WT BirA* (Figure 3.11A-B), suggesting this interaction may be 
specific in the auto-inhibited conformation.   
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To validate interaction partners in the nucleus that were identified in the FAK BioID 
interactome dataset, I performed streptavidin pulldowns using nuclear lysates from the 
FAK BioID cell lines, followed by western blotting. These showed that WWOX and 
LPP all bound to FAK KD BirA* and FAK WT BirA*, with only background binding 
in the FAK BirA* EV control cells (Figure 3.12A-B). Based on the MS analysis, 
WWOX is predicted to be a kinase-dependent interaction partner of nuclear FAK; 
however, the pulldown experiments analysed by western blotting showed that it bound 
to FAK independently of FAK’s kinase activity (Figure 3.12B).  
 
Figure 3.8 | Identification of FAK interactors in FAK WT BirA* SCC whole cell 
lysates using BioID. FAK WT BirA* and FAK -/- BirA* EV control cells were treated 
overnight with biotin before lysis. The resulting biotinylated proteins were isolated using 
Streptavidin C1 Dynabeads and submitted for MS analysis. Data was filtered using IPA 
software. Non-specific streptavidin binding was controlled by determining performing a 
two-tailed unpaired t-test between FAK WT BirA* data and FAK-/- BirA* EV datasets. 
Network files were imported into Cytoscape for final figure presentation. All known direct 
protein-protein interactions of FAK (red) as identified by mining BioGrid, InAct and 
Ingenuity Experit knowledge protein-protein interactions databases using IPA are 
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To determine the subcellular distribution of the FAK binders in this dataset, I analysed 
the FAK BioID interactome protein list using the DAVID database, which showed that 
the identified proteins were significantly enriched for proteins reported in focal 
adhesion complexes (P < 0.00001) and cell junctions (P < 0.00001) (Figure 3.13A). 
Although the search did not identify an enrichment of nuclear proteins, many of the 
focal adhesion proteins enriched in the ‘focal adhesion complexes’ term have dual 
roles in the cytoplasm and nucleus such as Paxillin (Sauthe et al., 2016) and HIC-5 
(Shibanuma et al., 2003). Furthermore, functional enrichment analysis in IPA 
indicated transcription was a significantly enriched term (P = 0.000234) (Figure 
Figure 3.9 | GO analysis of FAK WT BirA* whole cell lysate dataset. A) 
Subcellular localisation analysis was carried out by performing a functional 
annotation clustering analysis using the DAVID GO database. B) Functional 
analysis was carried out by performing Disease and Functions core analysis 
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3.13B), which was not the case in the FAK BioID interactome dataset prepared with 
whole lysates (Figure 3.9B). Proteins included under this term encompassed many 
focal adhesion proteins with known roles in transcription, such as HIC-5 (Chodankar 
et al., 2014, Li et al., 2011), as well as regulators of transcription which FAK has not 
been previously shown to bind, such as WWOX (Gaudio et al., 2008). Findings from 
the functional enrichment analysis indicated these FAK nuclear interaction proteins 
are implicated in a number of FAK-regulated processes including endocytosis (P = 
0.00728) and anoikis of tumour cell lines (P = 0.00225). Thus, the BioID approach has 
Figure 3.10 | Identification of FAK interactors in FAK WT BirA* SCC nuclear 
lysates using BioID. FAK WT BirA*, FAK KD BirA* and FAK -/- BirA* EV control cells 
were treated overnight with biotin before lysis. The resulting biotinylated proteins were 
isolated using Streptavidin C1 Dynabeads and submitted for MS analysis. Data was 
filtered using IPA software. Non-specific streptavidin binding was controlled by 
performing a two-tailed unpaired t-test between FAK WT BirA* data and FAK-/- BirA* 
EV datasets. Kinase-dependent interactions were determined performing a two-tailed 
unpaired t-test between FAK WT BirA* data and FAK-/- BirA* EV control datasets. 
Network files were imported into Cytoscape for final figure presentation. All novel 
kinase-dependent interactions of FAK (red), as identified by determining significantly 
enriched (via t-test, Benjamini-Hochberg P-value < 0.05) interaction partners in FAK 
WT BirA* over that of the FAK KD BirA* dataset, are coloured pink. Lines indicate 
protein-protein interactions. N=3 biological replicates. 
 
 
OMICs based identification of the mechanisms that underpin FAK’s  
regulation of gene expression  83 
successfully identified both known and novel proximal interaction partners of FAK in 
the sub-cellular nuclear fraction and some of these regulate transcription and other 






























Figure 3.12 | Validation of nuclear FAK WT BirA* interactors. FAK WT BirA*, 
FAK KD BirA*, and FAK -/- BirA* EV SCC cell lines were treated with biotin 
overnight, before nuclear fractionation. The resulting biotinylated proteins were 
captured using Streptavidin C1 Dynabeads magnetic beads, separated by SDS-
Page and probed for FAK and the nuclear marker PARP (lower panel) and A) LPP 
(upper panel) or B) WWOX (upper panel). Due to presence of the BirA* tag, FAK 
molecular weight is approximately 150kDa. N=1 
  
  
Figure 3.11 | Determination of kinase-dependent nuclear interactions of FAK. LFQ 
intensities between FAK WT BirA* and FAK KD BirA* dataset were tested for statistical 
significance using a one-way ANOVA test. A)  A heatmap of the normalised LFQ intensities 
of the FAK-kinase-dependent interactions in FAK WT BirA* and FAK KD BirA* replicates. 
Normalised LFQ intensities were standardised using the Z-score. Scale is 1.5 to -1.5, as 
indicated in the key. B) A volcano plot depicting the significance of the FAK WT BirA*/FAK 
KD BirA* analysis on the y-axis and the logarithm-transformed fold change of LFQ values 
from FAK WT BirA*/FAK KD BirA* (WT/KD) on the x-axis. N=3 biological replicates. 
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3.3.3 Common FAK nuclear interaction partners using 
different proteomic approaches 
 In order to identify robust interaction partners of FAK in the nucleus, I compared the 
proximity-dependent proteomics dataset with the nuclear FAK interactome dataset 
published in Serrels et al., 2015 (Figure 3.14). Due to the problems with fractionation 
Figure 3.13 | GO analysis of nuclear FAK WT BirA* dataset. A) 
Subcellular localisation analysis was carried out by performing a 
functional annotation clustering analysis using the DAVID GO 
database. B) Functional analysis was carried out by performing 
Disease and Functions core analysis using IPA software. The –log10 
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described above, the FAK RIME interactome dataset was not included. Comparisons 
between the nuclear FAK interactome and nuclear FAK BioID interactome MS 
datasets showed that there were 16 interaction partners in common, including UTRN, 
RAB11FIP5, NUP214, NUFIP2, RAI14, TECR, MTFR1l, OTUD4 and notably HIC-
5 (Figure 3.14). HIC-5 is a protein that shuttles from the cytoplasm to the nucleus 
(Shibanuma et al., 2003) and is a known FAK binder at focal adhesions (Nishiya et 
al., 2001). Like FAK, it has been shown to translocate to the nucleus when cells are 
exposed to stress signals such as hydrogen peroxide (Shibanuma et al., 2003). In the 
nucleus, HIC-5 functions as a co-regulator for glucocorticoid receptor target genes and 
the C-MYC gene by recruiting P300 or sequestering β-catenin from target promoters, 
respectively (Chodankar et al., 2014, Li et al., 2011). Therefore, HIC-5 was an 
interesting protein interaction partner to validate by co-immunoprecipitation 
experiments. These showed that FAK and HIC-5 robustly interact in the nucleus 
(Figure 3.15). Thus, HIC-5 is a robust interaction partner of FAK in the nucleus, 
validating the approach that identified that interaction. 
 
Figure 3.14 | Overlay between different nuclear FAK 
interactome datasets. The nuclear FAK BioID dataset 
and nuclear FAK interactome dataset (Serrels et al., 
2015) were overlaid using VENNy online software to 
determine common interaction partners of FAK between 
the datasets. N=3 for both proteomics datasets.  
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3.3.4 Use of proximal proteomics to determine the nuclear 
function of a novel interaction partner of FAK in the 
nucleus 
Our analyses in the previous section identified HIC-5 as a nuclear interaction partner 
of FAK in both the FAK BioID nuclear interactome and FAK nuclear interactome 
datasets (Serrels et al., 2015).  
 
To investigate the nuclear function of HIC-5, and to understand whether the presence 
of FAK can modulate the nuclear interactome of HIC-5, I generated a HIC-5 BirA* 
fusion protein and expressed this in FAK WT cells (denoted HIC-5 BirA* FAK WT) 
and in FAK -/- cells (denoted HIC-5 BirA* FAK -/-). The BirA* EV control was 
expressed in the FAK WT and FAK -/- SCC cells as background controls, denoted as 
FAK WT BirA* EV and FAK -/- BirA* EV control, respectively. To determine the 
nuclear HIC-5 interactome, I performed streptavidin pulldowns with three replicates 
of nuclear lysates extracted from each of the described cell lines and submitted these 
for mass spectrometry. LFQ intensities of the HIC-5 BirA* FAK WT and the FAK 
WT BirA* EV control SCC lines were statistically compared using a two-tailed 
unpaired t-test, in which all Benjamini-Hochberg corrected P-values below 0.05 were 
considered statistically significant.  This identified 76 significantly enriched proteins 
Figure 3.15 | FAK interacts 
with HIC-5 in the nucleus. 
Nuclear fractions were 
prepared from both FAK WT 
and FAK -/- SCC cells prior to 
immunoprecipitation with FAK 
antibody. Samples were 
subjected to SDS-PAGE and 
probed with antibodies to HIC-
5 and FAK. Lamin A/C served 
as a marker for the quality of 
nuclear fractionation. Courtesy 
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in the HIC-5 BioID nuclear interactome dataset (Listed in Table A4). GO enrichment 
analysis of the nuclear HIC-5 BirA* FAK WT MS dataset indicated there was a 
significant proportion of proteins reported to localise to the nuclear lumen (P = 0.0319) 
and the nucleoplasm (P = 0.0357) (Figure 3.16A), suggesting that the fractionation 
used here was valid reflecting the function of HIC-5 as a transcriptional regulator in 
the nucleus (Chodankar et al., 2014, Li et al., 2011). Furthermore, GO enrichment 
analysis of functional terms showed these potential HIC-5 binding partners play roles 
in cancer-related processes such as invasion (P < 0.00001), metastasis of cells (P = 
0.000299) and EMT (P = 0.000164) (Figure 3.16B). Additionally, the data showed a 
significant enrichment of proteins that regulate transcription of DNA (P = 0.00307), 
including β-catenin, JMJD1C, EHMT1, MTA3, WWOX and SUMO1. Interaction 
network analysis showed that HIC-5 associated with a putative network of 
transcriptional regulators in the nucleus, with β-catenin forming the most connected 
node in the network (Figure 3.17). Furthermore, the HIC-5 BirA* FAK WT dataset 
indicated that 24 (31% of the nuclear HIC-5 BirA* FAK WT dataset) proximal 
interaction partners are in common with the FAK WT BirA* dataset, including the 
transcriptional regulators WWOX, JMJD1C and TOX4 (Figure 3.17). 
 
Finally, comparison of the HIC-5-BirA* FAK WT and HIC-5-BirA* FAK -/- 
interactome proteomics datasets showed that deletion of FAK did not result in a 
significant loss of putative HIC-5 interactors in the nucleus (except for FAK itself) 
(Figure 3.18). Interestingly, loss of FAK in FAK -/- cells enriched for HIC-5 
association with the proline-rich coiled-coil protein (PRRC2B) and the scaffolding 
protein Synaptopodin-2 (Figure 3.18).  
 
Together, these data show that HIC-5 interacts with a network containing focal 
adhesion proteins and transcriptional regulators in the nucleus, many of which overlap 
with the FAK BioID nuclear interactome. Furthermore, comparison of the HIC-5 
BioID interactome in the FAK WT vs FAK -/- background identified that loss of FAK 
is associated with significantly enriched association of HIC-5 with the scaffolding 
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Figure 3.16 | GO enrichment analysis of nuclear HIC-5 BirA* FAK WT 
MS dataset. A) Subcellular localization analysis was carried out by 
performing a functional annotation clustering analysis using the DAVID 
GO database. B) Functional analysis was carried out by performing 
Disease and Functions core analysis using the IPA software. The –log10 
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3.4 Discussion  
Previous studies have shown FAK can translocate to the nucleus and bind to a number 
of transcriptional regulators to control the expression of specific genes (Lim et al., 
2008b, Lim et al., 2012, Serrels et al., 2015, Cardoso et al., 2016, Serrels et al., 2017, 
Canel et al., 2017). Using proximity-based proteomics, I identified that FAK has 
multiple putative interactions with novel transcriptional regulators in the nucleus, focal 
adhesion proteins that are known to translocate to the nucleus and a number of proteins 
involved in endocytosis. Characterisation of the function of a FAK nuclear interaction 
partner, HIC-5, indicated that it interacts with transcriptional regulators and focal 
adhesion proteins in the nucleus.  
 
3.4.1 FAK interacts with a network of focal adhesion 
proteins and transcriptional regulators in the nucleus 
As outlined above, I used two proteomics approaches, namely RIME and BioID, to 
define nuclear FAK protein interaction networks. My initial work applying RIME 
identified several known FAK interacting proteins, e.g. SRC, paxillin and cortactin 
(Figure 3.2A). However, the large number of adhesion/cytoplasmic proteins present 
Figure 3.18 | Determination of FAK-
dependent nuclear interactions of 
HIC-5. LFQ intensities between HIC-5 
BirA* FAK WT and HIC-5 BirA* FAK -/- 
dataset were tested for statistical 
significance using a one-way ANOVA 
test. Shows a volcano plot reporting 
the statistical significance of the HIC-5 
BirA* FAK WT and HIC-5 BirA* FAK -/- 
analysis on the y-axis and logarithm-
transformed fold change of LFQ values 
from HIC-5 BirA* FAK WT and HIC-5 
BirA* FAK -/- (WT/Null) analysis on the 
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in the final interaction networks suggested that the sub-cellular fractionation 
associated with RIME may not be efficient after crosslinking (Figure 3.3A), which 
was confirmed by checking the amount of cytoplasmic proteins in the ‘nuclear’ 
fractions prepared using the fractionation protocol within the RIME (Figure 3.4). The 
RIME protocol (Mohammed et al., 2016) is designed to enrich for chromatin 
complexes as it uses formaldehyde, which can both cross-link protein-protein and 
protein-DNA interactions. However, I found that cross-linking abolishes the ability to 
fractionate the cells effectively, and therefore this protocol may be best suited for the 
study of transcription factors that are located in the nucleus.  
 
More promising data was obtained using the BioID system, whereby nuclear FAK 
BioID streptavidin pulldown-MS experiments showed that FAK associates with a 
network of transcriptional regulators, including HIC-5, LPP, WWOX and TJP1 
(Figure 3.10). Further, validation by streptavidin pulldown-western blot experiments 
showed that FAK binds to both LPP and WWOX in the nucleus (Figure 3.12), 
indicating this approach is effective in determining novel nuclear interaction partners 
of FAK.  
 
As previously described, BioID is a proximity-dependent labelling approach which 
means that any protein in close proximity to any target protein (10 nm) is labelled with 
a biotin tag (reviewed in Trinkle-Mulcahy, 2019). BioID proximity-dependent 
labelling is a powerful approach to determine novel protein-protein interactions that 
are more likely to be direct than standard affinity purification/MS approaches. 
However, it does have some caveats. For example, it has been reported that the size of 
the tag can cause mislocalisation of the target protein (reviewed in Trinkle-Mulcahy, 
2019), but this was not a problem for FAK (125kDa) as the BirA tag did not impair its 
focal adhesion localisation (Figure 3.5). An additional caveat is that the BirA* tag can 
ablate the function of the protein (reviewed in Trinkle-Mulcahy, 2019). This did not 
seem to be the case with the FAK WT BirA* fusion protein as it was regulated 
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Another disadvantage of BioID is the time required to generate enough biotinylated 
proteins sufficient for proteomics analysis (18-24 hours), making it unsuitable for 
studying a dynamic process which may occur over a time scale of minutes (Branon et 
al., 2018). Other similar proximity-dependent labelling approaches are available, such 
as APEX, a different tag of 27kDa which is a monomeric ascorbate peroxidase which 
catalyses biotin-phenol oxidation to a radical that is short lived in the presence of 
hydrogen peroxide (reviewed in Trinkle-Mulcahy, 2019). Subsequent reaction with 
amino-acids that are electron rich results in biotinylation of proteins in close proximity 
(reviewed in Trinkle-Mulcahy, 2019). APEX only takes around 1 minute to label 
proteins, which means it can provide a snapshot of the interactome changes over a 
short time. This is not possible with BioID due to the slow kinetics, which results in 
the identification of all proteins proximal to the BirA* tag over a period of many hours 
(Branon et al., 2018, reviewed in Trinkle-Mulcahy, 2019). However, APEX requires 
the use of hydrogen peroxide, which is toxic to the cells and thus may cause artefacts 
in the interactome dataset. BioID only requires the use of biotin, which is non-toxic, 
and despite the slow kinetics of biotinylation, there have been over 100 applications 
of BioID since the protocol was published 6 years ago in Roux et al., 2013 (reviewed 
in Trinkle-Mulcahy, 2019).  
 
Recent efforts have tried to combined the fast labelling kinetics of APEX with the non-
toxicity of the BioID approach – whereby investigators changed the amino acid in the 
BirA* catalytic site mutation from R118G to R118S and introduced an additional 15 
mutations in the BirA* sequence (Branon et al., 2018). This approach, namely 
TurboID, results in the generation of sufficient biotinylated material for proteomics in 
10 minutes (Branon et al., 2018). This may be used in future studies to define the FAK 
interactome over a very short period of time. To understand FAK function in the 
nucleus, I believe the BioID approach I used here was informative.  
 
A key advantage of the BioID approach is the potential to enrich for direct interaction 
partners as the BirA*-tagged protein will attach a biotin moiety to a protein in close 
proximity. However, as the potential interaction partner does not need to bind the 
BirA*-tagged protein, this does not exclude the possibility that a scaffolding protein 
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could mediate the binding of FAK protein partners. Thus, experiments such as 
glutathione S-transferase (GST) pulldowns using recombinant proteins of potential 
FAK-binding partners could be used to determine if the interaction partners I identified 
are binding directly.  
 
I found 42 proteins that were identified to be significant FAK binding partners in the 
nucleus. Other reports studying the BioID interactome of predominantly nuclear 
proteins, such as Separase have yielded larger datasets identifying approximately 200 
interactors (Agircan et al., 2016). Reasons for this could be that a small proportion of 
FAK is in the nucleus relative to total FAK protein levels in the cell so it is more 
difficult to capture interactions in the nucleus that are significantly enriched over the 
BirA* EV control-expressing cells. 
 
In the FAK WT BioID nuclear interactome dataset, a number of focal adhesion 
proteins were identified as FAK-interacting proteins in the nucleus. Specifically, a 
number of proteins present in the consensus adhesome (Horton et al., 2015) have been 
shown to translocate to the nucleus, i.e., Paxillin (Sathe et al., 2016), LPP (Guo et al., 
2006), Zyxin (Nix and Beckerle, 1997) and HIC-5 (Shibanuma et al., 2003), the latter 
being in response to cellular stress. Interestingly, not all proteins in the consensus 
adhesome have NLS sequences. For example, although Paxillin and Zyxin have NES 
sequences they do not have a NLS sequence (reviewed in Lim et al., 2013), while FAK 
has been shown to have an NLS within its N-terminal FERM domain (Lim et al., 
2008b). Therefore, it is unknown whether other focal adhesion proteins containing 
NLS sequences can mediate nuclear translocation of other proteins in the consensus 
adhesome. Work from the Frame laboratory has identified that 70-80% of the 
consensus adhesome can be detected in the nuclear fraction of SCC cells (A. Byron, 
unpublished). Studying the nuclear functions of canonical focal adhesion proteins and 
the mechanism by which they translocate to the nucleus are of active interest to the 
Frame group, as this represents a mechanism by which signals are transmitted from 
focal adhesions to regulate the expression of genes. As FAK is upregulated in the 
nucleus of cancer cells, where it regulates the expression of genes that regulate the 
anti-tumour immune response to support tumour growth (Serrels et al., 2015), FAK 
 
 
OMICs based identification of the mechanisms that underpin FAK’s  
regulation of gene expression  94 
and potentially other focal adhesion proteins in the nucleus could be part of a 
mechanism to regulate cancer-associated processes.  
 
 It is possible that FAK-interacting partners in the nucleus that are focal adhesion 
proteins could be scaffolding FAK to the novel transcriptional regulators identified (or 
vice-versa), especially since many of these proteins are known direct interaction 
partners of FAK (i.e. Paxillin, HIC-5, SRC, ASAP1). Thus, it is plausible that these 
focal adhesion proteins could have a role in FAK-mediated transcription. This could 
be tested by firstly confirming these interactions with focal adhesion proteins in the 
nucleus, and secondly, confirming whether focal adhesion proteins can bind to 
transcriptional regulators that FAK regulates and whether binding to chromatin and/or 
gene promoters is impacted by FAK depletion. Furthermore, it would be interesting to 
determine whether focal adhesion protein nuclear localisation mutants impact on 
FAK-target gene expression (e.g. CCL5).  
 
However, it must be noted that it is possible that the proteins identified as proximal to 
FAK could be biotinylated at focal adhesions before translocating to the nucleus where 
they may not bind FAK. Thus, this stresses the need to use different approaches (such 
as co-immunoprecipitation) in order to validate that the nuclear interaction partners 
identified in the FAK BioID nuclear interactome dataset are in fact nuclear interactors. 
However, as presented in Figure 3.15, a novel interactor of FAK in the nucleus, HIC-
5, has been robustly validated by performing co-immunoprecipitation experiments. 
  
Several proteins identified in the FAK BioID nuclear interactome dataset have known 
importance in cancer. For example, HIC-5, a regulator of steroid receptor and 
canonical WNT signalling (Ghogomu et al., 2006), is linked to prostate cancer 
progression (Li et al., 2014). Furthermore, WWOX has been shown to interact with 
BCL9-2, to increase the activity of the β-catenin-TCF/LEF (T cell factor/lymphoid 
enhancers factors family) complex to regulate the WNT pathway in breast cancer (El-
Hage et al., 2015). Additionally, LPP has been shown to regulate the activity of the 
transcription factor ETV4 to regulate the mRNA expression of the invasion regulator 
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MMP1 (Guo et al., 2006). Thus, these proximal proteomic datasets have identified 
several FAK-transcriptional regulator interactions with notable importance in cancer.  
 
3.4.2 BioID identified FAK kinase-dependent nuclear 
interactions 
As described in the Introduction of this thesis, FAK’s kinase activity and nuclear 
function is important for its role in mediating cancer-associated gene expression 
changes (Serrels et al., 2015, 2017), which is mediated by its interactions with 
transcription factors such as IL33 (Serrels et al., 2017). The exact role of FAK’s kinase 
activity in the nucleus is not fully understood as no bona fide substrates of FAK have 
been identified in this cell compartment. However, it could be important in regulating 
the function of its binding partners and this could ultimately impact on its biological 
consequences. FAK kinase activity regulates its binding to protein partners such as 
SRC at focal adhesions (reviewed in Mitra et al., 2005), and therefore I set out to 
determine the importance of FAK kinase activity in potential nuclear protein-protein 
interactions.  
 
I therefore incorporated a FAK kinase-defective mutant (FAK KD BirA* cells) in the 
BioID nuclear pulldown MS experiments. A number of statistically significant 
potential kinase-dependent interactions were identified, including SRC, CORO1B, 
PEX14, CRK, PKCDBP, TECR, EPS15L1, 4932415D10RIK, MII1T4, TOX4, 
ASAP1, AKNAK2, MURC and WWOX (Figure 3.11). It could be that the enrichment 
of binding may be due to increased expression of some of these proteins at the protein 
or mRNA level, which requires further experimental data to investigate. 
 
Highly enriched potential kinase-dependent interactions included members of the 
cavin family of proteins, PKCDBP and MURC, which are important mediators of 
caveolae-dependent endocytosis (reviewed in Chidlow and Sessa, 2010). Caveolae are 
invaginations of the cell membrane that mediate uptake of molecules outside the cell 
(reviewed in Chidlow and Sessa, 2010). There is also evidence that these small 
invaginations can enhance signalling of some pathways that are important in cancer. 
For example, sustained activation of AKT in early endosomes is mediated by 
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PKCDBP and this stimulates pro-survival signalling in lung cancer cells (Yamaguchi 
et al., 2019).  
 
PKCDBP and MURC are associated with caveolae (reviewed in Chidlow and Sessa, 
2010), but their role in caveolae-dependent endocytosis has not been fully established. 
However, it has been shown that PKCDBP is important for regulating caveolae 
dynamics by regulating the amount of time caveolae spend on the plasma membrane, 
suggesting it may regulate the turnover of caveolae on the plasma membrane to 
regulate signalling, membrane tension or lipid homeostasis (Mohan et al., 2015). It is 
surprising that I detected caveolae-associated proteins in the nucleus, as caveolae-
dependent endocytosis is a cytoplasmic mechanism. However, a study has identified 
that a caveolin-1/TIE2 complex translocates to the nucleus in response to ionising 
radiation to facilitate the DNA repair in response to genotoxic stress in glioma cells 
(Hossain et al., 2017). Thus, components of the caveolae-dependent endocytosis 
pathway have been detected in the nucleus previously in the context of cellular stress, 
and this may promote cell survival in cancer.  
 
The role of FAK binding to these proteins and the function of cavins in the nucleus 
remains to be determined. Interestingly, the protein FLOT-2 is enriched in the FAK 
KD BirA* vs FAK WT BirA* analysis; FLOT-2, like cavins, is associated with 
caveolae membranes (Bickel et al., 1997). Furthermore, FLOT-2 expression has been 
reported to be associated with metastasis of nasopharyngeal carcinoma by activating 
the AKT and NF-κB pathways (Liu et al., 2015) and its expression has been correlated 
with poor prognosis in non-small cell lung cancer (Wen et al., 2015). Together, these 
findings suggest that FAK binding to members of the caveolae-dependent endocytosis 
pathway may be important for survival in SCC cells. Interestingly, FAK has already 
been shown to bind to caveolin-1 (Swaney et al., 2006) and it is a key mediator of 
caveolin-1 expression during EMT (Bailey and Lui, 2008). However, FAK binding to 
the caveolin components of the endocytic machinery in the nuclear compartment has 
not been reported before. This suggests that FAK kinase activity may be a regulator of 
the endocytic machinery in the nucleus, although the role of the latter in the nucleus is 
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not known. Further experiments will be required to confirm this and also to establish 
by what mechanism FAK kinase activity specifically contributes to this.  
 
As yet, we do not know the mechanism by which FAK binds to proteins in the nucleus. 
As mentioned, no substrates of FAK in the nucleus have been identified. Further work 
will be required to understand the significance of FAK kinase activity in regulating the 
binding to its protein partners in the nucleus and to address whether there are direct 
substrates or if it is a FAK kinase-dependent conformational change that alters its 
binding properties.  
 
3.4.3 HIC-5 interacts with an extensive network of 
transcriptional regulators in the nucleus 
HIC-5 was present in both of the FAK nuclear proteomic datasets and experimental 
validation indicated that FAK binds HIC-5 in the nucleus (Figure 3.15). Although 
FAK is shown to interact with HIC-5 at focal adhesions (Nishiya et al., 2001), binding 
in the nucleus had not been reported previously.  
 
Proximal proteomics using a HIC-5 BirA* protein expressed in a FAK WT SCC cell 
background showed that HIC-5 binds to a network of focal adhesion proteins and 
transcriptional regulators in the nucleus. ‘Transcription of DNA’ was a highly enriched 
GO term (Figure 3.16B), and proteins included under this term are implicated in 
cancer, such as β-catenin, which is a co-activator of WNT pathway genes (reviewed 
in MacDonald et al., 2009). HIC-5 has been shown to repress β-catenin-mediated 
MYC expression by competitive binding with T-cell factor-driven member 4 (TCF-4) 
on the MYC gene (Li et al., 2011). HIC-5 has also been shown to negatively regulate 
Lymphoid Enhancer Factor (LEF) target gene expression (Ghogomu et al., 2006), 
another β-catenin-regulated transcription factor. Another protein included under this 
GO term was the histone demethylase JMJD1C, which is a positive regulator of 
invasion and metastasis by regulating the expression of the transcription factor ATF2 
(Chen et al., 2018). Thus, the HIC-5 BioID interactome dataset has identified many 
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Interestingly, this dataset predicted that HIC-5 binds to the protein SUMO1 and 
RANBP2, which both regulate SUMOylation of proteins, a post-translational 
modification which regulates the structure and subcellular localisation of proteins, as 
well as transcription factor function (Pichler et al., 2002, reviewed in Lyst and 
Stancheval, 2007). RANBP2 is an E3 Sumo ligase that regulates SUMO1 conjugation 
to target proteins. Interestingly, transcriptional regulators in the HIC-5 nuclear 
interactome are SUMOylated with the SUMO1 moiety added by RANBP2 activity 
(Pichler et al., 2002). SUMOylation is essential for promyelocytic leukemia protein 
(PML) function by promoting P53 transcriptional activity (Satow et al., 2012). 
Furthermore, SUMOylated FAK has been reported to be enriched in the nucleus 
(Kadaré et al., 2003). However, the significance of this modification in FAK-mediated 
transcription has not been identified. Thus, the interactome data suggests that HIC-5 
can also potentially be SUMOylated or mediate SUMOylation (i.e. by scaffolding 
complexes) and it is possible this may impact on its own transcriptional activity or that 
of other transcriptional regulators, such as has been shown for PML (Satow et al., 
2012).  
 
Comparison of the HIC-5 BirA* FAK WT SCC and Hic5 BirA* FAK -/- SCC datasets 
showed that there were no interaction partners enriched in the nucleus in the FAK WT 
vs FAK -/- analysis (except for FAK itself) (Figure 3.18). However, in the FAK -/- vs 
FAK WT analysis, the proteins synaptopodin-2 and PRRC2B were enriched in the 
HIC-5-BirA* FAK -/- dataset. Synaptopodin-2 is a scaffolding protein that induces 
actin filament assembly (Kai, Fawcett and Duncan, 2015) and it is known to 
translocate to the nucleus in myotubules and myoblasts where it is hypothesised to 
potentially regulate mRNA transport in times of cellular stress (Weins et al., 2001). It 
is interesting to speculate whether HIC-5 could be binding to synaptopodin-2 to 
compensate for a potential scaffolding function FAK is providing in the nucleus. These 
data imply that FAK could play a scaffolding role in HIC-5-mediated transcription by 
scaffolding HIC-5 to nuclear complexes. I did not determine whether enriched proteins 
in the HIC-5 BirA* FAK -/- vs HIC-5 BirA* FAK WT SCC datasets are differentially 
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Together, these data suggest that HIC-5 binds to a network of transcriptional regulators 
in the nucleus. However, further experiments will be required to determine the 




The data presented in this chapter have shown that FAK interacts with focal adhesion 
proteins and transcriptional regulators in the nucleus. Many of these interaction 
partners both have functions in transcription and are important in cancer. Furthermore, 
I set out to determine the interactome of FAK’s nuclear interaction partner, HIC-5, to 
gain insight into its nuclear function, which showed that HIC-5 also interacts with 
transcriptional regulators in the nucleus. Thus, FAK and HIC-5 in the nucleus can 
independently bind to transcriptional regulators which could potentially regulate gene 
expression. Further characterisation of these individual interaction partners is required 
to determine the importance of these interactions for transcription in this cancer cell 
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Chapter 4 FAK regulates AP-1 and ETS 
transcription factor motif 
enrichment in accessible regions of 
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4.1 Introduction  
Nuclear FAK is an important regulator of gene expression in cancer (Serrels et al., 
2015). However, FAK does not contain a DNA binding sequence and therefore likely 
regulates transcription indirectly, potentially mediated through interactions with 
transcription factors and co-factors. Studies have shown FAK binds the transcription 
factors GATA4 (Lim et al., 2012), MBD2 (Luo et al., 2009b), MEF2 (Cardoso et al., 
2016) and IL33 (Serrels et al., 2017) to regulate the expression of VCAM-1, 
Myogenin, JUN and CCL5, respectively. To identify which transcription factors are 
the key drivers of FAK-dependent gene expression, I have used ATAC-seq (Assay for 
Transposase-Accessible Chromatin using sequencing) to determine FAK-dependent, 
FAK nuclear localisation-dependent and FAK kinase-dependent alterations in 
chromatin accessibility and transcription factor motif enrichment.   
 
ATAC-seq is a method for assaying chromatin accessibility, which uses a hyperactive 
Tn5 transposase to simultaneously digest and tag open chromatin regions of the 
genome with sequencing adapters (tagmentation). Regions of the genome where DNA 
is accessible will contain significantly more sequencing reads and form peaks in the 
ATAC-seq signal that are detectible by peak calling tools (Buenrostro et al., 2013). 
These regions can be further categorised into various regulatory element types 
(promoters, enhancers, etc.) by taking into account their distance from a transcriptional 
start site.  
 
ATAC-seq data also enables a computational method called motif enrichment analysis, 
which identifies transcription factor binding sites within accessible chromatin regions. 
Each ATAC-seq signal will contain more sequencing reads than less exposed regions 
of the genome and often the sequence within these peaks will contain motif sequences 
for particular transcription factors (Figure 4.1). Analysis of the sequence within these 
ATAC-seq peaks can identify binding sites for particular transcription factors and if 
the transcription factor motifs are differentially exposed on the chromatin between 
different cell lines and conditions. This technique can yield a list of transcription 
factors that have binding capability to these motifs sequences. However, this technique 
does not confirm that the transcription factor is bound to the chromatin and therefore 
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techniques need to be employed (i.e. ChIP) in order to confirm that the predicted 
transcription factor identified from motif enrichment analysis is in fact bound to the 
DNA in accessible regions of chromatin. 
 
In this section, I will define FAK-regulated chromatin accessibility changes and 
transcription factor motif enrichment in order to identify key genomic regions and 
transcription factors regulated by FAK. Specifically, I will use ATAC-seq to define 
global chromatin accessibility changes between FAK WT, FAK -/-, FAK NLS and 
FAK KD SCC cell lines. Furthermore, motif enrichment analysis will be performed to 
identify potential FAK-regulated transcription factors. I will then gain mechanistic 
insight into how FAK may be regulating these predicted transcription factors by 
integrating the FAK-regulated transcription factors identified by motif enrichment 
analysis with the FAK WT BioID and nuclear FAK interactome proteomics datasets. 
Finally, I use the same approach as outlined above to investigate the mechanism by 
which FAK regulates a known FAK-regulated gene, IL33. To validate my motif 
enrichment findings, I will confirm that the predicted FAK-regulated transcription 
factors are differentially regulated on the chromatin between FAK SCC cell lines by 




• Identify FAK-dependent global chromatin accessibility changes. 
• Predict global FAK-regulated transcription factors. 
Figure 4.1 | Motif enrichment analysis. 
Schematic of the logic underpinning motif 
enrichment analysis. The sequence within 
ATAC-seq peaks will contain binding sites for 
particular transcription factors which can be 
predicted by HOMER. Therefore, it is 
possible to predict which transcription factor 
is potentially binding to that particular region 
and whether this is differentially regulated 
between cell lines and conditions. The motif 














ATF2 binding site  
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• Integrate the FAK-regulated transcription factor dataset with nuclear FAK 
proteomic datasets to gain insight into the mechanism by which FAK regulates 
these transcription factors. 
• Investigate the mechanism by which FAK regulates the expression of the IL33 
gene. 
 
4.3 Results  
4.3.1 Optimisation of ATAC-seq conditions in the FAK SCC 
model 
ATAC-seq is generally considered to be a straightforward protocol. However, the main 
challenge of this approach is obtaining a sample of high yield and good DNA fragment 
profile. Too many small fragments in the sample (overtagmentation) cluster more 
easily in sequencing and therefore will create a huge bias for these fragments (some of 
which will simply be excess sequencing adapters). Additionally, it is important not to 
have too many large fragments as this disrupts the sequencing process by folding over 
and binding at both ends in the flow cell. As such, all ATAC-seq samples are analysed 
on an Agilent Bioanalyser, which essentially performs capillary electrophoresis to 
determine the distributions of DNA fragment size in the samples. Good and poor 
examples of DNA fragment disruptions are shown in Figure 4.2. 
 
ATAC-seq samples were prepared from FAK WT, FAK -/-, FAK NLS and FAK KD 
SCC lines. The FAK WT, -/- and KD SCC samples were prepared with 200,000 cells 
and 2x Tn5 transposase enzyme, which yielded good fragment profiles. However, the 
FAK NLS samples all showed overtagmentation in these conditions. Therefore, I 
reduced the cell number to 100,000 cells and enzyme concentration to 1x, which 
yielded good quality DNA fragment profiles for sequencing. The final conditions used 
for each of the SCC lines are summarised in Figure 4.3A and representative DNA 
fragment profiles are depicted in Figure 4.3B. The sequencing of the ATAC-seq 
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Figure 4.2 | Example of DNA size fragment spectra. DNA samples 
prepared following the ATAC-seq protocol (as described in Materials and 
Methods) were run on the Agilent Bioanalyser, along with high and low 
molecular weight markers. Virtual DNA gel shown to the right of the 
profiles. Arbitrary fluorescence units (FU) are plotted by time in seconds 
(s). A) is an example of a good example of a DNA fragment protocol. B) 
is an example of an overtagmented sample and C) is an example of a 
profile with too many large fragments.   
  
  
A Example of a good spectrum 
B Example of a bad spectrum = too many small fragments 
C Example of a bad spectrum = too many large fragments 
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FAK WT SCC FAK -/- SCC 
FAK NLS SCC FAK KD SCC 
  
Figure 4.3 | Samples submitted for ATAC-seq A) Final conditions used for preparation of 
ATAC-seq samples in the indicated cell lines. B) Representative DNA fragment profiles of 
FAK SCC samples submitted for ATAC-seq analysis. DNA samples prepared following the 
ATAC-seq protocol (as described in Materials and Methods) were run on the Agilent 
Bioanalyser, along with high and low molecular weight markers. Virtual DNA gel shown to the 
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Figure 4.4 | Global chromatin accessibility changes observed upon FAK 
loss. Heatmap representation of significantly different chromatin accessibility 
changes (FDR ≤ 0.05) between FAK WT SCC, FAK -/- SCC, FAK NLS an FAK 
KD SCC samples, as determined by Diffbind. To generate the heatmap, the data 
was z-scored (dark red representing a z-score of 0.5 and dark blue indicating a z-
score of -0.2). Only peaks in the FAK -/-, FAK NLS and FAK KD that have 
differential accessibility with respect to FAK WT are shown. Peaks are not shown 
in any particular order. In the FAK WT cells 595 peaks were open, while 112 were 
closed with respect to FAK -/-, NLS and KD cell lines (indicated by black lines to 
right of heatmap). Red indicates highly accessible regions (centre of peak), 
whereas blue indicates less accessible regions. Numbers indicate the biological 
replicate of the sample. Numbers at bottom of the heatmap represent distance 
from the centre of the ATAC-seq peak (0 is the centre of the peak). N=2 biological 
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4.3.2 ATAC-seq chromatin accessibility results 
 We aligned the sequencing results to the mm10 (Mus musculus) reference genome, 
before using the bcbio ATAC-seq pipeline to perform the accessibility analysis. Peaks 
(accessible regions) were called from the BAM files using the MACS2 algorithm. The 
number of peaks per sample can be found in Table 2.7. The distribution of peaks were 
similar in the FAK WT, -/-, NLS and KD cells; with the majority of peaks located 5 to 
100kb from the TSS. Differentially accessible regions were identified using the 
R/Bioconductor package DiffBind.  Differential peak calling was performed for each 
pairwise comparision and significantly, differential peaks were defined as those with 
a FDR of below or equal to 0.05. Results from the chromatin accessibility analyses 
indicated changes in a subset of genes between FAK WT, FAK -/-, FAK NLS and 
FAK KD SCC cell lines, as shown in the chromatin accessibility heatmap in Figure 
4.4. Specifically, there appeared to be a difference in chromatin accessibility in a 
subset of genes between FAK WT vs FAK -/-, FAK NLS and FAK KD SCC cell lines 
(Figure 4.4). Further investigation of the genes that are regulated by chromatin 
accessibility was performed in Chapter 5, where I have integrated the subset of genes 
that display FAK-dependent chromatin accessibility changes with FAK-regulated 
gene expression data to determine which FAK-dependent chromatin accessibility 
changes are associated with differential gene expression. 
 
Table 4.1 | FAK regulates AP-1 and ETS motif enrichment in accessible 
chromatin. Motif enrichment analysis was performed in FAK WT, FAK -/-, FAK NLS 
and FAK KD cell lines by searching the motif sequences within the ATAC-seq peaks 
which have predicted transcription factor binding. Most highly enriched AP-1 and 
ETS motifs  are shown for each FAK WT vs -/-, NLS or KD SCC analysis. TF = 
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4.3.3 Motif enrichment analysis to determine potential FAK-
regulated transcription factors 
As previously described, motif enrichment analysis allows one to predict if 
transcription factor motifs are differentially exposed on the chromatin between 
different cell lines and conditions based on enrichment of particular transcription 
factor motifs in accessible regions. We performed the motif enrichment analysis using 
the motif database HOMER, which identifies genomic sequences that matches the 
motifs (motif binding sites) in the differentially accessible peaks. All transcription 
factor motifs present in differentially accessible regions in FAK WT cells compared 
with that of FAK -/-, FAK NLS and FAK KD cells. This analysis detected multiple 
statistically significant (q-value ≤ 0.05) changes in motif enrichment in differentially 
accessible peaks in the FAK WT vs -/- SCC lines (196 transcription factor motifs), 
FAK WT vs KD SCC lines (118 transcription factor motifs) and FAK WT vs NLS 
SCC lines (205 transcription factor motifs) by comparative analysis. In particular, 
there were many highly enriched transcription factor motifs in the FAK WT cells that 
are known to be bound by members of the AP-1 and ETS domain transcription factor 
family. Some of the most highly significantly enriched transcription factor motifs 
known to be bound by the AP-1 and ETS domain transcription factor family 
Figure 4.5 | FAK regulates JUNB levels in the chromatin 
fraction. A) Chromatin was harvested and subjected to SDS-
PAGE analysis. The blot was probed with a JunB antibody and a 
histone H3 antibody to control for protein loading. B) JunB protein 
levels in the chromatin fraction were quantified using ImageJ and 
values normalised to histone H3 levels.  A two-tailed unpaired t-
test was used for statistical analysis. ** = P ≤ 0.01, N=3 biological 
replicates, mean+/-SEM.  
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determined by motif enrichment analysis in common between the FAK WT vs FAK -
/-, FAK NLS and FAK KD analysis are shown in Table 4.1. The transcription factors 
predicted from the motif enrichment analysis are herein referred to as ‘predicted 
transcription factors’. 
 
To investigate my global motif enrichment findings, I made chromatin preparations 
from FAK WT and FAK -/- cells to determine if any of the transcription factors known 
to bind to the FAK-regulated motifs in differentially accessible regions display 
increased protein levels in the chromatin fraction of FAK WT cells. The results showed 
a statistically significant enrichment of the AP-1 factor JUNB (A.k.a JunB) in the 
chromatin fraction of the FAK WT compared to FAK -/- cells (Figure 4.5A-B, P = 
0.0045). Further investigation showed reduced expression of JUNB in whole cell 
extracts from the FAK -/-, FAK NLS and FAK KD cells compared with the FAK WT 
cells (Figure 4.6), while there was no difference in JUNB mRNA expression between 
the cell lines (Figure 4.7, P > 0.05). Follow up of another highly enriched AP-1 
member, JUN (A.k.a. c-Jun), showed increased expression in the chromatin fraction 
in the FAK-/- cells compared to the FAK WT cells (Figure 4.8), suggesting FAK does 
not globally regulate the occupancy of this transcription factor to chromatin in the 
manner predicted from the motif enrichment data.  
 
As stated above, multiple transcription factor motifs in differentially accessible regions 
were significantly enriched between the FAK WT vs FAK -/-, FAK NLS and FAK 
KD cells lines according to the motif enrichment analysis (173 transcription factor 
motifs on average between the analyses). Use of HOMER also determined the 
transcription factors known to bind these FAK-regulated transcription factor motifs. 
Due to the large number identified by these analyses, I wanted to create a refined list 
in order to make it more manageable for further interactome downstream analysis, so 
as to establish how these transcription factors predicted from the motif enrichment 
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analysis are connected to one another and to the nuclear FAK interactome regulating 
these transcription factors. In order to do this, I filtered all the predicted transcription 
factors that are only enriched in the FAK WT cells (Figure 4.9A) and then constructed 
Figure 4.6 | FAK regulates JUNB protein levels. A) Whole cell lysates were 
harvested and protein was quantified prior to SDS-PAGE analysis, as described 
in Materials and Methods. The blot was probed with a JUNB antibody and a 
GAPDH antibody to control for protein loading. B) JUNB protein level in all 
replicates was quantified using ImageJ and then values normalised to GAPDH 
levels. A one-way ANOVA test was used for statistical analysis. * = P ≤ 0.05, ** = 
P ≤ 0.01, N=3 biological replicates, mean+/-SEM.  
Figure 4.8 | FAK does not regulate 
JUN levels in the chromatin 
fraction consistent with the motif 
enrichment findings. Chromatin 
was harvested and subjected to 
SDS-PAGE analysis. The blot was 
probed with a JUN antibody and a 
histone H3 antibody to control for 
protein loading. N=1 
  
  
Figure 4.7 | FAK does not regulate 
JUNB mRNA expression. RNA 
extraction and cDNA synthesis was 
carried out in FAK WT, -/- and KD 
cell lines as outlined in Materials 
and Methods. qRT-PCR was 
performed using JUNB primers. CT 
values were normalised to each 
samples respective GAPDH CT and 
then each replicate. A one-way 
ANOVA test was used for statistical 
analysis. ns = P > 0.05, N=3 
biological replicates, mean+/-SEM 
 
 
OMICs based identification of the mechanisms that underpin FAK’s  
regulation of gene expression  111 
a protein-protein and functional (i.e. protein-DNA interactions) interaction network 
with this list of transcription factors using IPA (Figure 4.9B). The resulting network 
indicated that these FAK WT enriched transcription factors are well-connected, i.e. 
many regulate the expression of the other transcription factors in the network. To gain 
mechanistic insight into how FAK may regulate these transcription factors, I integrated 
the nuclear FAK interactome datasets (described in Chapter 3) with that of FAK 
interactors and the FAK WT enriched transcription factor list (Figure 4.10A-B). 
Interestingly, in Figure 4.10B I have highlighted the established FAK interactors SP1 
(Serrels et al., 2017) and RUNX1 (Canel et al., 2017) as the motifs for these 
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Figure 4.9 | Identification of transcription factor networks regulated by FAK. (A) 
VENN diagram displaying overlap in the predicted FAK-regulated transcription 
factors identified by motif enrichment analysis.  Samples from FAK WT, FAK-/-, FAK 
NLS and FAK KD SCC were prepared for ATAC-seq analysis as described in 
Materials and Methods. All predicted FAK WT transcription factors are circled in red. 
B) The FAK WT SCC list created in A) (circled in red) was used to seed a network 
using Ingenuity pathway analysis and then exported into Cytoscape for final figure 
presentation. Only direct, mammalian interactions shown between transcription 
factors. Protein-protein and functional connections are detailed in the key. AP-1 
transcription factors members outlined in red and ETS members outlined in purple. 
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Figure 4.10 | Integration of predicted FAK WT enriched transcription factors with 
nuclear FAK interactome datasets show potential key nodes. Network detailing 
upstream, direct mammalian connections between A) FAK nuclear BioID (section 3.3.3) 
and B) FAK nuclear interactome (Serrels et al., 2015) and global predicted FAK WT 
enriched transcription factors were constructed using Ingenuity pathway analysis. 
Symbols for protein-protein and functional connections are shown as detailed in the key. 
Proteins highlighted in pink are present in A) nuclear FAK WT BioID and B) Nuclear FAK 
interactome datasets. Proteins in yellow are the global FAK WT enriched transcription 
factors, as predicted by motif enrichment analysis. Proteins in B) circled in red are 
proteins both present in the nuclear FAK interactome dataset (Serrels et al., 2015) and 
are FAK WT enriched transcription factors predicted by motif enrichment analysis. N=3 
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4.3.4 FAK-dependent changes in accessibility and 
transcription factor binding on IL33 gene   
In addition to looking at changes in transcription factor binding on a global scale, I 
have also used the ATAC-seq results to analyse the regulation of a specific gene, IL33. 
Previous work from the Frame group has shown FAK binds and regulates the nuclear 
cytokine IL33, and this functions downstream of FAK in regulating the expression of 
immunosuppressive cytokines, thereby supporting tumour growth (Serrels et al., 
2017). The mechanism by which FAK regulates IL33 mRNA expression has not been 
established which is what I will investigate in this next section. The mouse IL33 gene 
is located on chromosome 19 and consists of 8 exons and 7 introns with two 
overlapping transcripts – transcript 1 and transcript 2 (Figure 4.11). Transcript 2 may 
have an alternative transcriptional start site (TSS) to transcript 1 as transcript 2 has a 
large first intron, spanning over 20kb upstream of the IL33 transcript 1 TSS. Inspection 
of the chromatin accessibility traces on the IL33 gene from the FAK SCC cell lines 
indicated that there was a loss of chromatin accessibility on the IL33 
promoter/enhancer regions upon loss of FAK or FAK function (Figure 4.12A). This 
was particularly striking in the FAK NLS and FAK KD cells, which showed almost 
complete loss of chromatin accessibility at the IL33 promoter/enhancer regions 
(Figure 4.12A). We performed a motif enrichment analysis on the ATAC-seq peaks 
proximal to the IL33 promoter in the FAK WT cells, identifying 25 FAK-dependent 
transcription factor motifs such as motifs known to bind AP-1 components JUN, ATF2 
and ATF7. Interactome analysis using the Ingenuity pathway analysis software 
indicated that the transcription factors known to bind the FAK-regulated motifs on the 
IL33 promoter/enhancer are well connected and regulate the expression of other FAK 
WT enriched predicted transcription factors on the IL33 promoter (Figure 4.12B). 
Locations of the motifs within the ATAC-seq peaks for a number of the predicted 
FAK-regulated transcription factors on the IL33 gene are indicated in Figure 4.12C. 
Integration of the FAK BioID nuclear proteomics dataset with the transcription factors 
known to bind FAK-regulated motifs on the FAK WT IL33 promoter/enhancer regions 
showed a modest number of potential upstream connections between the proteomics 
data and the transcription factor list – namely WWOX:JUN and YEATS2:TBP 
(Figure 4.13A). Integration of the FAK nuclear interactome data (Serrels et al., 2015), 
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with that of the transcription factors on the FAK WT IL33 promoter/enhancer regions, 
indicated that there were many upstream connections between the FAK proteomics 
dataset and the FAK WT transcription factors on the IL33 promoter/enhancer regions 
(Figure 4.13B). The network formed 5 subnetworks all connected by the AP-1 factor, 
JUN, which formed the central node of the network. 
 
 
   
 
  
IL33 mRNA Transcript 2 (gene = 14.9kbp, coding region = 9.3kb) 
IL33 mRNA Transcript 1 (gene = 35kbp, coding region = 9.3kb) 
Figure 4.11 | Schematic of the IL33 gene. Schematic of the IL33 gene transcripts 
1 and 2. Both the IL33 transcripts have a total of 8 exons and are both identical 
except that the IL33 transcript 2 has a larger first intron than the IL33 transcript 1. 
Boxes indicate exons and blue indicate regions that are part of the IL33 transcripts. 
The black line upstream of IL33 transcript 1 schematic indicates an upstream 
genomic region. Red arrows indicate regions where there is an ATAC-seq peak of 
a probable enhancer, whereas purple arrows indicate regions where there is a 
possible promoter region.  
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Figure 4.12 | FAK regulates chromatin accessibility and transcription factor motif 
enrichment at the IL33 promoter and enhancer regions. A) Shows chromatin 
accessibility traces obtained from two replicates of each cell line used in the ATAC-seq 
experiment. Outlined is the region of interest. Y axis is coverage whereas x axis is kb. A 
schematic of the location of the IL33 gene (transcript 1 shown only) with respect to the 
chromatin accessibility trace is shown below. Courtesy of R. Upstill-Goddard. B) The list of 
transcription factors known to bind FAK-regulated motifs on the IL33 gene 
enhancer/promoter regions was used to seed a network using Ingenuity Pathway Analysis 
and then exported into Cytoscape for final figure presentation. Only direct, mammalian 
connections are shown between transcription factors known to bind FAK-regulated motifs. 
Protein-Protein and functional connections are detailed in the key. Transcription factors 
known to bind FAK-regulated motifs on the enhancer regions are circled in red and FAK-
regulted motifs on the promoter region are circled in purple. N=2 Biological replicates. C) 
Schematic showing locations of the transcription factor binding sites within the enhancer 
(red) and promoter (purple) ATAC-seq peaks on IL33 gene. Motif sequences reported 
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Figure 4.13 | Integration of the predicted FAK-regulated transcription factors on the 
IL33 promoter/enhancer with nuclear FAK interactome datasets show potential key 
nodes. Network detailing upstream, direct mammalian connections between A) nuclear 
FAK BioID and B) FAK nuclear interactome (Serrels et al., 2015) and predicted FAK WT-
enriched transcription factors on IL33 gene were constructed using Ingenuity pathway 
analysis. Symbols for protein-protein and functional connections are detailed in the key. 
Proteins highlighted in pink are present in A) Nuclear FAK BioID and B) Nuclear FAK 
interactome datasets. Proteins in yellow are the transcription factors predicted to be bound 
on the IL33 promoter/enhancer regions in the FAK WT cell lines, as determined by motif 
enrichment analysis. Proteins circled in red are those identified as FAK interactors by the 
Frame lab. N=3 biological replicates for proteomics datasets and N=2 biological replicates 
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JUN is a member of the AP-1 family which is an important regulator of skin 
inflammation (Schonthaler et al., 2011). In order to investigate the potential 
mechanism by which FAK regulates the expression of IL33, I performed siRNA 
mediated depletion of JUN mRNA (Figure 4.14A), which lead to a significant 
downregulation of IL33 mRNA (Figure 4.14B, P < 0.001). Furthermore, JUN mRNA 
knockdown also resulted in a reduction in IL33 protein expression (Figure 4.15A-B). 
Lastly, the FAK and IL33 target gene, CXCL10 also showed reduced mRNA levels as 
a result of JUN knockdown (Figure 4.16, P = 0.0024). This implies that JUN may be 






















Figure 4.14 | IL33 expression is disrupted upon JUN 
knockdown. FAK WT cells were transfected with a non-
targeting control (NTC) or JUN smartpool siRNA prior to RNA 
extraction and cDNA synthesis as described in Materials and 
Methods. A) JUN and B) IL33 qRT-PCRs were carried out using 
JUN and IL33 primers, respectively. CT values were normalised 
to each samples respective GAPDH CT and then each replicate 
FAK WT NTC to gain a fold change in gene expression. SP = 
smartpool. N=3 biological replicates. Unpaired two-tailed t-test 
used for statistical analysis *** = P ≤ 0.001. 
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Figure 4.16 | IL33 target gene 
expression is disrupted upon 
JUN knockdown. FAK WT cells 
were transfected with NTC or 
JUN smartpool siRNA prior to 
RNA extraction and cDNA 
synthesis as described in 
Materials and Methods. qRT-
PCR was performed using 
CXCL10 primers. N=3 biological 
replicates. SP = smartpool. 
Unpaired two-tailed t-test used 
for statistical analysis, ** = P ≤ 
0.01. 
Figure 4.15 | Reduced IL33 protein expression upon JUN knockdown. A) FAK 
WT cells were transfected with NTC or individual JUN siRNAs as described in 
Materials and Methods. Whole cell lysates were prepared and quantified prior to 
SDS-PAGE analysis. Blots were probed with IL33, JUN and GAPDH antibodies as 
indicated to the right of the blot.  B) IL33 protein expression was quantified using 
ImageJ and then values were normalised to GAPDH levels. N=3 biological 
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4.3.5 ChIP analysis indicated loss of JUN binding to the IL33 
enhancer in FAK-kinase defective mutant 
I performed ChIP analysis to determine if JUN binds to the JUN/AP-1 motif sequences 
on the IL33 enhancer and if there is FAK-dependent chromatin accessibility changes 
on the IL33 enhancer that may perturb JUN binding. ChIP is a widely used protocol in 
molecular genetic research which utilises formaldehyde cross-linking to stabilise 
protein-DNA complexes allowing one to identify genomic regions in which a target 
protein binds. The genomic DNA that a target protein binds can be analysed by q-PCR 
with primers to the region of interest and a region upstream of this site to control for 
background binding.  
 
Primers were designed for the region containing the JUN motif sequences on the IL33 
enhancer and a region upstream of this site to control for background binding (Figure 
4.17A). I performed the JUN ChIP experiments in the FAK WT and the FAK KD cells 
as the FAK KD cells had a striking loss of chromatin accessibility on the enhancer, 
whereas the FAK -/- cells still displayed a small peak at this region (Figure 4.12A). 
According to the ChIP experiment data JUN binds the IL33 enhancer in the FAK WT 
cells (Figure 4.17B, P = 0.0009). However, JUN did not significantly bind on the IL33 
enhancer in the FAK KD cells, when compared to the respective IgG control samples 
(Figure 4.17B). These data confirm the predictive motif enrichment findings 
presented in section 4.3.4 and indicates that FAK regulates chromatin accessibility of 
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4.4 Discussion  
4.4.1 FAK is a potential regulator of AP-1 and ETS domain 
transcription factor binding to chromatin 
The motif enrichment results presented here suggest that FAK is a potential regulator 
of AP-1 and ETS motif enrichment in accessible regions of chromatin. Interestingly, 
another ATAC-seq study comparing healthy cells with cancer cells found that genomic 
regions containing AP-1 and ETS motifs were more open in oesophageal 
adenocarcinoma versus healthy oesophageal cells (Britton et al., 2017). However, it 
was not determined what the consequence of this was for oesophageal adenocarcinoma 
cancer phenotypes. AP-1 and ETS proteins are key transcriptional regulators of many 
cancer-related process such as proliferation (reviewed in Sharrocks, 2001, Eferl and 
Figure 4.17 | JUN ChIP-qPCR analysis on IL33 enhancer shows loss of JUN 
binding in FAK-kinase deficient cells. A) Schematic showing location of 
primers used. B) ChIP-qPCR analysis was performed on FAK WT and FAK KD 
cells as described in Materials and Methods. Primers were designed around the 
JUN motif identified in HOMER (JUN motif primer). To control for non-specific 
binding, primers were designed to an upstream region of the IL33 gene where 
JUN is not predicted to bind (background primer). Pull down efficiency is reported 
as % Input, which was first normalised to the readings from the non-specific 
region and then the resulting value was compared to the IgG. N=5 biological 
replicates, mean +/- SEM. One-way ANOVA test was used for statistical analysis. 
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Wagner, 2003). This indicates that enrichment of available AP-1 and ETS binding sites 
could be important in driving cancer phenotypes. Further work will be required to 
understand whether these changes in AP-1 and ETS motif enrichment in accessible 
chromatin regions specifically drive FAK-dependent phenotypes. 
 
Transcription factor motif sequences predicted by HOMER identifies regions in the 
genome that are known DNA binding motifs for particular transcription factors, based 
on ChIP-seq data for particular transcription factors. However, many transcription 
factor family members will bind to the same motif sequence, and therefore this analysis 
does not rule out the possibility that another transcription factor from the same family 
can bind to the exact same sequence.  The motif enrichment analysis indicated that in 
some cases (i.e. AP-1 family) up to 5 transcription factor family members can bind the 
same motif sequence. It is therefore difficult to determine whether any one particular 
transcription factor is significantly enriched without performing the necessary ChIP-
seq experiments on the individual family members. Overlap in motif binding sites is 
exemplified in validation experiments which showed JUN was upregulated in the FAK 
-/- SCC cells compared to the FAK WT SCC cells (Figure 4.8), which is opposite to 
the predictions from the FAK WT motif enrichment data. Therefore, the motif 
enrichment analysis likely reflects the possibility that another AP-1 factor could 
potentially be enriched on the chromatin in the FAK WT SCC cells. However, the 
global analysis is a good indicator of the transcription factor family motifs that are 
enriched across the genome between cell lines and analysis of the functions of these 
transcription families can give an indication of the consequence of this enrichment of 
transcription factor binding motifs based on the general function of those transcription 
factor families. That said, members of the same transcription family display divergent 
functions. For example, JUN has oncogenic transformation activity, while JUND has 
no oncogenic transformation capabilities (reviewed in Eferl and Wagner, 2003).  
 
As previously described, FAK is a key regulator of inflammation in cancer which the 
Frame group has studied in detail using the K14 CreER FAKflox/flox cutaneous skin SCC 
mouse model (Serrels et al., 2015, 2017). Interestingly, JUNB is a key regulator of 
inflammation in the skin (reviewed in Schonthaler, Guinea-Viniegra and Wagner, 
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2011). This implies that JUNB could be a potential downstream effector in regulating 
FAK-dependent inflammation. The mechanism by which FAK downregulates JUNB 
protein expression and the significance of JUNB in these cells remains to be 
determined. The identification that one of the AP-1 members JUNB, had increased 
protein expression in the FAK WT cells compared to the mutant FAK -/-, NLS and 
KD cells is a reassuring result as it supports our predictive motif enrichment findings. 
However, FAK does not regulate the chromatin recruitment of JUNB per se. 
 
FAK has been shown previously to regulate the protein stability of P53 by binding to 
MDM2 and scaffolding its interaction with P53 (Lim et al., 2008b). Thus, it is a 
possibility that FAK could regulate the protein stability of JUNB. JUNB is known to 
be constantly turned over by the ubiquitin-dependent degradation, which is facilitated 
by JUNB binding the E3 ligase ITCH (Li et al., 2016). It would be interesting to 
determine whether FAK can facilitate JUNB turnover. However, it is not established 
whether JUNB is predominantly turned over inside the cytoplasm or nucleus, which is 
a point to consider since the ubiquitin-dependent degradation generally occurs in the 
cytoplasm. Interestingly, evidence showed that FAK’s nuclear localisation was 
important for regulating JUNB protein expression (Figure 4.6) suggesting that FAK 
may play a role in the nucleus to regulate its turnover. This work suggests FAK could 
potentially regulate transcription factor function by regulating protein expression. It 
would have been ideal to have validated the transcription factor levels in the chromatin 
fraction for more FAK-regulated transcription factors predicted by the motif 
enrichment analysis; however due to the lack of effective antibodies this was not 
possible.  
 
FAK is present in the chromatin fraction isolated from SCC cells (Serrels et al., 2015) 
consistent with it potentially regulating gene expression via direct binding of 
transcription factors at target genes. Integration of the nuclear FAK interactome and 
nuclear FAK BioID dataset with the FAK WT motif enrichment data indicated some 
possible mechanisms by which FAK could regulate AP-1 and ETS proteins. For 
example, WWOX was identified as a FAK interacting protein and it binds to JUN 
suppressing its transcriptional activity by sequestering it in the cytoplasm (Gaudio et 
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al., 2008). This report found the majority of WWOX and JUN co-localised in the 
cytoplasm and the significance of the WWOX:JUN interaction in the nucleus is 
unknown. A number of established FAK binding partners in the nucleus (Serrels et al., 
2015) identified previously have direct connections to transcription factors such as SP1 
(Serrels et al., 2017) and NANOG (Ho et al., 2012). SP1 has been reported to bind to 
JUN to regulate the expression of human 12(S)-lipooxygenase expression (Chen and 
Chang, 2000), while FAK directly binds NANOG in embryonic stem cells (ES) cells 
to regulate invasion (Ho et al., 2012). Additionally, the FAK nuclear BioID 
interactome data (Chapter 3) suggested that FAK binds to co-activators such as LPP 
which has been shown to regulate the ETS family member ETV4 in MDA-MB-321 
human breast cancer cells (Guo et al., 2006). Thus, there are a number of interesting 
upstream and direct connections in the nuclear FAK interactome and that of the 
predicted FAK WT enriched transcription factor binding proteins. This interactome 
analysis suggests that FAK could regulate  recruitment of the predicted  transcription 
factors to chromatin by binding co-activators such as LPP or by direct binding of the 
transcription factor such as NANOG. As discussed in section 4.3.4, it is possible that 
FAK can regulate the chromatin accessibility within target genes and this could 
potentially recruit transcription factor recruitment to that genomic region.  
 
The motif enrichment data suggests that FAK may be important for regulating 
transcription factor recruitment/function to specific gene promoters. However, we 
cannot distinguish between a direct effect of FAK mediating transcription factor 
recruitment to chromatin or FAK signalling that feeds down to regulate transcription 
factor chromatin recruitment. For example, it is known that MAPK phosphorylates 
ETS1 and ETS2 transcription factors, enhancing transactivation activity (Foulds et al., 
2004). Interestingly, FAK has been shown to function upstream of the 
GRB2/RAS/MAPK signalling pathway (Schlaepfer et al., 1994). It has also been 
shown that the Toll-like receptor 2 (TLR2) /FAK/PI3K/AKT signalling axis is 
important for downstream JUN activity in response to peptidoglycan that stimulates 
IL-6 expression (Chiu et al., 2009).  Thus, it is possible that FAK-dependent 
transcription factor recruitment could in fact be due to loss of upstream signalling 
functions of FAK in the cytoplasm.  
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By incorporating the FAK NLS mutant into the motif enrichment analysis, we found 
that 205 predicted transcription factors show FAK nuclear localisation dependent 
motif enrichment. Furthermore, the FAK WT vs KD cell line motif enrichment 
analyses indicate that there are 149 predicted transcription factors whose motif 
enrichment is regulated by FAK’s kinase activity, implying its importance for 
regulating transcription factor function. FAK’s kinase activity and FAK’s nuclear 
localisation are both important for regulating the anti-tumour immune response 
(Serrels et al, 2015). In this study, it was not established whether FAK’s kinase activity 
in the nucleus was important for this function. There are reported FAK kinase 
independent interaction partners with transcription factors in the nucleus i.e. P53 (Lim 
et al., 2008b) and RUNX1 (Canel et al., 2017). Thus, it remains to be established 
whether FAK’s kinase activity is important for transcriptional responses or is solely 
important for signalling upstream that regulate transcription factor function 
downstream.  
 
An important point to discuss is that this study has been performed in one cell model. 
No other research group has performed an analysis of FAK-dependent transcription 
factor motif enrichment and chromatin accessibility changes using ATAC-seq before. 
Therefore, to understand the significance of these results to other cell types and 
cancers, these analyses need to be expanded to other cell types. What this study has 
indicated is that FAK could have a more direct ability to regulate transcription factor 
function, especially apparent from FAK WT vs FAK NLS cell line motif enrichment 
analysis. Although in other cell types the particular transcription factors that FAK is 
regulating may change to account for cell- and tissue-specific gene expression.  
 
4.4.2 FAK regulation of IL33 enhancer chromatin 
accessibility  
FAK binds to the IL33 protein and also regulates its mRNA and protein expression 
(Serrels et al., 2017). Furthermore, it was shown that IL33 functions downstream of 
FAK in SCC cells regulating the expression of immuno-suppressive cytokines such as 
CXCL10 and CCL5, which promote tumour immune evasion (Serrels et al., 2017). I 
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next investigated the mechanism by which FAK regulates IL33 expression. Analysis 
of the chromatin accessibility traces showed that there was a reduction in accessible 
regions at the enhancer and promoter regions of the IL33 gene (Figure 4.12A).  
 
Building on these observations, I next identified which transcription factor motifs were 
enriched in accessible regions upstream of the IL33 gene by performing motif 
enrichment analysis, to predict the key transcription factors responsible for regulating 
IL33 expression. Previous work had used an in silico analysis to predict the 
transcription factors that regulate IL33 expression, which identified RUNX1 and SP1 
as potential regulators. However, knockdown studies found no significant reduction of 
IL33 protein level when RUNX1 or SP1 was suppressed individually (Serrels et al., 
2017), suggesting these transcription factors are not independently essential for 
regulating IL33 expression. Motif enrichment analysis in the FAK WT SCC cells 
detected AP-1 and MYB motifs on the IL33 enhancer regions, while the promoter 
mainly displayed enrichment of ETS and RUNX transcription factor motifs (Figure 
4.12B). Therefore, I focused on the predicted FAK-regulated AP-1 member, JUN as 
the interactome analyses indicated it may be a central node in the network (Figure 
4.13B) and it is highly implicated in oncogenesis (reviewed in Eferl and Wagner, 
2003).  Knockdown experiments showed that JUN indeed controls IL33 expression 
(Figure 4.14B, Figure 4.15A-B) and that of its target gene, CXCL10 (Figure 4.16). 
JUN ChIP experiments indicated that JUN binds to the enhancer region of IL33 and 
this is disrupted upon loss of FAK’s kinase activity (Figure 4.17B). Furthermore, our 
JUN ChIP results indicated a 0.04% enrichment over input which is similar to that 
reported in previous JUN ChIP studies (Veluscek et al., 2016). Thus, JUN can directly 
regulate IL33 expression by binding to the IL33 enhancer region. 
 
From this work, I hypothesise that FAK regulates chromatin accessibility at the 
enhancer/promoter region of the IL33 gene. Access to DNA is a highly regulated 
process which is dependent on a number of factors, including external stimuli and 
development cues (reviewed in Klemm et al., 2019. Mechanistically, chromatin 
accessibility is mediated by transcription factors and chromatin modifying complexes 
(reviewed in Klemm et al., 2019). AP-1 has been shown to recruit the BAF chromatin 
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remodelling complex to enhancers of genes to establish accessible chromatin 
(Vierbuchen et al., 2017). BAF is an ATP-dependent chromatin remodeling complex 
essential for the regulation of gene expression via modulating chromatin accessibility 
(reviewed in Alfert, Moreno and Kerl, 2019). Others have found that AP-1 binding is 
essential for maintaining chromatin accessibility at glucocorticoid target genes (Biddie 
et al., 2011). Taken together these data suggest that AP-1 can regulate chromatin 
accessibility at target genes by recruiting chromatin modifying complexes such as 
BAF.  
 
Finally, previous work using IL33-BirA*-proteomics found that IL33 interacts with 
multiple members of the BAF complex, along with a number of other chromatin 
modifying complexes (Serrels et al., 2017). Since FAK binds and regulates the 
expression of IL33 (Serrels et al., 2017), it is plausible that IL33, in complex with 
FAK, can regulate the expression of itself by recruiting chromatin modifying 
complexes to promoter/enhancers regions. Thus, there are a number of possible 
mechanisms by which FAK could be regulating chromatin accessibility at the IL33 
gene and these warrant further study in different cellular contexts.  
 
4.5 Conclusions  
The work presented here has indicated that FAK regulates AP-1 and ETS motif 
enrichment in accessible regions on chromatin and chromatin accessibility of a subset 
of genes. Chromatin accessibility data of an established FAK regulated gene, IL33, 
indicated FAK-dependent changes in chromatin accessibility in the promoter and 
enhancer region of this gene. Further experiments indicated that JUN can potentially 
regulate the expression of IL33 by binding to its enhancer, which is lost when FAK-
kinase activity is disrupted. Thus, these data implicate a potential mechanism by which 
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Chapter 5 FAK and FAK’s kinase activity is 
important in regulating the 
transcription of genes associated 
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5.1 Introduction 
FAK dependent gene programs were previously determined using Affymetrix 
microarrays (Serrels et al., 2015, Figure 5.1). Although this work identified FAK as a 
regulator of chemokines and cytokines, it stopped short of addressing FAK kinase 
dependent gene programs. In this section, I used mRNA-seq in the FAK WT, FAK -/- 
and FAK KD SCC cell lines to define FAK- and FAK-kinase regulated gene sets, in 
order to determine the range of genes regulated by FAK and the role of its kinase 
activity in transcription.  
 
In section 4, I identified that a known FAK-regulated gene, IL33, exhibits FAK-
regulated changes in chromatin accessibility at the IL33 promoter/enhancer regions. 
Building on these observations, I decided to investigate whether other FAK-regulated 
genes also exhibit FAK-dependent changes in chromatin accessibility at 
promoter/enhancer of genes (section 4.2.1). By doing this, I aimed to determine if 
regulation of chromatin accessibility is one potential mechanism by which FAK 
regulates transcription. I also investigated whether any of the identified FAK-regulated 
genes which display FAK-dependent chromatin accessibility changes at 
promoter/enhancer regions could potentially have roles in established FAK functions 












Figure 5.1 | FAK is a key regulator of the 
expression of inflammatory genes.   
Chemokine and cytokine expression in FAK 
WT and FAK -/- SCC cell lines were 
analysed using Affymetrix microarrays. 
Gray bar indicates cluster of inflammatory 
genes upregulated in FAK WT cell line. 
Green arrowheads highlight genes known to 
function in Treg recruitment and the red 
arrowhead indicates genes involved in 
peripheral Treg induction. Figure taken from 
Serrels et al., 2015 
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5.2 Aims 
• Define the range of FAK- and FAK-kinase regulated genes.  
• Identify the importance of FAK kinase activity in FAK-regulated transcription. 
• Integrate mRNA-seq data with the ATAC-seq chromatin accessibility findings 
to determine if FAK-regulated differentially expressed genes also display 
FAK-dependent changes in chromatin accessibility.  
• Establish whether novel FAK-regulated genes which display FAK-dependent 
chromatin accessibility changes at promoter/enhancer regions are biologically 
important for regulating FAK function. 
 
5.3 Results  
5.3.1 Identification of FAK- and FAK-kinase dependent gene 
sets using mRNA-seq 
To identify FAK and FAK-kinase dependent genes sets, I prepared three biological 
replicates of RNA from FAK WT, FAK -/- and FAK KD cell lines and submitted the 
samples to the transcriptomic company BGI (Hong Kong) for sequencing. RNA-seq 
analyses the presence and amount of RNA in a specific sample, allowing one to 
compare the amount of a particular RNA between cell lines and conditions (Finotello 
and Camillo 2014). Specifically, mRNA-seq was performed which analyses only 
mRNA transcripts and excludes non-coding RNA. We aligned transcripts to the 
GRCm38.cDNA mouse reference transcriptome and differential expression analysis 
was performed between FAK WT, FAK -/- and FAK KD cell lines results using the 
DESeq2 software. All compared transcripts that were differentially expressed in the 
FAK WT vs FAK -/- and FAK WT vs FAK KD cell lines that displayed above or 
below -1 (halved) or 1-fold (doubled) change, respectively and acquired a corrected P-
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Figure 5.2 | FAK mRNA-seq analysis identifies many known FAK-regulated genes. 
RNA from FAK WT, FAK -/- and FAK KD cell lines were submitted for mRNA-seq 
analysis and differential expression analysis performed as described in Material and 
Methods. A list of common differentially expressed genes between the FAK WT vs FAK 
-/- and FAK WT vs KD analyses was constructed using the VENNy online software. The 
data was Z-scored prior to hierarchical clustering using Cluster 3.0 software and 
visualisation in TreeView. A) Shows clustered heatmap representing the transcriptome 
of all common FAK- and FAK-kinase regulated genes. B) & C) Show heatmaps from 
Figure A), which include known FAK-regulated genes (indicated by green arrows). 
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The data showed approximately 400 differentially expressed genes in the FAK WT vs 
FAK -/- and the FAK WT vs FAK KD analyses. Hierarchical clustering analysis 
indicated that the biological replicates in each cell line showed consistent levels of 
expression for the majority of differentially expressed transcripts (Figure 5.2A). 
Furthermore, hierarchical clustering indicated that the FAK -/- and FAK KD cell line 
gene expression data showed similar changes in gene expression changes between the 
two cell lines (Figure 5.2A). Additionally, this analysis indicated there was a clear 
subset of genes that were either up or downregulated in both the FAK WT vs FAK -/- 
and FAK WT vs FAK KD cell lines (Figure 5.2A). These included a number of known 
FAK-regulated genes that regulate proliferation such as IGFBP3 (Canel et al., 2017, 
Figure 5.2B) and inflammation which included IL33 (Serrels et al., 2017), CCL5 and 
CCL2 (Serrels et al., 2015, Figure 5.2B-C). In summary, this analysis indicated that 
the expression changes were consistent in the differentially expressed genes between 
A 
Figure 5.3 | GO enrichment analysis of FAK WT vs FAK -/- differential expression 
analysis. Functional analysis was carried out by performing a Disease and Functions 
core analysis using Ingenuity pathway analysis software. A) Indicates GO enrichment 
analysis of upregulated genes and B) shows GO enrichment analysis of all 
downregulated genes in the FAK WT vs FAK -/- differential expression dataset. –Log10 
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the replicates within the replicates in each cell type, as well as identifying multiple 
known FAK-regulated genes. Together, these findings confirm the validity of this 
dataset.  
 
To establish the functions of the FAK- and FAK-kinase dependent genes identified in 
the whole dataset, I performed GO enrichment analysis on the differentially expressed 
genes identified in both the FAK WT vs FAK -/- and FAK WT vs FAK KD cell line 
differential expression analyses. This indicated that loss of FAK was associated with 
an increase in genes associated with invasion (P < 0.0001), migration of tumour cell 
lines (P < 0.0001) and angiogenesis (P = 0.00578) (Figure 5.3A).  It should be noted 
that there were overlapping terms in the GO enrichment analysis i.e. ‘migration’ and 
‘migration of tumour cells’. Loss of FAK was also associated with a downregulation 
of inflammatory genes specifically associated with the regulating T lymphocytes 
including CD4+ T cells (P = 0.000197) and Th1 cells (P = 0.000194) (Figure 5.3B). 
Figure 5.4 | GO enrichment analysis of FAK WT vs FAK KD cell line differential 
expression analysis.  Functional analysis was carried out by performing a Disease 
and Functions core analysis using Ingenuity pathway analysis software. A) Reports 
GO enrichment analysis of upregulated genes and B) shows GO enrichment analysis 
of all downregulated genes in the FAK WT vs FAK KD cell lines differential expression 
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Genes included under these terms included known FAK-regulated genes such as CCL2 
and CCL5 (Serrels et al., 2015). Similarly, the FAK WT vs FAK KD cell line 
differential expression analysis indicated loss of FAK’s kinase activity was also 
associated with an increase in the expression of genes associated with invasion (P < 
0.0001), migration (P < 0.0001), angiogenesis (P < 0.0001) and transcription (P < 
0.0001) (Figure 5.4A). Additionally, loss of FAK’s kinase activity was associated 
with downregulation of genes associated with inflammation, in particular genes 
regulating the quantity of CD4+ T lymphocytes (P < 0.0001), which was the most 
highly enriched inflammation term in the FAK WT vs FAK KD cell line differential 
expression analysis (Figure 5.4B). Together, the mRNA-seq results broadly align with 
well-known functions of FAK.  
 
Validation of the mRNA-seq data by qRT-PCR analysis confirmed that the mRNA 
expression of the invasion-regulator SFRP1, not previously been shown to be a FAK-
regulated gene, was significantly upregulated in the FAK -/- and FAK KD cells with 
respect to FAK WT cells (Figure 5.5A). The invasion-associated WNT7B gene was 
also upregulated in the FAK KD but was not significantly upregulated in FAK -/- with 
Figure 5.5 | Validation of FAK mRNA-seq data. FAK WT, FAK -
/- and FAK KD cells were harvested for RNA extraction and cDNA 
synthesis as described in Materials and Methods. qRT-PCR was 
carried out using A) SFRP1 or B) WNT7B primers, including 
GAPDH primers to control for loading. All CT values were 
normalised to GAPDH and respective FAK WT samples. Mean +/- 
SEM, N=3 biological replicates, *** = P < 0.001, **** = P < 0.0001. 
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respect to FAK WT cells (Figure 5.5B).  Therefore, WNT7B expression in the FAK -
/- with respect to FAK WT cells is not consistent with the mRNA-seq findings.  
 
Next I decided to investigate the contribution of FAK’s kinase activity to FAK-
dependent transcription as it is clear that there was similar functional term enrichment 
in the FAK WT vs FAK -/- and the FAK WT vs FAK KD differentially expressed 
genes GO enrichment analysis (Figure 5.3A-B, Figure 5.4A-B). All the differentially 
expressed genes present in the FAK WT vs FAK -/- and the FAK WT vs FAK KD 
differential expression analysis were compared using Venny online software. This 
indicated that approximately 40% of FAK-regulated genes are kinase-dependent 
(Figure 5.6). Further inspection established that many of the genes that were common 
between the two datasets were in fact genes associated with inflammation (i.e. CCL2, 
CCL5, CCL7, CCL9, IL33) and invasion (i.e. WNT7b, WNT10B, SFRP1). Thus, the 
comparative analysis presented here suggests that FAK’s kinase activity is important 
for the transcriptional regulation of genes associated with inflammation and invasion. 
Figure 5.6 | Large proportion of FAK-regulated genes are 
kinase dependent. Differentially expressed genes identified in 
the FAK WT vs FAK -/- differential expression analysis were 
compared to the FAK WT vs FAK KD cell line differential 
expression analysis using Venny online software to determine 
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5.3.2 Integration of mRNA-seq and ATAC-seq FAK datasets 
identifies differentially expressed genes regulated by 
chromatin accessibility 
In section 4, I identified that a known FAK-regulated gene, IL33, is regulated by FAK-
dependent chromatin accessibility changes at its promoter/enhancer regions. In this 
section, I next investigated whether FAK-regulated genes identified by mRNA-seq in 
section 5.1.2 are also regulated by chromatin accessibility changes at promoter and 
enhancer regions. To do this, we filtered genes that display FAK-, FAK-nuclear 
localisation and FAK-kinase dependent changes in chromatin accessibility by 
analysing the FAK WT, FAK -/-, FAK NLS and FAK KD ATAC-seq datasets. Peaks 
were assigned to genes using ChIPseeker, where each peak was matched to the gene 
with the closest TSS. This list of genes displaying FAK- and FAK-kinase regulated 
chromatin accessibility changes were then compared with differentially expressed 
genes identified in the FAK WT vs FAK -/- and FAK WT vs FAK KD differential 
expression analyses (Figure 5.7, upper and middle panels). All genes that displayed 
significantly decreased chromatin accessibility (Benjamini-Hochberg corrected P-
value < 0.05) at promoter/enhancer regions in the ATAC-seq dataset were matched 
with genes that exhibit significantly (Benjamini-Hochberg corrected P-value < 0.05) 
downregulated expression with respect the FAK WT in the mRNA-seq differential 
expression analysis (Figure 5.7, upper panel) and vice versa (Figure 5.7, middle 
panel), using Venny online software. Differentially expressed genes in common 
between the FAK WT vs FAK -/- and FAK WT vs KD differential expression analyses 
that display both FAK and FAK-kinase dependent changes in chromatin accessibility 
dataset were filtered (Figure 5.7, lower panel). This analysis included IL33 as a 
downregulated gene that displays reduced chromatin accessibility at its 
promoter/enhancer regions, which I investigated in Chapter 4. An upregulated gene in 
FAK -/- and FAK KD cells which displays changes in accessibility upstream of its 
gene is RBMS3, which is a negative regulator of invasion in breast cancer (Yang, Quan 
and Ling, 2018). The FAK NLS cells chromatin accessibility dataset was not compared 
with gene expression data as the FAK NLS was not included in the mRNA-seq 
analysis. However, comparison of the FAK nuclear localisation dependent chromatin 
accessibility changes to this subset of genes identified that most of these genes are also 
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regulated by FAK nuclear localisation dependent changes in chromatin accessibility 
at promoter/enhancer regions (Figure 5.7, lower panel). Thus, in this section I have 
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Figure 5.7 | Identification of differentially expressed genes regulated by 
chromatin accessibility. FAK WT vs FAK -/- and FAK WT vs FAK KD 
differentially expressed genes (right) were integrated with the FAK (left) and FAK 
kinase-dependent chromatin accessibility data (right), respectively. Upregulated 
genes were compared with genes that show increased chromatin accessibility 
at promoter/enhancer regions (upper panel) and vice versa (middle panel). 
Lower panel is where common down regulated genes (left) and common 
upregulated genes (right) in the FAK -/- and FAK KD (with respect to FAK WT) 
according to mRNA-seq analysis, which show changes in chromatin 
accessibility were identified in common between FAK WT vs KD and FAK WT 
vs KD analyses. In the lower panel, starred genes are those that display 
chromatin accessibility changes in FAK NLS cells and genes identified to have 
FAK and FAK-kinase dependent differential expression. -/- = FAK -/- and KD = 
FAK KD cell line. All data was filtered using Venny online software. Courtesy of 
B. Serrels 
Down regulated gene - RNAseq 
Genes associated with reduced 
chromatin accessibility  
Genes associated with increased 
chromatin accessibility  
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5.3.3 Knockdown of the FAK-regulated gene RBMS3 mRNA 
stimulates invasion in FAK -/- cells 
In this next section, I decided to investigate the function of RBMS3, a FAK-regulated 
differentially expressed gene which is also regulated by FAK-dependent changes in 
chromatin accessibility. RBMS3 is an RNA-binding protein proposed to inhibit the 
invasion of breast cancer cells (Yang, Quan and Ling, 2018) and its expression has 
been correlated with favourable prognosis in lung SCC (Liang et al., 2015). 
Interestingly, FAK -/- cells display perturbed invasive capacity due to loss of FAK-
dependent invasion (Schoenherr et al., 2017) and therefore I investigated whether 
downregulation of RBMS3 mRNA was important. Firstly, we confirmed that RBMS3 
is in fact upregulated in the FAK -/- cells with respect to FAK WT cells on the protein 
level (Figure 5.8). To study whether RBMS3 controls invasion in this cell line, I 
generated RBMS3 knockdown cells by transfecting cells with two separate shRNAs 
against RBMS3 into FAK -/- cells: cells were also transfected with empty pLKO vector 
to generate a control cell line. This generated a stable knockdown of the RBMS3 
transcript in the FAK -/- cells, which was confirmed by RBMS3 qRT-PCR as shown 
in Figure 5.9. To determine whether knockdown of RBMS3 increases invasion in 
FAK -/- cells, I performed inverted invasion assays using the RBMS3 knockdown 
cells. The results showed that there was an increase in invasive capacity of FAK -/- 
cells upon RBMS3 knockdown (Figure 5.10A), however this was not statistically 
significant (Figure 5.10B). Analysis of the invasion levels of the three biological 
replicates showed there was a large variation in invasive capacity between the RBMS3 
knockdown samples, which could explain the lack of a significant result (Figure 
5.10B). In conclusion, knockdown of RBMS3 stimulates the invasion of FAK -/- cells 
in an in vitro assay; however, this was not shown to be a statistically significant 
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Figure 5.9 | Confirmation of RBMS3 
knockdown in FAK -/- cells. RBMS3 
was depleted using shRNA and qRT-
PCR was carried out using RBMS3 
primers as described in Materials and 
Methods. CT values were normalised to 
GAPDH and set relative to FAK -/- pLKO 
samples. N=1 
  
Figure 5.8 | RBMS3 protein is 
upregulated in FAK -/- cells. 
Western blotting and whole cell 
lysates prepared from FAK WT and 
FAK -/- cell lines as outlined in 
Material and Methods. The proteins 
were separated by SDS-PAGE and 
blots were probed for RBMS3 (upper 
panel), FAK (middle panel) and 
GAPDH as a loading control (lower 
panel). N=1. Courtesy of B. Serrels.  
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Figure 5.10 | RBMS3 mRNA knockdown in 
FAK -/- cells results in increased 
invasiveness. FAK -/- pLKO and FAK -/- 
RBMS3 shRNA cells were seeded on 
growth-factor reduced matrigel and left to 
invade towards a serum gradient. The cells 
were stained with Calcein-AM for 
visualisation. A) Representative images 
shown from 3 biological replicates.  B) Shows 
quantification of results of all three replicates. 
One-way ANOVA test used for statistical 
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5.4 Discussion  
5.4.1 FAK’s kinase activity is important for regulating genes 
associated with inflammation and invasion 
In this section, I identified that approximately 400 genes were differentially expressed 
between the FAK WT vs the FAK -/- and FAK WT vs FAK KD cells using mRNA-
seq. GO enrichment analysis implied that FAK and FAK’s kinase activity regulates a 
number of gene sets important in various pathways associated with invasion and 
inflammation (Figure 5.3A-B, Figure 5.4A-B, respectively). It is established that 
FAK is a key regulator of FAK cancer-associated inflammation (Serrels et al., 2015) 
and indeed many of the inflammation-associated genes that were shown to be FAK-
regulated in the Affymetrix microarray analysis published previously (i.e. CCL2, 
CCL5, IL33, Figure 5.1, Serrels et al., 2015) were also shown to be regulated by FAK 
in the mRNA-seq results presented in this chapter, thereby confirming the validity of 
the mRNA-seq findings.  
 
Comparison of FAK WT vs FAK -/- and the FAK WT vs FAK KD differential 
expression analyses showed that approximately 30% of genes were specific to the FAK 
WT vs FAK KD differential expression analysis (Figure 5.6).  In the FAK -/- cells, all 
of FAK’s functions i.e. nuclear, kinase, scaffolding will be deleted. Therefore, one 
would expect that most genes that require FAK kinase activity change in expression 
in the FAK WT vs FAK -/- differential expression analysis. Comparison between the 
differentially expressed genes in the FAK WT vs the FAK -/- cells and the FAK WT 
vs FAK KD cells indicated that 40% of FAK dependent genes were also FAK kinase 
dependent (Figure 5.6). As the GO analysis for the FAK WT vs FAK KD cell line 
differential expression datasets enriched for terms associated with invasion and 
inflammation (Figure 5.3A-B, Figure 5.4A-B), this indicates that FAK kinase activity 
is important for the transcription of genes that regulate these processes. The reason for 
determining whether certain genes are regulated by FAK’s kinase activity is because 
of the incomplete understanding of its function as mentioned in the Introduction. I 
therefore used mRNA-seq to define FAK-regulated genes in order to identify whether 
the FAK kinase activity is important for transcription. FAK kinase inhibitors are in 
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clinical use and therefore gaining insight into the role of FAK’s kinase activity will 
ultimately allow us to understand the reasons FAK’s kinase is important in cancer and 
to potentially optimizing the sue of these inhibitors. Interestingly the most highly 
enriched inflammation term in the FAK WT vs KD differential expression analysis 
was ‘Quantity of CD4+ T lymphocytes’ which included CCL2 and CCL5. Certain types 
of CD4+ T cells can aid the anti-tumour immune response (Th1 cells), but a subset of 
CD4+ T cells which express FoxP3+ CD25+ (Tregs) suppress the anti-tumour immune 
response (reviewed in Balkwill, Capasso and Hagemann, 2012). The Frame group has 
identified that treatment of FAK WT SCC tumours with the FAK kinase inhibitor, VS-
4718, reduces the quantity of the tumour infiltrating Tregs (Serrels et al., 2015). This 
paper also identified that FAK regulates CCL5 expression and knockdown studies 
indicated that CCL5 was highly important in regulating the amount of tumour 
infiltrating Tregs in FAK WT tumours (Serrels et al., 2015). Thus, the FAK mRNA-
seq data presented in this section supports previous data identifying that FAK’s kinase 
activity is highly important for establishing an immuno-suppressive TME by 
regulating the transcription of chemokines (Serrels et al., 2015).  
 
To my knowledge, no group has carried out mRNA-seq analysis to analyse the FAK-
dependent transcriptome. However, a previous study has identified that treatment of 
mouse PDAC tumours with a FAK kinase inhibitor resulted in downregulation of a 
number of genes involved in regulating fibrosis such as LOXL4 (Jiang et al., 2016). 
LOXL4 was also shown to be downregulated as a result of loss of FAK or FAK’s kinase 
activity in SCC cells in my mRNA-seq analysis aligning with previous findings.  This 
implies that my mRNA-seq findings may also be relevant in other cell and tissue types.   
 
In addition, the differential expression analysis indicated that genes associated with 
‘apoptosis of cardiomyocytes’ and ‘apoptosis of macrophages’ were downregulated in 
FAK WT vs FAK -/- and FAK KD. This included CASP1 which is a key regulator of 
apoptosis. FAK has shown to be a negative regulator of apoptosis (Lim et al., 2008b), 
thus the increase of CASP1 expression in FAK WT SCCs is counterintuitive. That said, 
caspases require cleavage to be activated (reviewed in Elmore et al., 2007) and 
therefore changes in their expression alone won’t strictly lead to apoptosis. Therefore, 
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further work will be required to establish if there was biological significance of CASP1 
mRNA being downregulated in the FAK -/- and FAK KD cell lines. 
 
5.4.2 A subset of FAK-regulated differentially expressed 
genes display FAK-dependent changes in chromatin 
accessibility  
The sequence of events that result in chromatin accessibility changes are not fully 
understood (reviewed in Klemm et al., 2019). Furthermore, external stimuli, 
developmental cues and the cell cycle, can all impact on chromatin accessibility 
(reviewed in Klemm et al., 2019). To determine FAK-regulated genes that display 
changes in chromatin accessibility, I integrated the FAK WT vs FAK -/- and FAK WT 
vs FAK KD chromatin accessibility dataset with that of the FAK WT vs FAK -/- and 
FAK WT vs FAK KD mRNA-seq dataset (Figure 5.7). This identified a small subset 
of FAK-dependent and FAK-kinase dependent genes that displayed FAK and FAK 
kinase-dependent changes in chromatin accessibility. Far more genes displayed only 
changes in chromatin accessibility than those that were also differentially expressed. 
Therefore, chromatin accessibility per se is not sufficient to permit FAK-dependent 
transcription. For transcriptional activation to occur, this may require a stimulus from 
a particular growth factor or cytokine for the full complement of transcription factors 
to bind and stimulate the expression of any particular gene. All these experiments 
presented have been performed under basal conditions and further experiments will be 
required to understand FAK-dependent gene expression changes in response to 
different cytokines and growth factors in order to recapitulate a more realistic i.e. in 
vivo representation of FAK-dependent transcription.  
 
The data here suggest that FAK may regulate transcription, in part by regulating 
chromatin accessibility at promoter/enhancer regions of target genes. As discussed in 
the previous chapter, interaction partners of FAK can bind to complexes that regulate 
chromatin accessibility i.e. IL33 binds to components of the BAF complex (Serrels et 
al., 2017), which could link FAK to the regulation of chromatin accessibility. 
However, this does not rule out other potential mechanisms by which FAK can 
regulate transcription, for example by enhancing transcriptional activity which has 
 
 
OMICs based identification of the mechanisms that underpin FAK’s  
regulation of gene expression  145 
been demonstrated previously in the case of the transcription factor, MEF2 (Cardoso 
et al., 2016). Further analysis of the FAK ATAC-seq motif enrichment dataset and 
validation studies would be required to investigate alternative mechanisms by which 
FAK regulates transcription.  
 
5.4.3 FAK regulates the chromatin-accessibility and 
expression of the RBMS3 gene 
To determine whether any of the FAK-regulated genes display changes in chromatin 
accessibility, I integrated the ATAC-seq chromatin accessibility and mRNA-seq data. 
This identified a list of novel genes that are FAK- and FAK-kinase regulated, that also 
exhibit FAK- and FAK kinase changes in chromatin accessibility (Figure 5.7). These 
included a number of genes known to regulate FAK-regulated processes, such as 
regulation of migration, pluripotency and anoikis resistance. These genes included 
SHANK2 which was shown to be downregulated in FAK -/- and FAK KD cell lines. 
SHANK2 is a major component of post-synaptic density that has been shown to be 
important for inhibiting differentiation of stem cells from apical papilla (Guo et al., 
2017). NHSI1B has been reported to be important for regulating neuronal migration by 
regulating the planar cell polarity pathway (PCP), is also regulated by FAK (Walsh et 
al., 2011). In addition, INHBB, which is a negative regulator of anoikis resistance in 
nasopharyngeal carcinoma via suppression of TGF-β signalling, was upregulated in 
the FAK -/- and FAK KD cell lines with respect to FAK WT (Zou et al., 2018). In 
conclusion, many FAK-regulated genes that are also regulated by FAK-mediated 
changes in chromatin accessibility are involved in canonical FAK processes. 
 
Integration of FAK-dependent chromatin accessibility with FAK-dependent gene 
expression data also identified RBMS3 as a FAK-regulated gene that displays changes 
in chromatin accessibility at its promoter/enhancer region upon loss of FAK or FAK 
kinase activity (Figure 5.7). RBMS3 is an RNA-binding protein which, despite being 
discovered nearly 20 years ago (Penkov et al., 2000), has been understudied. The 
RBMS3 gene is an established tumour suppressor (Liang et al., 2015, Chen et al., 2012) 
and low expression of RBMS3 has been associated with poor prognosis in patients with 
gastric cancer (Zhang et al., 2016) and oesophageal SCC (Li et al., 2011).  In human 
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breast cancer cell lines, RBMS3 has been shown to be an inhibitor of invasion (Yang, 
Quan and Ling, 2018). It functions by binding to mRNA and decreases mRNA 
stability, which was shown for the transcription factor TWIST: this results in reduced 
expression of the TWIST1 target gene, MMP2 and a decrease in invasion in vivo (Zhu 
et al., 2019).    
 
FAK -/- cells are known to be defective in invasive capacity due to loss of FAK-
dependent invasion (Schoenherr et al., 2017). Therefore, I investigated whether 
downregulating RBMS3 expression by shRNA could increase the invasive capacity in 
FAK -/- SCC lines. Loss of RBMS3 was associated with an increased invasive capacity 
of FAK -/- cells (Figure 5.10A), however, this was not significant due to large 
variations in the increased invasion of RBMS3 shRNA FAK -/- cells between 
biological replicates (Figure 5.10B). Further work will involve optimising the 
conditions of this experiment in order to decrease variability between the biological 
replicates. However, the data do indicate that RBMS3 could be an important regulator 
of invasion in the FAK - /- SCC cell line. 
 
One unaddressed question is which transcription factors are responsible for driving 
RBMS3 expression. This could be determined by performing motif enrichment 
analysis, as performed in Chapter 4 for the IL33 gene. The mechanism by which 
RBMS3 expression is regulated is unknown. However, the human RBMS3 gene is 
predicted to have binding sites for AMEF-2, C-MYC, EVI-1, AREDB6, GATA-1, 
RP58, MAX1, and MEF2A (Genecards, 2020). I was unable to perform motif 
enrichment analysis to identify the specific transcription factors that regulate mouse 
RBMS3 mRNA expression due to time constraints but this will be the focus of future 
work to confirm which transcription factors are responsible for driving the expression 
of the RBMS3 gene and determining the functional importance. Future motif 
enrichment analysis may also provide insight into the mechanism by which FAK-
regulates chromatin accessibility at the RBMS3 promoter/enhancer region, as there is 
evidence that particular transcription factors can interact with epigenetic complexes to 
regulate chromatin accessibility e.g. AP-1 interacts with the BAF complex to regulate 
chromatin accessibility in mouse embryonic fibroblasts (Vierbuchen et al., 2017).  
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5.5 Conclusions  
The mRNA-seq data presented in this chapter indicates that FAK kinase activity is 
important to drive expression of genes that regulate inflammation and invasion. 
Integration of FAK mRNA-seq data with chromatin accessibility data showed that a 
small subset of FAK-dependent and FAK-kinase dependent genes display changes in 
chromatin accessibility. Further studies indicated that one of these genes, RBMS3 is 
potentially important in negatively regulating FAK-dependent invasion. Together, 
these findings implicate chromatin accessibility as a mechanism by which FAK 
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FAK has been shown to be a key regulator of gene expression in cancer (Serrels et al., 
2015, 2017). However, the mechanism by which FAK regulates transcription remains 
to be determined. With this in mind, I addressed the potential mechanisms by which 
FAK regulates transcription. To study this, I used a three-tiered OMICs approach in 
order to understand potential mechanisms by which FAK regulates transcription.  
 
Specially, I aimed to define; 
 
• Novel nuclear interaction partners of FAK using proximity-based 
proteomics to identify key proteins that FAK can directly bind that have 
roles in transcription 
• FAK-dependent chromatin accessibility changes and transcription 
factor motif enrichment using ATAC-seq 
• The full scope of FAK and FAK-kinase regulated genes using mRNA-
seq  
6.1 FAK regulates chromatin accessibility changes in 
SCC cell lines  
Chromatin accessibility is a key mechanism to regulate gene expression. Increases in 
chromatin accessibility allows RNA Pol II complexes to bind to DNA and initiate 
transcription. Therefore, I aimed to determine whether FAK regulates chromatin 
accessibility using ATAC-seq. This identified a subset of genes that are regulated by 
chromatin accessibility changes in a FAK-, FAK-kinase and a FAK-nuclear 
localisation-dependent manner (Chapter 4). However, I have not established the 
mechanism by which FAK regulates chromatin accessibility. This is a complex 
question to answer, as the sequence of steps required to stimulate chromatin 
accessibility changes are not known (reviewed in Klemm et al., 2019).  
 
One factor potentially contributing to changes in chromatin accessibility includes CpG 
DNA methylation, which has been shown to be associated with reduced chromatin 
accessibility (Thurman et al., 2012). Interestingly, the FAK-regulated gene, SFRP1, 
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which is upregulated in FAK -/- and FAK KD SCC lines when compared with the 
FAK WT SCC line in mRNA-seq analysis presented in Chapter 5, has aberrant 
cytosine promoter methylation in renal cell carcinoma in comparison to normal kidney 
tissues (Dahl et al., 2007). Furthermore, loss of SFRP1 expression by gene methylation 
contributes to tumour phenotypes (Gumz et al., 2007). Therefore, it would be 
interesting to determine whether there are FAK-dependent DNA methylation changes 
which contribute to tumour phenotypes in SCC cells by performing bisulphite 
sequencing and phenotypic assays on candidate FAK-regulated genes that show FAK-
dependent alterations in methylation. This dataset could be integrated with the ATAC-
seq chromatin accessibility dataset in order to understand whether FAK-dependent 
changes in methylation correspond to alterations in chromatin accessibility. If FAK-
regulated changes in DNA methylation are observed, it would be of interest to 
determine the mechanism by which FAK regulates DNA methylation and whether this 
results in the transcriptional repression of genes. FAK binds to the methyl-CpG 
binding protein with demethylase activity, MBD2, to induce myogenin expression and 
muscle differentiation (Luo et al., 2009b). This study suggested that FAK can 
potentially modulate regulators of DNA methylation.  
 
Transcription factors are also thought to play a key role in regulating chromatin 
accessibility. This is because chromatin accessibility is regulated differentially across 
the genome and chromatin remodelling complexes do not have DNA sequence 
specificity, while transcription factors can bind to specific DNA motifs (reviewed in 
Klemm et al., 2019). There are a number of models by which transcription factors can 
regulate chromatin accessibility, including via their ability to initiate accessibility by 
co-operating with chromatin remodellers to establish accessible chromatin (reviewed 
in Klemm et al., 2019). Motif enrichment predicted that FAK regulates transcription 
factor motif enrichment both globally and at the level of specific genes such as IL33.  
Interestingly, JUN (c-Jun), a predicted FAK-regulated transcription factor on the IL33 
enhancer, has been shown to recruit the BAF complex to target enhancers that regulate 
chromatin accessibility (Vierbuchen et al., 2017). Thus, it is possible that FAK could 
regulate accessibility by regulating transcription factor function. However, the 
mechanism by which FAK does this remains to be established (discussed below). It 
 
 
OMICs based identification of the mechanisms that underpin FAK’s  
regulation of gene expression  151 
must be noted that many transcription factors (including JUN, GATA1) have been 
shown to not be able to bind inaccessible chromatin (Thurman et al., 2012). However, 
‘pioneer transcription factors’ (transcription factors that can bind to inaccessible 
chromatin) such as ZFN274, KAP1 and SETDB1 have been implicated in regulating 
chromatin accessibility (Thurman et al., 2012). However, none of the aforementioned 
pioneer transcription factors were identified to display FAK-dependent motif 
enrichment in my work presented here. I conclude that regulation of chromatin 
accessibility is highly complex and further experiments will be required to understand 
the key FAK-dependent transcription factors driving chromatin accessibility in the 
SCC cell model used in these studies.  
 
Integration of the chromatin accessibility and mRNA-seq datasets indicated that there 
were many more FAK-dependent changes in chromatin accessibility than there were 
FAK-regulated genes. This suggests that changes in chromatin accessibility at one or 
multiple regions in promoter or enhancer regions is not sufficient to drive gene 
expression. This finding is in agreement with previous studies where authors integrated 
ATAC-seq and mRNA-seq data to study chromatin accessibility and gene expression 
changes during differentiation of mouse lens fibers (Zhao et al., 2019). These authors 
found that only 9-28% of differentially expressed genes exhibited corresponding 
changes in chromatin accessibility (Zhao et al., 2019). This could be due to the fact a 
gene has multiple regulatory genomic regions and changes in chromatin accessibility 
in one or multiple regulatory genomic regions (i.e. enhancer or promoter) is not 
sufficient to stimulate gene expression (Zhao et al., 2019). Furthermore, it is also likely 
that transcription factors in the differentially accessible regions require a particular 
extracellular stimulus and/or presence of additional activators (Zhao et al., 2019). For 
example, it has been shown that IL6 mRNA is induced by stimulation of IFN-β and/or 
IL1 in human mammary epithelial cells (Nan et al., 2018). Furthermore, recruitment 
of STAT2, IRF-9 and P65 to the IL6 promoter is essential for maximal activation of 
IL6 mRNA expression (Nan et al., 2018). Together, these findings emphasise the 
complexity of control of gene expression, which requires the correct combination of 
transcription factors, chromatin accessibility changes and external stimuli. Further 
studies will be required to determine the effects of cytokine or growth factor 
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stimulation on chromatin accessibly and gene expression in order to recapitulate a 
more realistic representation of FAK-regulated chromatin accessibility and gene 
expression changes. Figure 6.1 depicts the mechanism by which I hypothesise FAK 




6.2 FAK regulates transcription factor binding to 
chromatin  
The motif enrichment analysis presented in this thesis suggested that FAK is a 
regulator of transcription factor motif enrichment in accessible regions of chromatin. 
However, I have not addressed the mechanism by which FAK does so. Transcription 
factors can be regulated by a number of mechanisms including sequestration in the 
cytoplasm, protein turnover and post-translational modifications. The AP-1 member, 
JUNB, displays reduced protein expression but unaltered mRNA expression in FAK -
Figure 6.1 | FAK regulates chromatin accessibility at target genes. FAK likely 
co-operates with transcription factors (TF) and other regulators of transcription 
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/- SCC cells in comparison to FAK WT SCC cells, demonstrating that FAK regulates 
JUNB at the protein level. The levels of JUNB were checked in whole cell lysates and 
further work will be required to understand if the protein levels are changed in the 
nucleus relative to the cytoplasm, as this would indicate FAK regulates the 
translocation of JUNB to the nucleus. All the other transcription factors that were 
regulated by FAK and FAK function did not show changes in the mRNA expression 
according to the FAK mRNA-seq data, suggesting that FAK could potentially regulate 
transcription factors at the protein level. JUNB turnover is controlled by ubiquitin-
dependent degradation that is mediated by binding to an E3 ligase called ITCH (Li et 
al., 2016): the nuclear FAK interactome dataset did indicate that FAK could bind a 
number of E3 ubiquitin ligases including ITCH (Serrels et al., 2015). It is also relevant 
that, in response to staurosporine or loss of cell adhesion, FAK translocates to the 
nucleus in a FERM-dependent manner, where the FAK FERM domain scaffolds the 
MDM2:P53 interaction and enhances MDM2-mediated P53 degradation (Lim et al., 
2008b). Furthermore, Merlin may mediate the FAK mediated interaction between 
P53:FAK and P53:MDM2 in mesothelioma cells (Ou et al,. 2016). Future experiments 
will focus on confirming whether the protein levels of other FAK-regulated 
transcription factors are changed and understanding the mechanism by which FAK 
may regulate the protein levels of these transcription factors (i.e. proteasome-mediated 
turnover). It is possible that FAK may regulate these transcription factors by 
scaffolding E3 ligases to target proteins and thereby mediate ubiquitin-dependent 
degradation. It must be noted that FAK binding to E3 ligases may regulate stability of 
proteins in general, rather than just transcription factors. Indeed, ITCH has been shown 
to ubiquitinate the receptor CXCR4, in addition to transcription factors such as JUNB 
and SMAD2 (reviewed in Melino et al., 2008).  Further work would be needed to 
confirm whether FAK can bind to E3 ligases such as ITCH, and what effect this has 
on protein degradation of transcription factors.    
 
Nuclear FAK binds to the transcription factor, RUNX1, which regulates IGFBP3 
expression and a suppressor of RUNX1 transcriptional activity, SIN3A. Further 
studies found that FAK controlled the nuclear levels of SIN3A expression and thereby 
controlled SIN3A interaction with RUNX1 (Canel et al., 2017). This indicates that 
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FAK can regulate transcription factor function by modulating the nuclear levels of 
transcription factor regulators in the nucleus. This could be tested by determining if 
FAK-regulated transcription factors can still bind to canonical interaction partners in 
the absence of FAK and by determining the nuclear levels of known regulators of 
transcription factor function. That said, it cannot be excluded that FAK-regulated 
transcription factors may, in fact, be regulated by FAK function at focal adhesions. As 
previously mentioned, FAK functions upstream of GRB2/RAS/MAPK signalling 
(Schlaepfer et al., 1994) and the MAPK pathway leads to phosphorylation of ETS1 
and ETS2 leading to their transcriptional activation (Foulds et al., 2004). Furthermore, 
the TLR2 receptor/FAK/PI3K/AKT signalling axis is important for downstream JUN 
activation in response to peptidoglycan and this results in stimulation of IL6 mRNA 
expression (Chiu et al., 2009).  Thus, there are multiple reported connections between 
the upstream function of FAK in the cytoplasm or at focal adhesions and FAK-
regulated transcription factors identified in the ATAC-seq analysis. This emphasises 
the importance of the use of the FAK NLS SCC cell lines in the FAK ATAC-seq 
analysis, which indicated that 205 transcription factors are regulated by nuclear FAK, 
implying that FAK could have a more direct role by regulating transcription factors in 
the nucleus. Equally FAK could also bind to, and potentially phosphorylate, 
modulators of transcription factor function and thereby regulate the activity of 
transcription factors indirectly in the nucleus.  
 
To investigate whether FAK regulates transcription factors in a direct manner (i.e. 
protein binding), I analysed upstream connections between the nuclear FAK BioID 
proteomics dataset or the FAK nuclear interactome proteomics dataset (Serrels et al., 
2015) and the genome-wide FAK WT-enriched ATAC-seq data/motif enrichment 
dataset, using Ingeuity pathway analysis (IPA). This identified a number of upstream 
connections between nuclear FAK interactors and the FAK WT enriched genome-
wide predicted transcription factors, including the FAK interactor, YEATS2 binds to 
TBP (TATA-box binding protein).Additionally, the FAK interactors SP1 and WWOX 
both bind to the FAK-regulated transcription factor, JUN, respectively. The 
interactome analysis suggested that there are many links between the FAK ATAC-seq 
data and the FAK nuclear interactome, implying that FAK can potentially modulate 
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transcription factor function by binding to known transcription factor binding partners. 
The mechanisms by which FAK may potentially mediate transcription factor function 
are depicted in Figure 6.2. 
 
It is possible FAK could regulate transcription by acting as a transcription factor via 
direct binding to DNA. FAK ChIP-seq has been performed in WM858 melanoma cell 
lines, indicating that FAK binds to the consensus sequence GCGC[AC]TGCGC, 
which is similar to the motif sequence for the nuclear respiratory factor 1 (NRF1) , 
(T/C)GCGCA(C/T)GCGC(A/G) (Heim  et al., 2017). Although this suggests that FAK 
could potentially bind to DNA directly, no DNA-binding domain of FAK has been 
discovered to date. Furthermore, since formaldehyde can also cross-link protein-
protein interactions in addition to protein-DNA (Hoffman et al., 2015), it is possible 
that the work by Heim and colleagues could reflect FAK complexing with 
transcriptional complexes that are associated with DNA, without FAK binding to DNA 
directly. 
Figure 6.2 | Mechanisms that FAK may regulate 
transcription factor function. FAK can regulate 
transcription factor function by signalling downstream of 
integrins and growth factor receptors. Alternatively, FAK 
can signal in the nucleus to regulate activation, protein 
stability or recruitment of transcription factors to the 
chromatin. αβ = integrin αβ heterodimer, RTK = Receptor 
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6.3 FAK regulates IL33 expression via the regulation 
of JUN 
As outlined above, FAK-dependent chromatin accessibility changes were found on the 
IL33 promoter/enhancer regions. IL33 is a cytokine secreted form cells when they are 
damaged (alarmin), which alerts immune cells that express the ST2 receptor and this 
stimulates CD8+ T cell recruitment (Lu et al., 2016). It can also be present in the 
nucleus, where IL33 function is largely undefined. Nuclear IL33 is reported to regulate 
the expression of the P65 subunit of NF-κB by binding to its promoter and thereby 
regulating ICAM1 and VCAM1 expression (Choi et al., 2012).  Work from our 
laboratory found that FAK controls the expression of IL33 mRNA and the IL33 protein 
functions downstream of FAK in the regulation of an anti-tumour response (Serrels et 
al., 2017). This work implicated IL33 as a key mediator of nuclear FAK signalling; 
however, the mechanism by which FAK regulates IL33 expression was unknown. 
Therefore, I here addressed the mechanism by which FAK regulates the expression of 
the IL33 gene as a platform for understanding the role of FAK in the nucleus.  
 
As previously mentioned, there was reduced chromatin accessibility on the IL33 
promoter/enhancer regions upon loss of FAK, FAK-kinase activity and FAK nuclear 
localisation. Motif enrichment analysis of the IL33 promoter/enhancer identified peaks 
in the FAK WT SCC cell line, predicted that AP-1, RUNX and MYB transcription 
factor family members bind to the promoter/enhancer regions of the IL33 gene. 
Interactome analysis identified JUN as a central node in the network, implicating it as 
a signal integrator between the other transcription factors predicted by the motif 
enrichment analysis. Knockdown experiments indicated that JUN regulates IL33 
mRNA expression and IL33 protein expression. Furthermore, ChIP validated that JUN 
directly binds to the IL33 enhancer region in the FAK WT SCC cells and this is lost in 
the FAK kinase-defective mutant-expressing cells. Together this suggests that JUN 
regulates the expression of IL33 by binding to the IL33 enhancer and that FAK can 
regulate the binding of this transcription factor, in turn, by regulating changes in 
chromatin accessibility at specific sequences in a kinase-dependent manner. As 
outlined above, it is not known if some of the transcription factors identified in the 
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motif enrichment analysis (i.e. JUN/AP-1) can regulate chromatin accessibility which 
has been implicated previously (Vierbuchen et al., 2017). Therefore, it is possible that 
FAK mediates changes in chromatin accessibility by modulating transcription factor’s 
ability to recruit chromatin modifying complexes to promoters/enhancers. Future work 
will aim to define the mechanism by which FAK can directly regulate JUN function 
recruitment to promoters/enhancers and whether this is important for regulating 
accessibility.  
  
Motif enrichment data also found that the motifs for the TATA-box binding protein 
(TBP) was lost from the promoter region of the IL33 gene upon loss of FAK, its FAK-
kinase activity or its nuclear localisation. Integration of the nuclear FAK interactome 
dataset published previously (Serrels et al., 2015) with the motif enrichment results, 
i.e. the predicted FAK WT enriched transcription factors on the IL33 promoter, 
revealed a number of upstream connections between TBP and the FAK interactome. 
Indeed, cells require the basal transcription factor complex TFIID (composed of TBP 
and TAF components) to scaffold RNA Polymerase II to promoter regions to initiate 
transcription of many genes (reviewed in Butler and Kadonaga, 2002). TAF9 is a key 
component of the basal transcription factor complex, which is a FAK interacting 
protein, as shown by co-immunoprecipitation experiments (Serrels et al., 2015). FAK 
is thought to regulate the anti-tumour immune response by binding to the basal 
transcription factor complex component, TAF9, which regulates of CCL5 expression 
(Serrels et al., 2015). This represents a direct link between FAK and the basal 
transcription complex that regulates gene expression. However, whether FAK 
regulates TAF9 remains to be determined. Further experiments would include ChIP of 
the TBP or TAF9 protein on the TATA-box of the IL33 promoter to establish whether 
FAK-dependent changes in chromatin accessibility modulates binding of the basal 
transcription factor machinery at the IL33 promoter.  
 
The biological consequences of JUN regulating IL33 expression has not been defined 
yet. As previously described, FAK’s regulation of IL33 expression is important for the 
anti-tumour immune evasion (Serrels et al., 2017).  It may be that JUN regulation of 
IL33 mRNA expression is responsible.  Indeed, JUN is a key regulator of inflammation 
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(reviewed in Schonthaler, Guinea-Viniegra and Wagner, 2011). It would be interesting 
to perform animal studies to understand the role of FAK-regulated JUN binding on the 
IL33 enhancer in the anti-tumour immune response (as performed in Serrels et al., 
2015, 2017). However, JUN is an important transcription factor in many biological 
processes that are essential for the cell, such as proliferation (reviewed in Eferl and 
Wagner, 2003); therefore, performing animal experiments with JUN knockdown cells 
would not be informative to address the question posed above.   
 
6.4 Nuclear FAK function regulates FAK-dependent 
phenotypes  
FAK is involved in a number of cellular processes including invasion, angiogenesis 
and inflammation. In my thesis, I used proteomics in order to investigate the function 
of nuclear FAK by identifying novel interaction partners of FAK in the nucleus. Use 
of BioID, a proximity-based biotin ligation approach (Roux et al., 2013), identified 
that FAK can potentially interact with a number of proteins involved in regulating 
transcription factors (i.e. WWOX, LPP) in the nucleus (Chapter 3). GO enrichment 
analysis indicated that FAK protein binding partners in the nucleus, identified by the 
FAK BioID nuclear interactome, are involved in FAK-regulated processes, such as 
invasion, migration and anoikis. Thus, the ability of FAK to bind these nuclear 
interaction partners may control established FAK-regulated processes from the 
nucleus, likely via modulating gene expression. 
 
Interestingly, analysis of the nuclear FAK BioID interactome dataset also predicted 
that FAK binds to a number of other focal adhesion proteins in the nucleus. These 
proteins included SRC, Paxillin and HIC-5 and, as expected, GO enrichment analysis 
indicated these were associated with regulating invasion and metastasis. Many focal 
adhesion proteins present in the nuclear FAK BioID dataset have been shown to 
translocate to the nucleus before, as is the case for LPP (Guo et al., 2006), Paxillin 
(Sathe et al., 2016) and HIC-5 (Shibanuma et al., 2003). Interestingly, 70-80% proteins 
present in the consensus adhesome, have been shown to translocate to the nucleus (A.  
Byron, unpublished), even though some do not have nuclear localisation sequences i.e. 
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Paxillin and Zyxin (reviewed in Lim et al., 2013). FAK does have more than one 
potential NLS in its FERM domain (Lim et al., 2008b, Serrels et al., 2015) and 
therefore FAK could potentially mediate trafficking of other focal adhesion proteins 
to the nucleus as complexes. This suggests that nuclear translocation of focal adhesion 
proteins could be a mechanism by which the cells transmit signals from focal 
adhesions to the nucleus to regulate cellular processes. It would also be of interest to 
determine whether other focal adhesion proteins could assist in the transcriptional roles 
of FAK in the nucleus. This may be addressed by knockdown of focal adhesion 
proteins known to bind FAK and determining whether they regulate FAK-dependent 
gene expression i.e. CCL5, IL33. Furthermore, it would be interesting to determine 
whether other focal adhesion proteins influence binding of FAK to transcription 
factors or transcriptional regulators. Ultimately, validation using co-
immunoprecipitation from nuclear lysates prepared using a recently developed 
fractionation protocol in the Frame/Brunton groups that separates the peri-nuclear 
from the nuclear fraction would be valuable.   
 
Integration of FAK ATAC-seq chromatin accessibility data with mRNA-seq data 
indicated that a subset of FAK and FAK-kinase regulated genes specifically display 
changes in chromatin accessibility. RBMS3 was one of the genes that showed FAK-
dependent changes in chromatin accessibility in its promoter region. This gene is 
upregulated in the FAK KD and FAK -/- SCC cells when compared to FAK WT SCC 
cells in mRNA-seq analyses, and it is known to be an inhibitor of breast cancer cell 
invasion (Yang, Quan and Ling, 2018). Therefore, I performed an initial invasion assay 
using RBMS3 knockdown FAK -/- SCC cells to determine whether RBMS3 could be 
inhibiting FAK-dependent invasion in the FAK -/- SCC cells, in which FAK is 
required for invasion (Schoenherr et al., 2017). Although the results were not 
significant in this first experiment (time did not permit repetition), they did show that 
knockdown of RBMS3 mRNA resulted in a trend towards increased invasion, 
suggesting RBMS3 may indeed negatively regulate invasion in these cells. I was also 
not able to address the nature of the transcription factors that regulate RBMS3 
expression due to time constraints. Future work would define this by performing motif 
enrichment analysis upstream of the RBMS3 gene. Furthermore, siRNA-mediated 
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knockdown experiments would ideally be carried-out on potential RBMS3-regulated 
transcription factors to determine if they do in fact regulate RBMS3 expression. After 
identifying transcriptional regulators of RBMS, ChIP analysis could be performed to 
establish whether they regulate RBMS3 expression by binding to its promoter/enhancer 
regions. Although I did not perform mRNA-seq analysis on the FAK NLS SCC cells, 
FAK NLS SCC cells showed increased accessibility on the RBMS3 gene promoter 
when compared to FAK WT SCC cells. This suggests that FAK could regulate 
chromatin accessibility at the RBMS3 gene, potentially by interaction with chromatin 
modifying complexes and transcription factors identified in the FAK nuclear 
interactome. This work suggests a potential transcriptional mechanism by which FAK 
regulates invasion from activities within the nucleus, which could function in addition 
to, or independently of, FAK-regulation of invadopodia formation at the plasma 
membrane (Chan et al., 2009).  
 
6.5 Role of FAK kinase activity in the nucleus  
With FAK kinase inhibitors in clinical trials, it is important to understand the role of 
FAK’s kinase activity in the regulation of cancer-associated processes. The work 
presented here indicates that FAK’s kinase activity is important for mediating its 
chromatin accessibility changes, transcription binding and FAK nuclear protein 
interactions. However, the mechanism by which FAK kinase activity can regulate 
these functions has not been established, e.g. whether it phosphorylates exogenous 
substrates or simply alters its own conformation. Previous reports on nuclear FAK 
signalling have reported that FAK’s kinase activity is not important for interacting 
with transcription factors in the nucleus (Lim et al., 2008b, Lim et al., 2012). However, 
FAK’s kinase activity regulates its structure allowing it to adopt an ‘open 
conformation’ whereby its kinase domain and linker regions are exposed resulting in 
its autophosphorylation, SRC binding and full catalytic activation (Lietha et al., 2008). 
As the active FAK kinase is in a different conformation to the autoinhibited state, this 
could potentially allow binding of alternative interaction partners. FAK has also been 
shown to phosphorylate proteins including Paxillin (Bellis et al., 1995), and p130CAS 
(Tachibana et al., 1997). However, it is uncertain whether this can occur in the nuclear 
compartment and whether there are any nuclear substrates. FAK has been shown to 
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phosphorylate the transcription factor NANOG to regulate cancer cell invasion (Ho et 
al., 2012). NANOG and FAK co-localise in the nucleus and perinuclear regions, 
suggesting that FAK could potentially phosphorylate NANOG in the nuclear 
compartment (Ho et al., 2012).  That said, no other potential substrates of FAK have 
been found in the nucleus and it may be that FAK primarily has an adaptor function in 
that cell compartment. 
 
In Chapter 5, I showed that 40% of FAK-regulated genes are FAK kinase-dependent, 
suggesting FAK’s catalytic activity is important in regulating gene expression. It is 
possible that many of the FAK- and FAK kinase-regulated genes are, in fact, regulated 
by upstream pathways into which FAK feeds (e.g. MAPK). Thus, future work on this 
aspect should focus on defining the importance of FAK kinase activity in the nucleus 
for transcriptional events, and whether or not there are exogenous substrates. 
 
6.6 Clinical implications of findings  
There is a desperate need for new cancer therapies that are more effective and are less 
toxic than chemotherapy or irradiation. FAK is a highly attractive target in cancer 
therapy due to its involvement in a number of cancer processes such as invasion, 
angiogenesis and regulation of the anti-tumour immune response. That said, FAK 
kinase inhibitors are not effective as a monotherapy likely because many proteins are 
able to compensate for FAK loss in promoting cell survival. There has been a number 
of trials that examine the efficacy of FAK kinase inhibitors for the treatment of cancer 
in combination with other drugs such as MEK/RAF inhibitors (clinicalTrials.gov, 
NCT02428270, NCT03875820) and PD-1 antibodies (clinicalTrials.gov, 
NCT02546531, NCT02758587) for a range of cancers, such as pancreatic cancer, 
NSCLC, breast and mesothelioma.  
 
Drugs that target epigenetic regulators are of active interest as a mechanism to ‘re-
program’ the cancer genome to a ‘healthy’ epigenome (reviewed in Ahuja, Sharma 
and Baylin, 2016). Interestingly, in vitro studies have found co-targeting of MYC 
signalling and FAK kinase activity using JQ1, a bromodomain/Extra-Terminal motif 
(BET) family protein inhibitor and the FAK inhibitor VS-6063, respectively, results 
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in arrest of ovarian cancer cells at G2/M and a decrease in cell survival (Xu et al., 
2017). Interestingly, recent work from our laboratory has used multi-parametric 
phenotypic screening to identify drugs that may synergise with FAK inhibition (J. 
Dawson, unpublished). This work found that FAK kinase and HDAC co-inhibition 
resulted in proliferation arrest in SCC, lung cancer and oesophageal adenocarcinoma 
cells, as well as a reduction of tumour growth of these in vivo (J. Dawson, 
unpublished). Thus, it appears that co-targeting epigenetic regulators and FAK kinase 
activity may be effective in treating cancer. Whether this targeting of epigenetic 
regulators affects nuclear FAK signalling remains to be established.  
 
In Chapter 4, I showed that FAK regulates the chromatin binding of AP-1 factors to 
chromatin across the genome and, specifically at the IL33 enhancer region. AP-1 
transcription factors are commonly dysregulated in cancer and are also of interest as 
potential targets for cancer therapeutics (Ye et al., 2014). Even although there has been 
interest in using AP-1 inhibitors in the treatment of cancer and inflammatory 
conditions, no drugs targeting AP-1 are approved for clinical use (Ye et al., 2014). AP-
1 inhibitors such as SR11302 have been shown to reduce metastatic lesions in an ex 
vivo 4D model of lung cancer, without affecting tumour growth (Mishra and Kim, 
2017). However, use of this inhibitor in an immune competent mouse model will be 
required to understand whether there is an effect of the tumour micro-environment on 
the anti-tumour effect of this drug. In my thesis presented here, I have shown that FAK 
can modulate JUN/AP-1 chromatin binding in a kinase-dependent manner. Therefore, 
it is possible that a combination of an AP-1 inhibitor and FAK kinase inhibitors may 
enhance the anti-tumour effect of FAK kinase inhibitors. Other ATAC-seq studies 
have identified that there is an increase in accessibility at AP-1 and ETS motif regions 
of promoters in oesophageal adenocarcinoma cells versus healthy oesophageal cells 
(Britton et al., 2017). It has not yet been determined what increased AP-1 and ETS 
transcription factor binding actually contributes to cancer biology. Further work would 
be required to establish the biological consequence of increases in accessibility at AP-
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6.7 Conclusions and future experiments required for 
publication  
In conclusion, the work presented here suggests that FAK regulates transcription factor 
motif enrichment in accessible regions of chromatin, potentially via mediating 
chromatin accessibility changes. This work has stimulated questions regarding the 
importance of chromatin accessibility in controlling the expression of genes, and 
emphasises the complexity of transcriptional regulation. These results are intriguing 
given that FAK is generally regarded as a focal adhesion protein; it clearly has 
interesting molecular functions in the nucleus that regulate biological outcomes. 
 
Based on my findings, my conclusions are that; 
 
1) FAK regulates transcription factor motif enrichment globally and also potentially 
connects (directly and/or indirectly) to the transcription factors known to bind to these 
FAK-regulated motifs. 
2) FAK regulates the chromatin accessibility and expression of a subset of genes  
3) FAK regulates chromatin accessibility at the promoter and enhancer regions of the 
IL33 gene and thereby modulates JUN transcription factor binding to the IL33 
enhancer region. 
 
I will now describe the key experiments required for publication in a high impact 
journal, as we intend to publish this work. This work will form two papers: 1) detailing 
the mechanism by which FAK regulates transcription using FAK-regulation of IL33 
expression as a model and 2) defining the functional role of RBMS3 in FAK-
dependent invasion. These papers will inform on mechanisms by which FAK can 
regulate gene expression by modulating chromatin accessibility and how this, in turn, 
controls FAK-dependent phenotypes (i.e. inflammation and invasion). The 
experiments that remain to be performed include:  
 
1)  i) Firstly, I would define the key chromatin remodelling complexes that JUN binds 
to in the FAK SCC cells and whether this is impacted upon by loss of FAK, FAK 
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catalytic activity or nuclear localisation. I would also determine if the nuclear level of 
these chromatin modifying complex components is altered as FAK has previously 
been shown to regulate nuclear levels of chromatin modifying component SIN3A 
(Canel et al., 2017). I will perform IPA and literature searches to identify which are 
the best candidate chromatin modifying complexes that have connections to JUN. 
ii) Perform ChIP to analyse JUN binding chromatin modifying complex components 
on the IL33 enhancer using antibodies directed against the chromatin modifying 
component.  
iii) Perform genome-editing on the AP-1 site on the IL33 enhancer in FAK WT SCC 
cells in culture. This would generate FAK WT SCC cells with a mutation in the AP-1 
motif in the IL33 enhancer. I will then use ChIP to define if the chromatin modifying 
component binds to the AP-1 site in the IL33 enhancer – if it does not bind this would 
imply that AP-1 may regulate the recruitment of this chromatin remodelling complex 
component. 
 
2) i) Confirm that RBMS3 is inhibiting invasion in the SCC FAK SCC cells by 
optimising the inverted invasion assays presented in Chapter 5.  
ii) Perform motif enrichment analysis on the RBMS3 promoter/enhancer regions to 
predict which transcription factors are driving RBMS3 expression. 
iii) Knockdown candidate RBMS3-transcription factors and determine whether they 
regulate the expression of RBMS3. This will confirm whether RBMS3 expression is 
regulated by FAK-dependent chromatin accessibility changes at its promoter/enhancer 
regions. 
iv) Since reduced expression of RBMS3 has been associated with metastasis (Zhu et 
al., 2019), I would like to determine whether knockdown of RBMS3 in the FAK WT 
cells can perturb metastasis in the SCC model by performing a tail-vein metastasis 
assay. 
 
Overall, I hope to show that FAK in the nucleus is an important regulator of cancer-
associated phenotypes and that this occurs via the regulation of transcription factor 
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Protein names Gene names 
P34152 Focal adhesion kinase 1 PTK2 





P11499 Heat shock protein HSP 90-beta HSP90AB1 





P58252 Elongation factor 2 EEF2 
Q9QXS1 Plectin PLEC 
P17182 Alpha-enolase ENO1 
Q8BTM8 Filamin-A FLNA 
P05064 Fructose-bisphosphate aldolase A ALDOA 
P09411 Phosphoglycerate kinase 1 PGK1 
P19096 Fatty acid synthase FASN 
P62702 40S ribosomal protein S4, X isoform RPS4X 
P47963 60S ribosomal protein L13 RPL13 
P27659 60S ribosomal protein L3 RPL3 
P26041 Moesin MSN 
Q6ZWN5 40S ribosomal protein S9 RPS9 
P14148 60S ribosomal protein L7 RPL7 
D3Z2H9 Tropomyosin 3, related sequence 7 TPM3-RS7 
E9QAZ2 Ribosomal protein L15 RPL15 
P26039 Talin-1 TLN1 
P12970 60S ribosomal protein L7a RPL7A 
P62918 60S ribosomal protein L8 RPL8 
P47962 60S ribosomal protein L5 RPL5 
Q9D8N0 Elongation factor 1-gamma EEF1G 
P62965 Cellular retinoic acid-binding protein 1 CRABP1 
P42932 T-complex protein 1 subunit theta CCT8 
P14131 40S ribosomal protein S16 RPS16 
F6YVP7 40S ribosomal protein S18 RPS18 
P14069 Protein S100-A6 S100A6 
P07901 Heat shock protein HSP 90-alpha HSP90AA1 
E9PZF0 Nucleoside diphosphate kinase NME2 
P80317 T-complex protein 1 subunit zeta CCT6A 
P25444 40S ribosomal protein S2 RPS2 
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P62242 40S ribosomal protein S8 RPS8 
E9PYL9 60S ribosomal protein L11 RPL11 
Q6ZWV3 60S ribosomal protein L10 RPL10 
P62717 60S ribosomal protein L18a RPL18A 
P62754 40S ribosomal protein S6 RPS6 
P41105 60S ribosomal protein L28 RPL28 
P57776 Elongation factor 1-delta EEF1D 
P61255 60S ribosomal protein L26 RPL26 
P80315 T-complex protein 1 subunit delta CCT4 
P62281 40S ribosomal protein S11 RPS11 
O55142 60S ribosomal protein L35a RPL35A 
O09167 60S ribosomal protein L21 RPL21 
P80316 T-complex protein 1 subunit epsilon CCT5 
P53026 60S ribosomal protein L10a RPL10A 
Q9CY58 
Plasminogen activator inhibitor 1 RNA-
binding protein 
SERBP1 
Q60864 Stress-induced-phosphoprotein 1 STIP1 
P11983 T-complex protein 1 subunit alpha TCP1 
P62301 40S ribosomal protein S13 RPS13 
P63101 14-3-3 protein zeta/delta YWHAZ 
Q9JHU4 Cytoplasmic dynein 1 heavy chain 1 DYNC1H1 
P62900 60S ribosomal protein L31 RPL31 
P68134 Actin, alpha skeletal muscle ACTA1 
Q9CPR4 60S ribosomal protein L17 RPL17 





P08207 Protein S100-A10 S100A10 
P62264 40S ribosomal protein S14 RPS14 
P80313 T-complex protein 1 subunit eta CCT7 
P62911 60S ribosomal protein L32 RPL32 
P14115 60S ribosomal protein L27a RPL27A 
P23116 
Eukaryotic translation initiation factor 3 
subunit A 
EIF3A 
O08807 Peroxiredoxin-4 PRDX4 
Q9D1R9 60S ribosomal protein L34 RPL34 
P17751 Triosephosphate isomerase TPI1 
Q64727 Vinculin VCL 
O55131 Septin-7 SEPT7 
P60867 40S ribosomal protein S20 RPS20 
P08113 Endoplasmin HSP90B1 
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P61514 60S ribosomal protein L37a RPL37A 
Q91VI7 Ribonuclease inhibitor RNH1 





Q8VI36 Paxillin PXN 
P16110 Galectin-3 LGALS3 
Q9CZX8 40S ribosomal protein S19 RPS19 
P62827 GTP-binding nuclear protein Ran RAN 
Q60598 Src substrate cortactin CTTN 
Q9D0I9 Arginine--tRNA ligase, cytoplasmic RARS 
P63323 40S ribosomal protein S12 RPS12 
Q80UG5 Septin-9 SEPT9 
Q9DCL9 Multifunctional protein ADE2 PAICS 
Q8C1B7 Septin-11 SEPT11 
Q8BGD9 Eukaryotic translation initiation factor 4B EIF4B 
Q99MN1 Lysine--tRNA ligase KARS 
P13020 Gelsolin GSN 
Q8BMJ2 Leucine--tRNA ligase, cytoplasmic LARS 
O70456 14-3-3 protein sigma SFN 
Q9Z1Q9 Valine--tRNA ligase VARS 
P46935 E3 ubiquitin-protein ligase NEDD4 NEDD4 
P62259 14-3-3 protein epsilon YWHAE 
Q6NZJ6 




Transitional endoplasmic reticulum 
ATPase 
VCP 
Q922B2 Aspartate--tRNA ligase, cytoplasmic DARS 
O88342 WD repeat-containing protein 1 WDR1 
P60229 
Eukaryotic translation initiation factor 3 
subunit E 
EIF3E 
P97461 40S ribosomal protein S5 RPS5 
Q91W50 Cold shock domain-containing protein E1 CSDE1 
Q9Z0N1 
Eukaryotic translation initiation factor 2 
subunit 3, X-linked 
EIF2S3X 
Q8R1B4 
Eukaryotic translation initiation factor 3 
subunit C 
EIF3C 
P34022 Ran-specific GTPase-activating protein RANBP1 
Q61316 Heat shock 70 kDa protein 4 HSPA4 
P28656 Nucleosome assembly protein 1-like 1 NAP1L1 
P21107 Tropomyosin alpha-3 chain TPM3 
Q8BGQ7 Alanine--tRNA ligase, cytoplasmic AARS 
P61982 14-3-3 protein gamma YWHAG 
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Q8CI51 PDZ and LIM domain protein 5 PDLIM5 
Q6ZWU9 40S ribosomal protein S27 RPS27 
P31230 
Aminoacyl tRNA synthase complex-
interacting multifunctional protein 1 
AIMP1 
Q9WU78 




Eukaryotic translation initiation factor 3 
subunit I 
EIF3I 
P50247 Adenosylhomocysteinase AHCY 
Q922F4 Tubulin beta-6 chain TUBB6 
Q9CR16 Peptidyl-prolyl cis-trans isomerase D PPID 
Q8BMK4 Cytoskeleton-associated protein 4 CKAP4 
Q9WV32 
Actin-related protein 2/3 complex subunit 
1B 
ARPC1B 
Q8BU30 Isoleucine--tRNA ligase, cytoplasmic IARS 
Q08509 




Eukaryotic translation initiation factor 2 
subunit 1 
EIF2S1 
Q61171 Peroxiredoxin-2 PRDX2 
Q68FL6 Methionine--tRNA ligase, cytoplasmic MARS 
Q8QZY1 
Eukaryotic translation initiation factor 3 
subunit L 
EIF3L 
P62889 60S ribosomal protein L30 RPL30 
P67984 60S ribosomal protein L22 RPL22 
P47226 Testin TES 
Q61699 Heat shock protein 105 kDa HSPH1 
P11440 Cyclin-dependent kinase 1 CDK1 
P34884 Macrophage migration inhibitory factor MIF 
P10639 Thioredoxin TXN 
P83882 60S ribosomal protein L36a RPL36A 
P50543 Protein S100-A11 S100A11 
Q6PHZ2 
Calcium/calmodulin-dependent protein 
kinase type II subunit delta 
CAMK2D 
Q61768 Kinesin-1 heavy chain KIF5B 
Q9CQC6 
Basic leucine zipper and W2 domain-
containing protein 1 
BZW1 
P63037 DnaJ homolog subfamily A member 1 DNAJA1 
P05977 
Myosin light chain 1/3, skeletal muscle 
isoform 
MYL1 
Q920E5 Farnesyl pyrophosphate synthase FDPS 
P30416 
Peptidyl-prolyl cis-trans isomerase 
FKBP4 
FKBP4 
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Q61792 LIM and SH3 domain protein 1 LASP1 
Q99PT1 Rho GDP-dissociation inhibitor 1 ARHGDIA 
P39447 Tight junction protein ZO-1 TJP1 
Q99LF4 tRNA-splicing ligase RtcB homolog RTCB 
P61222 
ATP-binding cassette sub-family E 
member 1 
ABCE1 
Q9CXW3 Calcyclin-binding protein CACYBP 
O70194 
Eukaryotic translation initiation factor 3 
subunit D 
EIF3D 
P16546 Spectrin alpha chain, non-erythrocytic 1 SPTAN1 
P62874 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-1 
GNB1 
O55222 Integrin-linked protein kinase ILK 
P61161 Actin-related protein 2 ACTR2 
Q6ZWY3 40S ribosomal protein S27-like RPS27L 
Q99L47 Hsc70-interacting protein ST13 
P14685 








Eukaryotic peptide chain release factor 
GTP-binding subunit ERF3A 
GSPT1 





Q61035 Histidine--tRNA ligase, cytoplasmic HARS 
Q9QYJ0 DnaJ homolog subfamily A member 2 DNAJA2 
Q5XJY5 Coatomer subunit delta ARCN1 
Q9Z1D1 
Eukaryotic translation initiation factor 3 
subunit G 
EIF3G 
Q9ER72 Cysteine--tRNA ligase, cytoplasmic CARS 
Q99JY9 Actin-related protein 3 ACTR3 
P58771 Tropomyosin alpha-1 chain TPM1 
P40142 Transketolase TKT 
Q9QUM9 Proteasome subunit alpha type-6 PSMA6 
Q8VDM4 









1;Phosphoglycerate mutase 2 
PGAM1 
P05480 
Neuronal proto-oncogene tyrosine-protein 
kinase Src 
SRC 
Q9WTM5 RuvB-like 2 RUVBL2 
Q99K51 Plastin-3 PLS3 
O35685 Nuclear migration protein nudC NUDC 
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P19157 Glutathione S-transferase P 1 GSTP1 
Q61696 Heat shock 70 kDa protein 1A HSPA1A 
Q04736 Tyrosine-protein kinase Yes YES1 
P63001 
Ras-related C3 botulinum toxin substrate 
1 
RAC1 
Q9DBG3 AP-2 complex subunit beta AP2B1 
Q62523 Zyxin ZYX 
Q9D823 60S ribosomal protein L37 RPL37 
Q9CWJ9 
Bifunctional purine biosynthesis protein 
PURH 
ATIC 
Q8CIE6 Coatomer subunit alpha;Xenin;Proxenin COPA 
Q9WVK4 EH domain-containing protein 1 EHD1 
P70677 
Caspase-3;Caspase-3 subunit 
p17;Caspase-3 subunit p12 
CASP3 
Q8BP47 Asparagine--tRNA ligase, cytoplasmic NARS 
Q9D0R2 Threonine--tRNA ligase, cytoplasmic TARS 
Q61553 Fascin FSCN1 
Q99L45 
Eukaryotic translation initiation factor 2 
subunit 2 
EIF2S2 
Q8CDN6 Thioredoxin-like protein 1 TXNL1 
Q8BJW6 Eukaryotic translation initiation factor 2A EIF2A 
O55029 Coatomer subunit beta COPB2 
Q8BFY9 Transportin-1;Transportin-2 TNPO1 
Q99LE6 




Trifunctional purine biosynthetic protein 
adenosine-3 
GART 
P50516 V-type proton ATPase catalytic subunit A ATP6V1A 
Q9WUA2 Phenylalanine--tRNA ligase beta subunit FARSB 
P63254 Cysteine-rich protein 1 CRIP1 
O35226 
26S proteasome non-ATPase regulatory 
subunit 4 
PSMD4 
P62274 40S ribosomal protein S29 RPS29 
Q8CAQ8 MICOS complex subunit Mic60 IMMT 
P26638 Serine--tRNA ligase, cytoplasmic SARS 
Q61166 
Microtubule-associated protein RP/EB 
family member 1 
MAPRE1 
P27546 Microtubule-associated protein 4 MAP4 
Q62448 
Eukaryotic translation initiation factor 4 
gamma 2 
EIF4G2 
Q8R1F1 Niban-like protein 1 FAM129B 
P68510 14-3-3 protein eta YWHAH 
Q3UZ39 
Leucine-rich repeat flightless-interacting 
protein 1 
LRRFIP1 
Q99K85 Phosphoserine aminotransferase PSAT1 
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Q6A028 Switch-associated protein 70 SWAP70 
Q9QYI3 DnaJ homolog subfamily C member 7 DNAJC7 
Q9Z2U1 Proteasome subunit alpha type-5 PSMA5 
Q9JLV1 
BAG family molecular chaperone 
regulator 3 
BAG3 
Q9EPC1 Alpha-parvin PARVA 
P55821 Stathmin-2 STMN2 
O88487 
Cytoplasmic dynein 1 intermediate chain 
2 
DYNC1I2 
Q9ERK4 Exportin-2 CSE1L 
Q91WQ3 Tyrosine--tRNA ligase, cytoplasmic YARS 
P54227 Stathmin STMN1 
Q9WTI7 Unconventional myosin-Ic MYO1C 
Q9R1P4 Proteasome subunit alpha type-1 PSMA1 
Q76MZ3 
Serine/threonine-protein phosphatase 2A 
65 kDa regulatory subunit A alpha 
isoform 
PPP2R1A 
P46471 26S protease regulatory subunit 7 PSMC2 
Q9D051 
Pyruvate dehydrogenase E1 component 
subunit beta, mitochondrial 
PDHB 
Q62418 Drebrin-like protein DBNL 
Q9WVJ2 
26S proteasome non-ATPase regulatory 
subunit 13 
PSMD13 
Q60692 Proteasome subunit beta type-6 PSMB6 
P84091 AP-2 complex subunit mu AP2M1 
P26043 Radixin;Ezrin RDX 
Q9R059 Four and a half LIM domains protein 3 FHL3 
Q3UPL0 Protein transport protein Sec31A SEC31A 
Q60930 
Voltage-dependent anion-selective 
channel protein 2 
VDAC2 
Q62261 Spectrin beta chain, non-erythrocytic 1 SPTBN1 
Q8C0C7 Phenylalanine--tRNA ligase alpha subunit FARSA 
Q80W21 Glutathione S-transferase Mu 7 GSTM7 
Q99K30 
Epidermal growth factor receptor kinase 
substrate 8-like protein 2 
EPS8L2 
Q80UM3 
N-alpha-acetyltransferase 15, NatA 
auxiliary subunit 
NAA15 
P28658 Ataxin-10 ATXN10 
Q6PB66 








Vacuolar protein sorting-associated 
protein 35 
VPS35 
P52293 Importin subunit alpha-1 KPNA2 
P26883 
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Q9DBG6 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 2 
RPN2 
Q8R2Q0 Tripartite motif-containing protein 29 TRIM29 
P63073 Eukaryotic translation initiation factor 4E EIF4E 
P70336 Rho-associated protein kinase 2 ROCK2 
Q61598 Rab GDP dissociation inhibitor beta GDI2 
P62334 26S protease regulatory subunit 10B PSMC6 
P62892 60S ribosomal protein L39 RPL39 
O70435 Proteasome subunit alpha type-3 PSMA3 
Q8R010 
Aminoacyl tRNA synthase complex-
interacting multifunctional protein 2 
AIMP2 
P68181 
cAMP-dependent protein kinase catalytic 
subunit beta 
PRKACB 
Q7TMB8 Cytoplasmic FMR1-interacting protein 1 CYFIP1 
Q6P542 




26S proteasome non-ATPase regulatory 
subunit 6 
PSMD6 
Q08093 Calponin-2 CNN2 
P46735 Unconventional myosin-Ib MYO1B 
Q99JX4 
Eukaryotic translation initiation factor 3 
subunit M 
EIF3M 
P59325 Eukaryotic translation initiation factor 5 EIF5 
Q7TT37 Elongator complex protein 1 IKBKAP 
Q5SWU9 




Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-2 
GNB2 
P15532 Nucleoside diphosphate kinase A NME1 
Q4VAA2 Protein CDV3 CDV3 
A2AGT5 Cytoskeleton-associated protein 5 CKAP5 
Q9DB05 Alpha-soluble NSF attachment protein NAPA 
P97355 Spermine synthase SMS 
Q9Z2U0 Proteasome subunit alpha type-7 PSMA7 
Q9DCT8 Cysteine-rich protein 2 CRIP2 
Q8CG47 
Structural maintenance of chromosomes 
protein 4 
SMC4 





P54775 26S protease regulatory subunit 6B PSMC4 
Q9D358 
Low molecular weight phosphotyrosine 
protein phosphatase 
ACP1 
Q9QUI0 Transforming protein RhoA RHOA 
Q3TLH4 Protein PRRC2C PRRC2C 
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Q99JW4 
LIM and senescent cell antigen-like-






Q8BML9 Glutaminyl-TRNA Synthetase 1 QARS 
E9QA15 Caldesmon 1 CALD1 
Q62095 ATP-dependent RNA helicase DDX3Y DDX3Y 
Q60631 Growth factor receptor-bound protein 2 GRB2 
Q8R1Q8 




Solute carrier family 2, facilitated glucose 
transporter member 1 
SLC2A1 
E9PVA8 GCN1 Activator Of EIF2AK4 GCN1L1 
P30999 Catenin delta-1 CTNND1 
Q9Z108 
Double-stranded RNA-binding protein 
Staufen homolog 1 
STAU1 
Q6ZQ58 La-related protein 1 LARP1 
O70591 Prefoldin subunit 2 PFDN2 
O08585 Clathrin light chain A CLTA 






Platelet-activating factor acetylhydrolase 
IB subunit alpha 
PAFAH1B1 
P48024 Eukaryotic translation initiation factor 1 EIF1 
Q3UHX2 
28 kDa heat- and acid-stable 
phosphoprotein 
PDAP1 
Q9JI10 Serine/threonine-protein kinase 3 STK3 
Q5SXY1 Cytospin-B SPECC1 
Q8BFR5 Elongation factor Tu, mitochondrial TUFM 
Q3THK7 GMP synthase [glutamine-hydrolyzing] GMPS 
P02468 Laminin subunit gamma-1 LAMC1 
Q9DCF9 
Translocon-associated protein subunit 
gamma 
SSR3 
E9Q0S6 Tensin-2;Tensin-3 TNS1 
P24527 Leukotriene A-4 hydrolase LTA4H 
Q61033 
Lamina-associated polypeptide 2, 
isoforms alpha/zeta 
TMPO 
Q9D2R0 Acetoacetyl-CoA synthetase AACS 
Q68FF6 ARF GTPase-activating protein GIT1 GIT1 
P45376 Aldose reductase AKR1B1 
Q9QZ88 







Q9QZQ1 Afadin MLLT4 
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O88544 COP9 signalosome complex subunit 4 COPS4 
E9PYG6 Ras GTPase-activating protein 1 RASA1 
P27612 Phospholipase A-2-activating protein PLAA 
P51881 ADP/ATP translocase 2 SLC25A5 
Q9ES46 Beta-parvin PARVB 
P49722 Proteasome subunit alpha type-2 PSMA2 
P28740 Kinesin-like protein KIF2A KIF2A 
Q9EPL8 Importin-7 IPO7 
Q8BT07 Centrosomal protein of 55 kDa CEP55 
Q8CG48 




Ras GTPase-activating protein-binding 
protein 2 
G3BP2 
Q9QYB1 Chloride intracellular channel protein 4 CLIC4 
E9Q634 Unconventional myosin-Ie MYO1E 
Q9DBR7 
Protein phosphatase 1 regulatory subunit 
12A 
PPP1R12A 
P61089 Ubiquitin-conjugating enzyme E2 N UBE2N 
Q9Z0U1 Tight junction protein ZO-2 TJP2 
G5E8K5 Ankyrin-3 ANK3 
Q9D7S7 60S ribosomal protein L22-like 1 RPL22L1 
Q9D0T1 NHP2-like protein 1 NHP2L1 
Q9DBG7 




Arf-GAP with SH3 domain, ANK repeat 
and PH domain-containing protein 1 
ASAP1 
O35344 
Importin subunit alpha-4;Importin subunit 
alpha-3 
KPNA3 
Q8BZ98 Dynamin-3 DNM3 







PP1-gamma catalytic subunit 
PPP1CC 
Q3THS6 








Protein kinase C and casein kinase 
substrate in neurons protein 2 
PACSIN2 
Q3U9G9 Lamin-B receptor LBR 
Q9R0Y5 Adenylate kinase isoenzyme 1 AK1 
Q8K1M6 Dynamin-1-like protein DNM1L 
P70460 Vasodilator-stimulated phosphoprotein VASP 
P35278 Ras-related protein Rab-5C RAB5C 
Q8BJ71 Nuclear pore complex protein Nup93 NUP93 
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O09131 Glutathione S-transferase omega-1 GSTO1 
Q8K2Z4 Condensin complex subunit 1 NCAPD2 
Q91VK1 
Basic leucine zipper and W2 domain-
containing protein 2 
BZW2 
Q9CZW5 
Mitochondrial import receptor subunit 
TOM70 
TOMM70A 
Q9CWM4 Prefoldin subunit 1 PFDN1 






Dual specificity mitogen-activated protein 
kinase kinase 2 
MAP2K2 
Q9DCN2 NADH-cytochrome b5 reductase 3 CYB5R3 
Q8BJY1 
26S proteasome non-ATPase regulatory 
subunit 5 
PSMD5 
P46460 Vesicle-fusing ATPase NSF 
Q9JMA1 Ubiquitin carboxyl-terminal hydrolase 14 USP14 
Q9JMH6 Thioredoxin reductase 1, cytoplasmic TXNRD1 
Q9D1E6 Tubulin-folding cofactor B TBCB 
E9Q3T0 60S acidic ribosomal protein P1 RPLP1 
Q01730 Ras suppressor protein 1 RSU1 
P63330 
Serine/threonine-protein phosphatase 2A 
catalytic subunit alpha isoform 
PPP2CA 
Q9DBS9 




Transcription elongation factor B 
polypeptide 1 
TCEB1 
P63168 Dynein light chain 1, cytoplasmic DYNLL1 
Q8K297 Procollagen galactosyltransferase 1 COLGALT1 
Q9CQM5 
Thioredoxin domain-containing protein 
17 
TXNDC17 
Q9JK48 Endophilin-B1;Endophilin-B2 SH3GLB1 
P50518 V-type proton ATPase subunit E 1 ATP6V1E1 
O88811 Signal transducing adapter molecule 2 STAM2 
Q922W5 







Q9EQP2 EH domain-containing protein 4 EHD4 






cAMP-dependent protein kinase type I-
alpha regulatory subunit 
PRKAR1A 
Q505F5 Leucine-rich repeat-containing protein 47 LRRC47 
Q8C5L3 
CCR4-NOT transcription complex 
subunit 2 
CNOT2 
Q61335 B-cell receptor-associated protein 31 BCAP31 
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Q6P2B1 
Transportin-3;Fanconi anemia group I 
protein homolog 
TNPO3 
Q8VEM8 Phosphate carrier protein, mitochondrial SLC25A3 
Q61595 Kinectin KTN1 
Q9D8S3 
ADP-ribosylation factor GTPase-
activating protein 3 
ARFGAP3 
Q9D819 Inorganic pyrophosphatase PPA1 
Q9R0Q7 Prostaglandin E synthase 3 PTGES3 
P97429 Annexin A4 ANXA4 
P97807 Fumarate hydratase, mitochondrial FH 
E9PWG6 Condensin complex subunit 3 NCAPG 
Q9R0P5 Destrin DSTN 
P46061 Ran GTPase-activating protein 1 RANGAP1 
Q3UWL8 Prefoldin subunit 4 PFDN4 
Q6PAM1 Alpha-taxilin TXLNA 




A2 FAK BioID whole cell lysate proteomics hits  
 
Protein IDs Protein names Gene 
names 
E9Q616 Neuroblast differentiation-associated protein 
AHNAK 
AHNAK 
P34152 Focal adhesion kinase 1 PTK2 
Q6URW6 Myosin-14 MYH14 
P26443 Glutamate dehydrogenase 1, mitochondrial GLUD1 
A2AGL3 Ryanodine receptor 3 RYR3 
E9PYB0 AHNAK Nucleoprotein 2 AHNAK2 
Q91WK0 Leucine-rich repeat flightless-interacting 
protein 2 
LRRFIP2 
P20029 78 kDa glucose-regulated protein HSPA5 
Q8VI36 Paxillin PXN 
Q8BTM8 Filamin-A FLNA 
Q60598 Src substrate cortactin CTTN 
P61161 Actin-related protein 2 ACTR2 
P14069 Protein S100-A6 S100A6 
P62204;Q9D6P8 Calmodulin CALM1 
Q80X90 Filamin-B FLNB 
Q8BFW7 Lipoma-preferred partner homolog LPP 
Q6ZWU9 40S ribosomal protein S27 RPS27 
Q9Z2H5 Band 4.1-like protein 1 EPB41L1 
Q9QWY8 Arf-GAP with SH3 domain, ANK repeat 
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P57776 Elongation factor 1-delta EEF1D 
Q8BX02 KN motif and ankyrin repeat domain-
containing protein 2 
KANK2 
P42208 Septin-2 SEPT2 
Q9WTI7 Unconventional myosin-Ic MYO1C 
Q60930 Voltage-dependent anion-selective channel 
protein 2 
VDAC2 
Q80UG5 Septin-9 SEPT9 
Q6NZJ6 Eukaryotic translation initiation factor 4 
gamma 1 
EIF4G1 
Q9WUM3 Coronin-1B CORO1B 
Q62219 Transforming growth factor beta-1-induced 
transcript 1 protein 
TGFB1I1 
Q8CI51 PDZ and LIM domain protein 5 PDLIM5 
P58252 Elongation factor 2 EEF2 
Q99P72 Reticulon-4 RTN4 
O55131 Septin-7 SEPT7 
Q69Z38 Pseudopodium-enriched atypical kinase 1 PEAK1 
Q99K30 Epidermal growth factor receptor kinase 
substrate 8-like protein 2 
EPS8L2 
P60122 RuvB-like 1 RUVBL1 
Q61081 Hsp90 co-chaperone Cdc37 CDC37 
P50543 Protein S100-A11 S100A11 
Q3TLH4 Protein PRRC2C PRRC2C 
Q8BGD9 Eukaryotic translation initiation factor 4B EIF4B 
Q9QXD8 LIM domain-containing protein 1 LIMD1 
P08207 Protein S100-A10 S100A10 
Q9QXT8 Calsenilin KCNIP3 
E9Q0S6 Tensin-1 TNS1 
Q9QYJ0 DnaJ homolog subfamily A member 2 DNAJA2 
P39061 Collagen alpha-1(XVIII) chain;Endostatin COL18A1 
Q8BH59 Calcium-binding mitochondrial carrier 
protein Aralar1 
SLC25A12 
Q6ZQ58 La-related protein 1 LARP1 
P05480 Neuronal proto-oncogene tyrosine-protein 
kinase Src 
SRC 
Q6PAJ1 Breakpoint cluster region protein BCR 
Q9CWK8 Sorting nexin-2 SNX2 
Q8BK67 Protein RCC2 RCC2 
P42669 Transcriptional activator protein Pur-alpha PURA 
Q64010 Adapter molecule crk CRK 
O88342 WD repeat-containing protein 1 WDR1 
Q9DBJ1 Phosphoglycerate mutase 1 PGAM1 
Q8CGB3 Uveal autoantigen with coiled-coil domains 
and ankyrin repeats 
UACA 
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A3 FAK BioID nuclear proteomics hits  
 
Protein IDs Protein names Gene names 
E9Q616 Neuroblast differentiation-
associated protein AHNAK 
AHNAK 
P34152 Focal adhesion kinase 1 PTK2 
Q9WUM3 Coronin-1B CORO1B 
Q60598 Src substrate cortactin CTTN 
E9PYB0 Protein AHNAK2 AHNAK2 
Q9WUM4 Coronin-1C CORO1C 
P39447 Tight junction protein ZO-1 TJP1 
P57776 Elongation factor 1-delta EEF1D 
Q3TLH4 Protein PRRC2C PRRC2C 
E9QA15 Caldesmon CALD1 
O70400 PDZ and LIM domain protein 
1 
PDLIM1 
Q8VI36 Paxillin PXN 
E9Q0S6 Tensin-1 TNS1 
P26039 Talin-1 TLN1 
Q80X50 Ubiquitin-associated protein 
2-like 
UBAP2L 
Q9QZQ1 Afadin MLLT4 
E9Q6R7 Utrophin UTRN 
Q91WL8 WW domain-containing 
oxidoreductase 
WWOX 
Q62417 Sorbin and SH3 domain-
containing protein 1 
SORBS1 
Q9QWY8 Arf-GAP with SH3 domain, 
ANK repeat and PH domain-
containing protein 1 
ASAP1 
Q8R361 Rab11 family-interacting 
protein 5 
RAB11FIP5 
Q80U93 Nuclear pore complex protein 
Nup214 
NUP214 
Q9Z0U1 Tight junction protein ZO-2 TJP2 
Q3TUF7 YEATS domain-containing 
protein 2 
YEATS2 




Q8BU11 TOX high mobility group box 
family member 4 
TOX4 
Q8BFW7 Lipoma-preferred partner 
homolog 
LPP 
P05480 Neuronal proto-oncogene 
tyrosine-protein kinase Src 
SRC 
Q9EP71 Ankycorbin RAI14 
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Q69ZK6 Probable JmjC domain-
containing histone 
demethylation protein 2C 
JMJD1C 
Q8CI51 PDZ and LIM domain protein 
5 
PDLIM5 
Q91VJ2 Protein kinase C delta-binding 
protein 
PRKCDBP 
Q64010 Adapter molecule crk CRK 
A0A1W2P6U8 RIKEN cDNA 4932415D10 
gene 
4932415D10RIK 
Q62219 Transforming growth factor 
beta-1-induced transcript 1 
protein 
TGFB1I1 
Q1W617 Protein Shroom4 SHROOM4 
Q8CDG3 Deubiquitinating protein 
VCIP135 
VCPIP1 
Q60902 Epidermal growth factor 
receptor substrate 15-like 1 
EPS15L1 
A2AMM0 Muscle-related coiled-coil 
protein 
MURC 
Q9CY27 Very-long-chain enoyl-CoA 
reductase 
TECR 
Q60634 Flotillin-2 FLOT2 
Q9R0A0 Peroxisomal membrane 
protein PEX14 
PEX14 
Q91YR1 Twinfilin-1 TWF1 
Q9CWE0 Mitochondrial fission 
regulator 1-like 
MTFR1L 
B2RRE7 OTU domain-containing 
protein 4 
OTUD4 
Q9QXD8 LIM domain-containing 
protein 1 
LIMD1 




A4 HIC-5 BioID nuclear proteomics hits 
 
Protein IDs Protein names Gene names 




atypical kinase 1 
PEAK1 
Q9ERU9 E3 SUMO-protein ligase 
RanBP2 
RANBP2 
Q60598 Src substrate cortactin CTTN 
Q1W617 Protein Shroom4 SHROOM4 
P39447 Tight junction protein ZO-1 TJP1 
E9Q0S6 Tensin 1 TNS1 
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Q8C0T5 Signal-induced proliferation-
associated 1-like protein 1 
SIPA1L1 
Q9WUM3 Coronin-1B CORO1B 
E9Q6R7 Utrophin UTRN 
E9PYB0 AHNAK nucleoprotein 2 AHNAK2 
Q62417 Sorbin and SH3 domain-
containing protein 1 
SORBS1 
Q3TLH4 Protein PRRC2C PRRC2C 
P26039 Talin-1 TLN1 
E9PYF4 LIM domain only 7 LMO7 
Q9Z0U1 Tight junction protein ZO-2 TJP2 
Q80U93 Nuclear pore complex protein 
Nup214 
NUP214 
O35691 Pinin PNN 
Q80U72 Protein scribble homolog SCRIB 
O70400 PDZ and LIM domain protein 
1 
PDLIM1 
H3BKP8 RIKEN cDNA 9930021J03 
gene 
9930021J03RIK 
Q8BX02 KN motif and ankyrin repeat 
domain-containing protein 2 
KANK2 
Q91YE8 Synaptopodin-2 SYNPO2 
Q9QZQ1 Afadin MLLT4 
E9Q3T0 60S acidic ribosomal protein 
P1 
RPLP1 





associated 1-like protein 3 
SIPA1L3 
Q61235 Beta-2-syntrophin SNTB2 
Q69ZK6 Probable JmjC domain-
containing histone 
demethylation protein 2C 
JMJD1C 
Q61263 Sterol O-acyltransferase 1 SOAT1 
Q9EP71 Ankycorbin RAI14 
Q80X50 Ubiquitin-associated protein 2-
like 
UBAP2L 
Q8BU11 TOX high mobility group box 
family member 4 
TOX4 
Q9DBR7 Protein phosphatase 1 
regulatory subunit 12A 
PPP1R12A 
Q80UG5 Septin-9 SEPT9 
Q91VX2 Ubiquitin-associated protein 2 UBAP2 
Q3TAQ9 WD repeat domain 36 WDR36 
P46062 Signal-induced proliferation-
associated protein 1 
SIPA1 
A2AQ25 Sickle tail protein SKT 
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Q62219 Transforming growth factor 
beta-1-induced transcript 1 
protein 
TGFB1I1 
Q8R361 Rab11 family-interacting 
protein 5 
RAB11FIP5 
Q8R4U7 Leucine zipper protein 1 LUZP1 
Q9R0L6 Pericentriolar material 1 
protein 
PCM1 
P62259 14-3-3 protein epsilon YWHAE 
Q810A7 ATP-dependent RNA helicase 
DDX42 
DDX42 
Q8C0D9 Centrosomal protein of 68 kDa CEP68 
P62141 Serine/threonine-protein 






Q9D666 SUN domain-containing 
protein 1 
SUN1 
P63166 Small ubiquitin-related 
modifier 1 
SUMO1 





containing gene 6B protein 
TNRC6B 
Q02257 Junction plakoglobin JUP 
Q9R0E1 Procollagen-lysine,2-
oxoglutarate 5-dioxygenase 3 
PLOD3 
P35831 Tyrosine-protein phosphatase 
non-receptor type 12 
PTPN12 
Q921L3 Transmembrane and coiled-
coil domain-containing protein 
1 
TMCO1 
Q8C1B7 Septin-11 SEPT11 
Q924K8 Metastasis-associated protein 
MTA3 
MTA3 
Q60953 Protein PML PML 
G5E8K5 Ankyrin-3 ANK3 
O54833 Casein kinase II subunit alpha CSNK2A2 
O55201 Transcription elongation factor 
SPT5 
SUPT5H 
Q99KW3 TRIO and F-actin-binding 
protein 
TRIOBP 
P70399 Tumor suppressor p53-binding 
protein 1 
TP53BP1 
Q8C115 Pleckstrin homology domain-
containing family H member 2 
PLEKHH2 






Q8R3N6 THO complex subunit 1 THOC1 
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P05977;P09542 Myosin light chain 1/3, 
skeletal muscle 
isoform;Myosin light chain 3 
MYL1 
Q6R891 Neurabin-2 PPP1R9B 
Q02248 Catenin beta-1 CTNNB1 
Q9Z108 Double-stranded RNA-binding 
protein Staufen homolog 1 
STAU1 






Q9D0F3 Protein ERGIC-53 LMAN1 
O55131 Septin-7 SEPT7 
Q7TSC1 Protein PRRC2A PRRC2A 
Q6RHR9 Membrane-associated 




Q3UJB9 Enhancer of mRNA-decapping 
protein 4 
EDC4 
Q6A065 Centrosomal protein of 170 
kDa 
CEP170 
Q8CI51 PDZ and LIM domain protein 
5 
PDLIM5 
Q8CJG0 Protein argonaute-2 AGO2 
Q8R2U0 Nucleoporin SEH1 SEH1L 
Q4VBE8 WD repeat-containing protein 
18 
WDR18 
Q8CG79 Apoptosis-stimulating of p53 
protein 2 
TP53BP2 
Q6DFV3 Rho GTPase-activating protein 
21 
ARHGAP21 
Q91ZX7 Prolow-density lipoprotein 
receptor-related protein 1 
LRP1 
Q60974 Nuclear receptor corepressor 1 NCOR1 
Q99NH2 Partitioning defective 3 
homolog 
PARD3 
Q9DB85 Ribosomal RNA-processing 
protein 8 
RRP8 
Q99PP7 E3 ubiquitin-protein ligase 
TRIM33 
TRIM33 
Q9ES28 Rho guanine nucleotide 
exchange factor 7 
ARHGEF7 
Q69ZL1 FYVE, RhoGEF and PH 
domain-containing protein 6 
FGD6 
Q4FZF3 Probable ATP-dependent RNA 
helicase DDX49 
DDX49 
E9Q9R9 Disks large homolog 5 DLG5 
Q8R2N2 Cirhin CIRH1A 
Q61103 Zinc finger protein ubi-d4 DPF2 
Q9D2N4;O70585 Dystrobrevin alpha DTNA 
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Q9R0A0 Peroxisomal membrane protein 
PEX14 
PEX14 
Q9D0L8 mRNA cap guanine-N7 
methyltransferase 
RNMT 
Q9Z2H5 Band 4.1-like protein 1 EPB41L1 
Q7TPM1 Protein PRRC2B PRRC2B 
Q9D0M0 Exosome complex exonuclease 
RRP42 
EXOSC7 
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